WO2025090945A1

WO2025090945A1 - Formulations having a glycoside and a lipophilic component

Info

Publication number: WO2025090945A1
Application number: PCT/US2024/053080
Authority: WO
Inventors: Brad Douglass; Kimberly Ann Zubris
Original assignee: Spoke Sciences Inc
Current assignee: Spoke Sciences Inc
Priority date: 2023-10-27
Filing date: 2024-10-25
Publication date: 2025-05-01
Anticipated expiration: 2026-04-27

Abstract

Formulations having a glycoside and a high lipophilic component (LC) to surfactant ratio are described. The formulations can be used to efficiently deliver LC through a variety of formulation types, including beverages.

Description

FORMULATIONS HAVING A GLYCOSIDE AND A LIPOPHILIC COMPONENT CROSS=REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to U.S. Provisional Patent Application No.63/593,947 filed on October 27, 2023 and U.S. Provisional Patent Application No.63/624,664 filed on January 24, 2024, the contents of both of which are incorporated by reference herein in their entirely. FIELD OF THE DISCLOSURE [0002] The present disclosure provides formulations having a glycoside and a lipophilic component (LC). The formulations can include a high LC to surfactant ratio. The formulations can include two to five times more LC than total glycosides. DISCLOSURE [0003] A number of lipophilic components that have beneficial physiological effects are difficult to formulate into liquid carriers for administration. Cannabinoids are one such lipophilic component, having a water-solubility of less than 1 μg/mL. [0004] Attempts to prepare oral formulations of cannabinoids have involved preparing capsules or formulations in alcohol or using various emulsification approaches that require large amounts of carriers and surfactants. For example, achieving desired package and serving sizes of cannabinoids in beverages (upwards of 100 mg per ounce) requires elevated concentrations of surfactants, often well beyond the quantities generally recognized as safe (GRAS) for use in beverages and possibly in the range where toxicological issues arise. [0005] The major classes of surfactants currently used include saponins, fatty acid sucrose esters (e.g., sucrose palmitate), lecithins (e.g., phosphatidylcholines, glycerophospholipids), and fatty esters or polyoxylated esters of sorbitate (e.g., polysorbate 80, sorbitan monooleate). [0006] Saponin is a natural extract of the soap bark tree. When highly purified (type 2, > 98%), saponins are a great natural emulsifier for cannabinoids, however, they have a somewhat bitter aftertaste and create foaming issues during manufacture. Used alone, saponins also typically demand concentrations well beyond the generally recognized as safe (GRAS) limits for beverages to successfully emulsify standard quantities of cannabinoids. [0007] Sucrose esters, while including two natural components that have been chemically conjugated, are artificial molecules and have either consumer perception or regulatory limits on use. Lecithins have poor mouth feel and taste. Synthetic surfactants do not allow the growing consumer demands for “clean labels” (i.e., natural or naturally-occurring ingredients only) to be met. Page 1 of 138 [0008] Thus, strong currently available surfactants lead to one or more of foaming during manufacture, poor mouth feel (soapy) and taste (bitter and long-lasting), consumer perception or regulatory limits on use, and failure to meet growing consumer demands for “clean labels” (i.e., natural or naturally-occurring ingredients only) to be met. [0009] Some high-intensity sweeteners are terpenoid glycosides. For example, mogrosides are a family of triterpenoid glycosides found naturally-occurring in Siraitia grosvenorii (Swingle, Lo Han Guo) whereas steviosides and rebaudiosides are related families of diterpenoid glycosides found naturally-occurring in Stevia rebaudiana (Stevia). These high-intensity terpenoid glycosides have found burgeoning use in beverages as non-caloric sugar replacements at low concentrations. Although roughly in the range of 200-500 times the sweetness of sucrose, above 100 ppm (0.01 wt. %) these high-intensity sweeteners exhibit a number of negative organoleptic properties, including a metallic off-taste, temporally delayed/extended flavor impacts and what has been termed the disturbing “pain effect” believed to be the result of the glycosides coating the tongue and oral cavity. [0010] Quillaja saponins are a class of diterpenoid glycosides extracted from Quillaja saponaria (Soapbark Tree) and appear to be the only terpenoid glycosides that have found utility in beverages for surfactant and foam-enhancing properties. Unlike mogrosides, steviosides, and rebaudiosides, which are also terpenoid glycosides, Quillaja saponins do not have sweet organoleptic properties. They are not high-intensity sweeteners. However, Quillaja saponins do share a variety of the negative organoleptic properties of the high-intensity sweeteners even at moderate concentrations. [0011] Recent publications (Zhang, et al., Int J Nanomedicine, 18:1031-1045, 2023, Luo 2020) have reported the use of various terpenoid glycosides, including mogrosides and steviosides, as so-called biosurfactants that have found utility in fabricating solid dispersions between one glycoside and one lipophilic compound. These solid dispersions are described as creating core- shell micelles where the lipophilic compound occupies the core and the terpenoid glycoside creates the shell. All reported references utilize an excess—and often a 10x or 20x excess—of glycosides to lipophilic compound to achieve solubility enhancement of the lipophilic compounds (Zhang, et al., Int J Nanomedicine, 18:1031-1045, 2023 Table 2). This abundant excess of glycosides in their use as biosurfactant has been explained as necessary given the ability of the glycoside shell to completely surround the lipophilic compound in three dimensions to enable effective micellization. [0012] One report in the patent literature (US8551507B2 by Liu) makes clear the extreme limits of this functional utility by detailing how the glycoside solubilizers were found to be particularly Page 2 of 138 effective from 5 to 40% w/v solubilizer of the entire solution and preferably 10% w/v solubilizer. This equates to a concentration of 10,000 ppm and one that exceeds the threshold of negative organoleptic aspects for these glycoside high-intensity sweeteners, including the pain effect, by several orders of magnitude. Additionally, this same patent also utilizes a consistent loading of 2 mg of lipophilic substance in 1 ml of 10% glycoside solution. That equates to a paltry concentration of lipophilic active of only 0.2% and, perhaps more limitingly, a glycoside to lipophilic ratio of 50:1. Clearly, such high ratios of glycoside to lipophilic compound prohibits the application of such technology in beverage applications since the negative organoleptic threshold of high intensity sweeteners (>100 ppm) limits lipophilic active concentrations to parts-per-billion (ppb) levels. [0013] Other recent research (Zhang, et al., Journal of Food Engineering, Volume 289, 110264, 2021) has reported the synergistic effects of steviol glycosides on soy protein isolate (SPI) as a primary surfactant. This study was limited to SPI as the only reported anionic and proteinaceous surfactant. In fact, the researchers demonstrated that the synergistic effect of steviol glycosides appeared to involve the decrease (made more negative) of zeta potential by -10 mV as compared to SPI alone. Furthermore, modeling studies by the authors demonstrated that the synergistic effect was mechanistically reliant upon the docking of steviol glycosides at a specific binding pocket on the SPI protein structure. As a result, this synergistic effect of steviol glycosides would be expected to be limited to either occurring with anionic surfactants, protein surfactants or both, including the possibility that it is limited to soy protein alone and no other proteins. [0014] Other reports (Wolfrum, 2016) demonstrate the ability of rebaudioside A (Reb A) to act synergistically with fatty acid salts, namely sodium oleate, to produce more stable blank emulsions using corn oil as lipid carrier oil, than can be achieved with sodium oleate alone. Unfortunately, Wolfrum, et al. do not disclose loading any lipophilic substances into this case-study emulsion so it is unclear what percentage loadings to expect of this system. However, considering that oleate is also an anionic surfactant and the authors theorized that the hydroxyl groups of Reb A would need to interact with the anionic carboxylate moiety of the oleate, it seems clear that this system would be expected to be restricted to anionic surfactants and glycosides mechanistically impact the system by stimulating a more negative zeta potential. [0015] The current disclosure provides lipophilic component (LC) formulations with improved taste and performance. The use of specific flavor and sweetener agents unexpectedly facilitate emulsification and stabilize the resulting emulsions, thus decreasing the quantity of standalone surfactants necessary. High ratios of LC to glycosides and high LC loadings make it possible to create palatable formulations. Without these features the threshold concentration of high-intensity sweetener would create an unpalatable or un-ingestible formulation. Page 3 of 138 [0016] The present disclosure provides at least one glycoside in formulations having a LC. In particular embodiments, the formulations include a glycoside and a LC. In particular embodiments, the formulations include a glycoside a surfactant, and a LC. In particular embodiments, the formulations may include at least two glycosides, a surfactant, and a LC. [0017] According to aspects of the current disclosure, glycosides by themselves or in combination are not capable of emulsifying a LC. However, with the addition of less than 10 % molar equivalent (ca.1:10 surfactant to glycoside 1 + glycoside 2) the glycosides are capable of emulsifying a LC. This is not simply the result of surfactant because the total quantity of surfactant required is 1/10th that of what would be required for emulsifying the same quantity of LC if only surfactant were used. For example, emulsifying 100 mg of a LC in an 8 fluid ounce beverage normally requires X mg surfactant. However, in combination with two glycosides, only X/10 mg of surfactant is required to emulsify 100 mg of LC in an 8 fluid ounce beverage. [0018] The formulations can include five to ten times more LC than individual glycosides or two times more LC than total glycosides. For example, the ratio of LC to an individual glycoside can be 5:1, 6:1, 7:1, 8:1, 9:1, 10:1 or higher. The ratio of LC to total glycosides can be 1:1, 1.5:1, 2:1 or higher. This benefit was unexpected given Zhang’s work and publication describing ten times or more glycoside to lipophilic component to produce lipophilic core / glycoside shell micelles. [0019] Formulations disclosed herein also allow LC content in excess of 5% by weight. For example, formulations disclosed herein can include LC at 5% by weight, 6% by weight, 8% by weight, 10% by weight, 15% by weight, 20% by weight, 25% by weight and 50% by weight. This benefit was also unexpected given the teaching of Liu (US8551507) which describes lipophilic component loading of 0.2% by weight while using a fifty times excess of glycoside. [0020] Formulations disclosed herein can maintain stability achieved at high LC content even when diluted 100-1000 fold in a formulation, for example to form an ingestible formulation. This feature would not have been predicted according to Zhang (Zhang, et al., Journal of Food Engineering, Volume 289, 110264, 2021, Zhang, et al., Int J Nanomedicine, 18:1031-1045, 2023), Liu, Wolfrum (2016) and Banerjee (Banerjee et al., J Cannabis Res., 3(1):43, 2021) in the model of critical micelle concentrations and Krafft temperatures. [0021] The formulations also do not require a lipophilic carrier oil or a particular surfactant type for functionality. These features were unexpected because Banerjee (2021) reports that it is necessary to use a carrier oil to create a cannabinoid emulsion. Zhang (Zhang, et al., Journal of Food Engineering, Volume 289, 110264, 2021) demonstrated that increasing the effective negative on soy protein isolate and glycoside “docking” at a key position on soy protein isolate was required to produce the impact reported while Wolfrum (2016) demonstrated a case-study Page 4 of 138 emulsion using a single anionic surfactant, sodium oleate, and did not load lipophilic substances into the emulsion. [0022] In particular embodiments, the glycoside includes a steviol-type glycoside and/or a curcurbitane-type glycoside. In particular embodiments, the glycoside includes a terpene glycoside. In particular embodiments, the glycoside includes a diterpenoid glycoside and/or a triterpenoid glycoside. In particular embodiments, the glycoside includes a rebaudioside (REB) and/or mogroside (MOG). Most MOG and REB are generally regarded as high-intensity sweeteners (HIS), while the presence of sweetening functionality and intensity appears to be related to the number of glycoside units present in MOG and REB species. [0023] There are two major classes of terpene glycosides: monodesmosidic where there is only a single sugar chain attached at C-3 and bidesmosidic where a second sugar chain is also attached at C-24 or C-28. It is theorized that the quillaja extract including predominantly monodesmosidic saponins alters the three-dimensional conformations of the bidesmosidic REB and MOG to orient and align the polar and apolar moieties. Without being limited by theory, this alignment functions to create surfactant properties. [0024] As another particular example, the addition of less than 10 % molar equivalent (ca.1:10 saponin to REB + MOG) of saponin to either REB or MOG, individually or as a combination of the two, is capable of emulsifying cannabinoids. This is not simply the result of saponins because the total quantity of saponins required in this formulation is 1/10th that of what would be required for emulsifying the same quantity of cannabinoids if only saponin were used. For example, emulsifying 100 mg of THC in an 8 fluid ounce beverage normally requires X mg saponin. However, in using this formulation that additionally includes REB and/or MOG, only X/10 mg of saponin are required to emulsify 100 mg of THC in an 8 fluid ounce beverage. [0025] In particular embodiments, present in the emulsion are natural stabilizers in each phase: vitamin c in the aqueous phase, ascorbyl palmitate and/or tocopheryl succinate in the surfactant phase, and vitamin e in the oil phase. The traditional surfactants are saponins and/or those listed above that include sucrose and sorbitan esters. The high-intensity sweeteners that also function as co-emulsifiers and emulsion stabilizers are REB and MOG. The oil phase may contain any and all LC, such as cannabinoids (e.g., endocannabinoids, artificial cannabinoids, THC, CBD, CBG, CBC, CBN, and their respective carboxylic acids, isomers and 3-C side-chain analogues). [0026] Formulations disclosed herein can be aqueous formulations or dry formulations. [0027] Within certain examples described herein, aqueous formulations refer to any liquid composition in which the majority of the liquid component is water. In certain examples, aqueous formulations refer to any liquid composition in which the liquid component is pure water. Other Page 5 of 138 examples include liquid compositions in which the liquid component is at least 80% water, at least 85% water, at least 90% water, at least 95% water, or at least 98% water, or at least 99% water. [0028] Aqueous formulations described herein can take the form of, for example, solutions, emulsions, syrups, concentrations, or suspensions, or they can be presented as a dry composition for constitution with water or other suitable vehicle before use or as ingestible solid oral dosage forms such as pills, tablets, mucoadhesive tablets or capsules. Aqueous formulations can include from 10% to 99.99% moisture. In particular embodiments, the aqueous formulation may include a moisture content from 10% to 99%, 10% to 70%, 20% to 60%, 30% to 50%, 20% to 40%, 10 to 30%, 50% to 99%, 50% to 80%, 60% to 70%, 70% to 99%, 80% to 99%, or 90% to 99.99%. Within this aspect of the disclosure 10% is a precise value and should not be interpreted as preceded by the word “about”. [0029] A dry formulation may for example, be formulated as a powder, a granular material, a crystalline material, other types of dry particle preparations or combinations thereof. In some cases, dry formulations may include ingestible solid oral dosage forms such as pills, tablets, mucoadhesive tablets or capsules. The dry formulation includes less than 10% moisture. The dry formulation may be formulated by mixing dry ingredients without the addition of a liquid. In one aspect, the dry formulation may be prepared by mixing the dry ingredients and liquid ingredients, as disclosed herein, to form a solution, emulsion, syrup, concentrate, or suspension, and then drying the solution, emulsion, syrup, concentrate, or suspension to a dry powder form by conventional drying methods. Representative drying methods may include for example, lyophilization (or freeze drying), spray drying, fluid bed drying, drum drying, pulse combustion drying and various combinations thereof. In one aspect, the method is a spray drying method. The dried composition may include a moisture content from 1% to 9%, 1% to 6%, 2% to 5%, 3% to 4%, 0.01% to 3%, 2% to 3%, 3% to 6%, 4% to 5%, 4% to 9%, 5% to 9%, 6% to 8%, 7% to 9%, or 8% to 9%.The current disclosure provides aqueous and dry formulations having high LC concentrations and high LC to surfactant ratios. The aqueous and dry formulations can be used to efficiently deliver active components and/or active ingredients, such as cannabinoids. [0030] Aspects of the current disclosure are now described with additional detail and options as follows: (i) Glycosides, (ii) Surfactants, (iii) Lipophilic Components (LC), (iv) Formulations, (v) Beverages or Beverage Kits, (vi) Food Products, (vii) Oral Formulations, (viii) Mucosal Formulations, (ix) Consumer Products, (x) Common Considerations & Components for Drinkable, Ingestible, and/or Inhalable Products & Formulations (xi) Ocular Formulations, (xii) Topical Formulations, (xiii) Pharmaceutical Formulations, (xiv) Common Considerations for all Products and Formulations, (xv) Administration, (xvi) Exemplary Embodiments, (xvii) Exemplary Page 6 of 138 Formulations, and (xviii) Closing Paragraphs. While section headings are provided, these headings are for organizational purposes only and do not limit the scope or interpretation of the disclosure with the following caveat: because the disclosed formulations may include a glycoside, a surfactant, and a LC, glycosides are selected from section (i), surfactants are selected from section (ii), and LC are selected from section (iii). This requirement is imposed due certain compounds being, for example, both a glycoside and a surfactant (e.g., saponin). [0031] (i) Glycosides. A glycoside is any molecule in which a sugar group (the glycone) is bonded through its anomeric carbon to another group (the aglycone), which may or may not be another carbohydrate, via a glycosidic bond. Glycosides can be linked by an O- (an O-glycoside), N- (a glycosylamine), S-(a thioglycoside), or C- (a C-glycoside) glycosidic bond. [0032] The term ‘glycoside’ is a general one which embraces all the many and varied combinations of sugars and aglycones. More precise terms are available to describe particular classes. Terms used for aglycones are generally self-explanatory (e.g., phenol, anthraquinone and sterol glycosides). The names ‘saponin’ (soap-like), ‘cyanogenetic’ (producing hydrocyanic acid) and ‘cardiac’ (having an action on the heart), although applied to these substances when little was known about them, are useful terms which do in fact bring together glycosides of similar chemical structure. [0033] Terpene Glycosides. The flavor and sweetener agents that unexpectedly facilitate emulsification are included within the class of terpene glycosides. Rebaudiosides (REB), found naturally-occurring in Stevia rebaudiana, are steviol-type diterpene glycosides, and mogrosides (MOG), found naturally occurring in Siraitia grosvenorii, are curcurbitane-type triterpene glycosides. The structure of steviol and curcurbitane are shown below. [0034]

sources. They generally are terpene aglycons attached to at least one glucose or other simple sugars (e.g., xylose or galactose), and the most common forms are monoterpene glycosides, diterpene glucosides, and triterpene glucosides. Many of these compounds are known to be non-toxic and Page 7 of 138 natural sweeteners. [0035] Monoterpene glycosides consist of a monoterpene (2 isoprene unit) aglycone bound to a glycone group of one, two, three, or more sugar residues. Exemplary monoterpene glycosides include paeoniflorin, albiflorin, geniposide, rosiridin, monoterpenol dihexose pentose 1, monoterpenol hexose pentose 1, monoterpenol hexose pentose 2, monoterpenol glucoside 1, monoterpenol hexose pentose 3, monoterpenol glucoside 2, monoterpenol glucoside 3, monoterpenol hexose deoxyhexose 1, monoterpenol hexose pentose 4, malonylated monoterpenol glucoside 1, monoterpenol hexose pentose 5, malonylated monoterpenol glucoside 2, monoterpenol hexose pentose 6, monoterpenol hexose pentose 7, malonylated monoterpenol glucoside 3, monoterpenol hexose pentose 8, monoterpenol hexose deoxyhexose 2, malonylated monoterpenol glucoside 4, Decyl-Beta-D- Glucopyranoside, Paeonihybridin, Paeobrin, Salicylpaeoniflorin, 6-O-β-d-Glucopyranosyl-8-O-benzoyl-paeonisuffrone, 9-Epi-paeonidanin, Paeonidanin, 3-Methyl-O-[α-arabinopyranosyl-(1 → 6)-β- glucopyranosyl]-6-methyl-benzofuran, (3S)-hydroxyl Terpane-10-O-β-D-glucopyranoside, (3R)-hydroxyl Terpane-10-O-β-D- glucopyranoside. Exemplary monoterpene glycosides include glycosides of limonene, geraniol, geranyl acetate, linalool, α-terpineol, α-pinene, sabinene, β-myrcene, δ-3-carene, β-pinene, α- thujene, γ-terpinene, α-terpinolene, terpinen-4-ol, α-terpinene, nerol, isomenthone, perillyl alcohol, perillic acid (perillic acid), and dihydro perillic acid. [0036] Diterpene glycosides consist of a diterpene (4 isoprene unit) aglycone bound to a glycone group of one, two, three, or more sugar residues. Exemplary diterpene glycosides include, steviol glycosides such as rebaudioside, rebaudioside D, rebaudioside A, rebaudioside N, rebaudioside 0, rebaudioside E, stevioside, steviol monoside, steviolbioside, rubusoside, rubusoside A, dulcoside B, dulcoside A, rebaudioside B, rebaudioside G, rebaudioside C, rebaudioside F, rebaudioside I, rebaudioside H, rebaudioside L, rebaudioside K, rebaudioside J, rebaudioside M2, rebaudioside D2, rebaudioside S, rebaudioside T, rebaudioside U, rebaudioside V, rebaudioside W, rebaudioside Z1, rebaudioside Z2, rebaudioside IX, and enzymatically glucosylated steviol glycosides. The structure of rebaudioside A is shown below. Other diterpenes that contain various numbers of glucose moieties are known in the art. These compounds include: paniculoside IV, suaviosides A, B, C1, D1, D2, E, F, G, H, I, and J as identified by Ohtani et al., (1992, Phytochemistry 31(5): 1553-1559), and goshonosides F1 to F5 as identified by Seto et al., (1984, Phytochemistry 23 (12): 2829-2834). Page 8 of 138

[0037] Triter und to a glycone group of one, two, three, or more sugar residues. Exemplary triterpene glycosides include mogrosides, astragaloside, astragaloside IV, actein, cimicifugoside, cimigoside, 20-hydroxy-11 - oxomogroside IAi, 11 -oxomogroside NE, 11 -oxomogroside IAi, mogroside ME, mogroside III, mogroside IV, mogroside V, siamenoside I, triterpenoid glycoside V, neogroside, Kaempferol 7- α-ι-rhamnopyranoside, Kaempferol 3,7-α-ι-dirhamnopyranoside, 11 -oxomogroside III, 11- Dehydroxymogroside III, 11 -oxomogroside IV, mogroside II, mogroside Vl, 11 -oxo-mogroside and siamcroside-l, 23-epi-26 deoxyactein, cimiracemoside A, 27-deoxyactein, 26- deoxycimicifugoside, acetyl shengmanol xyloside, cimicifugoside (cimigenol-3-O-β-D- Xylopyranoside), cimiaceroside A, 12β-hydroxycimigenol-3-O-β-D-xylopyranoside, 12β- hydroxycimigenol-3-O-α-L-arabinopyranoside, 21-hydroxycimigenol-3-O-α-L-arabinopyranoside, 21-hydroxycimigenol-3-O-β-D-xylopyranoside, cimigenol-3-O-α-L-arabinopyranoside, 12β- acetoxycimigenol-3-O-α-L-arabinopyranoside, 24-acetylisodahurinol-3-O-β-D-xylopyranoside, 20(S),22(R),23(S),24(R)-16β:23;22;:25-diepoxy-12β-acetoxy-3β,23,24-trihydroxy-9,19- cycloanost-7-ene-3-O-β-D-xylopyranoside, 20(S),22(R),23(S),24(R)-16β:23;22;:25-diepoxy-12β- acetoxy-3β,23,24-trihydroxy-9,19-cycloanost-7-en-3-O-β-L-arabinopyranoside, and 20(S),22(R),23(S),24(R)-16β:23;22;:25-diepoxy-12β-acetoxy-3β,23,24-trihydroxy-9,19- cycloanostane-3-O-β-D-xylopyranoside. Exemplary triterpene glycosides also include glycosides of amyrin, such as α-amyrin β-amyrin and δ-amyrin. The structure of amyrin is shown below. Page 9 of 138

[0038] Exemplary mogrosides include grosmogroside I, mogroside IA, mogroside IE, 11- oxomogroside IA, mogroside II, mogroside II A, mogroside IIB, mogroside II E, 7-oxomogroside II E, mogroside III, Mogroside IIIe, 11-deoxymogroside III, mogroside IV, 11-oxomogroside IV, 11- oxomogroside IV A, mogroside V, isomogroside V, 11-deoxymogroside V, 7-oxomogroside V, 11- oxomogroside V, isomogroside V, mogroside VI, mogrol, 11-oxomogrol, siamenoside I and combinations thereof. The structure of mogroside V is shown below.

[0039] There are two major classes of terpene glycosides: monodesmosidic where there is only a single sugar chain attached at C-3 and bidesmosidic where a second sugar chain is also Page 10 of 138 attached at C-24 or C-28. [0040] Saponin Glycosides. Saponins are naturally occurring amphiphilic glycosides, which contain polar glycone structure moieties (sugars) separated from nonpolar aglycones structure moieties (also known as sapogenins). Saponin glycosides are mostly originated from plants, such as the Quillaja^plant, licorice root, and Camellia plants, and tend to foam with water. Saponins are classified according to their aglycone counterparts as (i) steroidal saponins and (ii) triterpenoid saponins. The difference between these two classes is that the steroidal saponins are molecules with 27 C-atoms whereas the triterpenoid saponins are molecules with 30 C-atoms. Triterpenoid saponins are further subcategorized into (i) oleanane saponins (e.g., Sapindus mukorossi, Camellia oleifera, etc.) (ii) ursolic acid saponins (e.g., Ilex paragariensis) and (iii) dammarane saponins (e.g., Panax gingseng). Steroid saponins are also further divided into furostanol type and spirostanol type. Saponins from some families such as Solanaceae have steroidal glycoalkaloids as aglycone backbone. Based on number of sugar units, saponins are classified into (i) monodesmosidic saponins, which have a single sugar unit attached to carbon-3, (ii) bidesmosidic saponins having two sugar units attached to C-3 and C-26 or 28 and (iii) tridesmosidic saponins: a compound that consists of three sugar units attached. Branched or linear chains of sugars are attached to the aglycone. These sugar units are mostly composed of D-glucose (Glc), D-galactose (Gal), L-arabinose (Ara), L-rhamnose (Rha), D-xylose (Xyl), D- fructose (Fuc), and glucuronic acid (GlcA) [21,22]. The ginsenosides are triterpene glycosides and ginseng saponins from Panax ginseng (Chinese ginseng) and Panax quinquefolius (American ginseng). Exemplary saponin glycosides include Saponin from Quillaja, Furostan saponins, Glycyrrhizin, escin (aescin), and tea saponin. [0041] The structure of a bidesmosidic Saponin from Quillaja is shown below. Page 11 of 138

[0042] Fur h a glucose monosaccharide is attached at the 26-OH group of the aglycone (with few exceptions), and an oligosaccharide chain is usually connected at 3-OH. The structure of furostan is shown below. [0043] Glycyrrhizin is a

licorice root, which occurs as a mixture of calcium and potassium salts of glycyrrhizic acid. The structure of glycyrrhizic acid is shown below. Page 12 of 138

[0044] Escin or vasoconstrictor and vasoprotective effects found in Aesculus hippocastanum (the horse chestnut). Escin is the main active component in horse chestnut and is responsible for most of its medicinal properties. The main active compound of escin is β-aescin, although the mixture also contains various other components including α-aescin, protoescigenin, barringtogenol, cryptoescin and benzopyrones. The structure of Escin is shown below.

[0045] The structure of a tea saponin, found in Camellia plants, is shown below. Page 13 of 138

[0046] examples presented above and may include natural, naturally occurring. non-natural, non-naturally occurring, and/or synthetic glycosides. For example, the glycoside can be extracted from a natural source, or the glycoside can be synthetically produced. In other embodiments, the glycoside can be artificial meaning that it that can be synthesized but does not otherwise exist in the natural environment. [0047] (ii) Surfactants. Surfactants can be classified as nonionic, anionic, cationic, or amphoteric depending on the charge of the hydrophilic head. Nonionic surfactants are neutral and do not have any charge on their hydrophilic end. Anionic surfactants have a negative charge while cationic surfactants have a positive charge on their hydrophilic end. Amphoteric surfactants, also referred to as zwitterionic surfactants, can have either a positive, negative, or neutral net charge on their hydrophilic end depending on the pH of the environment. In acidic environments, the amphoteric surfactant behaves like a cationic surfactant and in alkaline environments, it behaves similar to an anionic surfactant. [0048] Nonionic surfactants include sorbitan esters, polyethylene glycol sorbitan fatty acid esters, polyoxyethylene alkyl ethers, polyoxyethylene fatty acid esters, polyethylene-polypropylene glycols, saturated polyglycolized glycerides, polyethylene glycols, quillaia, polyethylene glycol stearates, polyethylene glycol glycerides, sucrose esters of fatty acids, and chemical equivalents. [0049] Sorbitan esters include sorbitan monolaurate, sorbitan monopalmitate, sorbitan Page 14 of 138 monostearate, sorbitan tristearate, sorbitan monooleate, and sorbitan trioleate. [0050] Polyethylene glycol sorbitan fatty acid esters include polyethylene glycol sorbitan monolaurate (polysorbate 20), polyethylene glycol sorbitan monopalmitate (polysorbate 40), polyethylene glycol sorbitan monostearate (polysorbate 60), polyethylene glycol sorbitan tristearate (polysorbate 65), polyethylene glycol sorbitan monooleate (polysorbate 80), polyethylene glycol sorbitan trioleate (polysorbate 85), polyethylene glycol sorbitan hexaoleate, and polyethylene glycol sorbitan tetraoleate. [0051] Polyoxyethylene fatty acid^esters^include polyoxyl 40 hydrogenated castor oil. [0052] Polyethylene-polypropylene glycols include polyethylene-polypropylene glycol (poloxamer) 124, poloxamer 188, poloxamer 407, poloxamer 108, poloxamer 217, poloxamer 238, poloxamer 288, poloxamer 338, poloxamer 182, poloxamer 183, poloxamer 212, poloxamer 331, or poloxamer 335. [0053] Saturated polyglycolized glycerides include lauroyl macrogol 32 glycerides. [0054] Polyethylene glycols include polyethylene glycol (PEG) 400. [0055] Quillaia include quillaia/quillaja saponins or quillaia extract. [0056] Polyethylene glycol stearates include PEG 8 stearates or PEG 40 stearates. [0057] Polyethylene glycol hydrogenated castor oils include PEG 25 hydrogenated castor oil and PEG 40 hydrogenated castor oil. [0058] Polyethylene glycol glycerides include PEG 8 caprylic/capric glycerides or PEG 300 oleic glycerides. [0059] Sucrose esters of fatty acids include sucrose distearate, sucrose dilaurate, sucrose palmitate. [0060] Common anionic surfactants include dioctyl sodium sulfosuccinate (DOSS), perfluorooctanesulfonate (PFOS), linear alkylbenzene sulfonates, sodium lauryl ether sulfate, lignosulfonate, and sodium stearate. [0061] Cationic surfactants include benzalkonium chloride^(BAC),^cetylpyridinium chloride^(CPC),^Benzethonium chloride^(BZT), cetyl trimethylammonium bromide (CTAB), and^cetyl trimethylammonium chloride^(CTAC). [0062] Amphoteric surfactants include lauryl betain, betaine citrate, sodium lauroamphoacetate, sodium hydroxymethylglycinate, (carboxymethyl)dimethyl-3-[(1-oxododecyl)amino] propyl ammonium hydroxide, rennin, coco alkyldimethyl betaines, (carboxymethyl) dimethyloleylammonium hydroxide, cocoamidopropyl betaine, and (carboxylatomethyl) dimethyl (octadecyl)ammonium. [0063] In particular embodiments, the surfactant is a nonionic surfactant. In particular Page 15 of 138 embodiments, the surfactant includes sorbitan monooleate. In particular embodiments, the surfactant includes polysorbate 80. In particular embodiments, the surfactant includes two or more surfactants. In particular embodiments, the surfactant includes sorbitan monooleate and polysorbate 80. [0064] In particular embodiments, the surfactant and LC are derived from a common plant type. In particular embodiments, the common plant type is Cannabis sativa. In particular embodiments, the surfactant is hemp protein. [0065] Surfactants can also be characterized by the hydrophilic-lipophilic balance (HLB) which is the balance of the size and strength of the hydrophilic and lipophilic moieties of a surfactant molecule ranging from 0 to 20. Lower values are more hydrophobic and higher numbers are more hydrophilic. In particular embodiments anti-foaming agents have an HLB of 1.5-3, water-in-oil emulsifiers have an HLB of 3-6, wetting agents have an HLB of 7-9, oil-in-water emulsifiers have an HLB of 8-12, and solubilizers have an HLB of 15-20. In particular embodiments, the^surfactant^has an HLB value greater than 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In other embodiments, the^surfactant^has an HLB value between 4-6, 5-9, 8-17, 9-16.7, 9- 16, 9-15, 9-14, 10-17, 10-16.7, 10-16, 10-15, 14-16, 14-17, 15-17, and between 10-14. In certain examples, the surfactant or plurality of surfactants can be chosen according to the HLB requirement of the LC. [0066] In particular embodiments, the formulations include surfactant in an amount selected from: less than 20% w/w, less than 19% w/w, less than 18% w/w, less than 17% w/w, less than 16% w/w, less than 15% w/w, less than 14% w/w, less than 13% w/w, less than 12% w/w, less than 11% w/w, less than 10% w/w, less than 9% w/w, less than 8% w/w, less than 7% w/w, less than 6% w/w, or less than 5% w/w wherein the formulation includes at least 0.001% w/w surfactant. [0067] In particular embodiments, the formulations include surfactant in an amount selected from: 0.001% w/w to 1% w/w, 0.001% w/w to 2% w/w, 0.001% w/w to 3% w/w, 0.001% w/w to 4% w/w, 0.001% w/w to 5% w/w, 0.001% w/w to 6% w/w, 0.001% w/w to 7% w/w, 0.001% w/w to 8% w/w, 0.001% w/w to 9% w/w, or 0.001% w/w to 10% w/w surfactant. [0068] (iii) Lipophilic Components (LC). A LC refers to a compound that has the ability to at least partially dissolve in lipids and non-polar solvents. In particular embodiments, an LC is a lipid active component (LAC). LAC have an intended physiological effect in the body. In certain examples, LAC can be regulated LAC (rLAC). rLAC have an intended physiological effect in the body and are also subject to government approval by a regulatory body, such as the U.S. Food & Drug Agency (FDA). LC have an affinity for lipids. Lipophilic components generally include oils, fatty esters, hydrocarbon oils, silicones, waxes, fatty alcohols, lipophilic vitamins, some proteins, and Page 16 of 138 phospholipids. Within the context of the current disclosure, hydrophobic fluorocarbons are considered lipophilic components. [0069] In certain examples, the present disclosure includes a LC that is a lipophilic protein or peptide. A lipophilic protein or peptide may be an active ingredient and may be used alone or in combination with other LCs according to aspects of the present disclosure. In certain examples, the LC protein may include enzymes, such as nattokinase and bromelain that may be taken as supplements. In certain cases, the LC protein may include a membrane protein that may, for example, be used in cellular membrane targeting of lipophilic proteins. In certain examples, a lipophilic protein or peptide may be a surfactant and may be used alone or in combination with other surfactants according to aspects of the present disclosure. [0070] In particular embodiments, the present disclosure includes a LC that is naturally-occurring in plants. A LC that is naturally-occurring in plants means that the LC can be found in a plant but does mean that the LC originates from any plant. For example, the LC can be extracted from the plant or the LC can be synthetically produced. In other embodiments, LC can be artificial meaning that they are compounds that can be synthesized but do not otherwise exist in the natural environment. [0071] Many families of plants exist, each including several species of plants. Exemplary species within plant families are provided below, and liphophilic components can be derived from each of them. [0072] Acanthaceae: Acanthus mollis; Justicia adhatoda. [0073] Actinidiaceae: Actinidia chinensis; Actinidia deliciosa; Actinidia sp. [0074] Adoxaceae: Sambucus canadensis; Sambucus chinensis; Sambucus edulus; Sambucus nigra; Sambucus sieboldiana; Sambucus sp.; Viburnum lantana; Viburnum opulus; Viburnum rhytidophyllum; Viburnum sp.; Viburnum tinus. [0075] Aizoaceae: Mesembryanthemum crystallinum. [0076] Alstroemeriaceae: Alstroemeria sp. [0077] Amaranthaceae: Alternanthera sp.; Amaranthus blitum; Amaranthus caudatus; Amaranthus graecizans; Amaranthus hybridus; Amaranthus mangostanus; Amaranthus palmeri; Amaranthus retroflexus; Amaranthus sp.; Amaranthus spinosus; Amaranthus viridis; Atriplex canescens; Atriplex lentiformis; Atriplex semibaccata; Beta vulgaris; Celosia argentea; Chenopodium album; Chenopodium murale; Chenopodium sp.; Dysphania ambrosioides; Haloxylon ammodendron; Iresine herbstii; Salsola vermiculata; Spinacia oleracea. [0078] Amaryllidaceae: Allium ampeloprasum; Allium cepa; Allium fistulosum; Allium sativum; Allium sp.; Narcissus sp. Page 17 of 138 [0079] Anacardiaceae: Mangifera indica; Pistacia terebinthus; Pistacia vera. [0080] Annonaceae: Annona muricata; Annona reticulata; Annona squamosa. [0081] Apiaceae: Aegopodium podagraria; Ammi majus; Apium graveolens; Apium nodiflorum; Arracacia xanthorrhiza; Athamanta macedonica; Bupleurum lancifolium; Coriandrum sativum; Cryptotaenia canadensis; Daucus carota; Eryngium sp.; Foeniculum vulgare; Pastinaca sativa; Petroselinum crispum; Peucedanum japonicum; Phellolophium madagascariense; Spananthe sp. [0082] Apocynaceae: Ampelamus laevis; Apocynum cannabinum; Asclepias sp.; Catharanthus roseus; Mandevilla sp.; Matelea carolinensis; Nerium oleander; Plumeria sp.; Raphionacme sp.; Rauvolfia serpentina; Vinca major; Vinca sp. [0083] Aquifoliaceae: Ilex crenata. [0084] Araceae: Alocasia macrorrhizos; Alocasia sp.; Anthurium sp.; Arum italicum; Arum sp.; Caladium bicolor; Caladium sp.; Calla sp.; Colocasia esculenta; Colocasia sp.; Dieffenbachia sp.; Epipremnum pinnatum; Philodendron sp.; Symplocarpus foetidus; Xanthosoma sp.; Zantedeschia aethiopica. [0085] Araliaceae: Aralia sp.; Hedera canariensis; Hedera helix; Hedera sp.; Hydrocotyle umbellata; Polyscias balfouriana; Schejflera actinophylla; Schejflera elegantissima; Schejflera sp.; Tetrapanax papyrifer. [0086] Araucariaceae: Agathis sp.; Araucaria sp. [0087] Arecaceae: Dypsis sp.; Phoenix dactylifera; Phoenix sp.; Veitchia sp. [0088] Aristolochiaceae: Aristolochia clematitis. [0089] Asparagaceae: Asparagus laricinus; Asparagus officinalis; Asparagus setaceus; Asparagus sp.; Aspidistra elatior; Cordyline fruticosa; Cordyline sp.; Dracaena braunii; Dracaena fragrans; Dracaena goldieana; Dracaena sp.; Hyacinthus orientalis; Eachenalia ensifolia; Maianthemum racemosum; Ornithogalum sp.; Polygonatum odoratum; Ruscus aculeatus; Yucca sp. [0090] Balsaminaceae: Impatiens balsamina; Impatiens sp.; Impatiens walleriana. [0091] Berberidaceae: Berberis cretica; Berberis thunbergii; Berberis vulgaris; Berberis wilsoniae; Nandina domestica. [0092] Betulaceae: Alnus incana; Betula maximowicziana; Betula papyrifera; Betula pendula; Carpinus sp.; Corylus avellana. [0093] Bignoniaceae: Campsis radicans; Pyrostegia venusta; Tecoma capensis; Tecoma stans. Boraginaceae: Borago officinalis; Cynoglossum columnae; Heliotropium arborescens; Heliotropium eichwaldii; Heliotropium europaeum; Nama hispidum; Omphalodes verna. Page 18 of 138 [0094] Brassicaceae: Aethionema saxatile; Brassica juncea; Brassica napus; Brassica oleracea; Brassica rapa; Brassica sp.; Capsella bursa-pastoris; Diplotaxis erucoides; Diplotaxis viminea; Eruca vesicaria; Erysimum graecum; Erysimum sp.; Erysimum x cheiri; Hirschfeldia incana; Eepidium didymum; Malcolmia sp.; Matthiola fruticulosa; Matthiola incana; Matthiola odoratissima; Nasturtium sp.; Raphanus raphanistrum; Raphanus sp.; Rapistrum rugosum; Rorippa indica; Sinapis arvensis; Zilla spinosa. [0095] Bromeliaceae: Tillandsia sp. [0096] Buxaceae: Buxus sempervirens. [0097] Calophyllaceae: Mammea Americana. [0098] Campanulaceae: Campanula erinus; Lobelia sp.; Platycodon grandiflorus. [0099] Cannabaceae:^Cannabis^sativa; Cannabis indica; Cannabis ruderalis; Celtis australis; Celtis occidentalis;^Humulus^lupulus; americanus; Humulus cordifolius; Humulus neomexicanus; Humulus pubescens;^Humulus^scandens;^Trema^micrantha. [0100] Cannaceae: Canna indica. [0101] Capparaceae: Capparis nummularia. [0102] Caprifoliaceae: Cephalaria gigantea; Diervilla sp.; Leycesteria formosa; Lonicera etrusca; Lonicera nigra; Lonicera periclymenum; Lonicera sp.; Lonicera tatarica; Lonicera xylosteum; Pterocephalus plumosus; Scabiosa sicula; Symphoria racemosa; Symphoricarpos albus; Symphoricarpos orbiculatus; Weigela hortensis. [0103] Caricaceae: Carica papaya. [0104] Caryophyllaceae: Dianthus armeria; Dianthus barbatus; Dianthus caryophyllus; Dianthus chinensis; Dianthus sp.; Dianthus tenuiflorus; Drymaria cordata; Gypsophila paniculata; Myosoton aquaticum; Silene chalcedonica; Silene vulgaris; Stellaria media. [0105] Celastraceae: Celastrus orbiculatus; Celastrus scandens; Euonymus europaeus; Euonymus japonicus; Euonymus sp. [0106] Cistaceae: Helianthemum salicifolium. Cleomaceae: Cleome sp.; Cleome viscosa. [0107] Clethraceae: Clethra arborea. [0108] Combretaceae: Terminalia catappa. [0109] Commelinaceae: Commelina benghalensis; Commelina communis; Commelina diffusa. [0110] Compositae: Acanthospermum hispidum; Achillea filipendulina; Achillea fraasii; Ageratum conyzoides; Ageratum houstonianum; Ambrosia trifida; Anthemis chia; Arctium lappa; Arctium minus; Arctotheca calendula; Arctotis sp.; Artemisia dracunculus; Beilis annua; Bidens bipinnata; Bidens biternata; Bidens pilosa; Bidens sp.; Boltonia sp.; Brachyscome sp.; Calendula arvensis; Calendula officinalis; Calendula sp.; Callistephus chinensis; Carduus crispus; Carthamus Page 19 of 138 tinctorius; Centaurea cyanus; Centaurea hyalolepis; Centaurea iberica; Centaurea imperialis; Centaurea montana; Chaenactis stevioides; Chrysanthemum coronarium; Chrysanthemum indicum; Chrysanthemum morifolium; Chrysanthemum segetum; Chrysanthemum sp.; Chrysothamnus viscidiflorus; Cichorium endivia; Cichorium intybus; Cichorium pumilum; Cichorium spinosum; Conyza bonariensis; Conyza canadensis; Conyza sp.; Cosmos bipinnatus; Cosmos sp.; Crassocephalum crepidioides; Crepis neglecta; Crepis rubra; Cynara cardunculus; Cynara sp.; Dahlia coccinea; Dahlia sp.; Dahlia variabilis; Elephantopus mollis; Erigeron annuus; Erigeron sp.; Euryops sp.; Euthamia graminifolia; Galinsoga caracasana; Galinsoga ciliata; Galinsoga parviflora; Gerbera jamesonii; Gerbera sp.; Helianthella quinquenervis; Helianthus annuus; Helichrysum luteoalbum; Helichrysum tenax; Helichrysum thianschanicum; Heliopsis sp.; Helminthotheca echioides; Lactuca saligna; Lactuca sativa; Lactuca serriola; Eapsana communis; Eeontodon autumnalis; Eeucanthemum vulgare; Melampodium perfoliatum; Melanthera aspera; Mikania micrantha; Montanoa bipinnatifida; Notobasis syriaca; Osteospermum sp.; Parthenium sp.; Pentzia globosa; Picris pauciflora; Picris sprengeriana; Pseudo gnaphalium obtusifolium; Rudbeckia amplexicaulis; Rudbeckia sp.; Schkuhria pinnata; Scolymus maculatus; Scorzonera sp.; Senecio lividus; Senecio sp.; Senecio vulgaris; Solidago gigantea; Sonchus arvensis; Sonchus asper; Sonchus oleraceus; Sonchus sp.; Tagetes erecta; Tagetes microglossa; Tagetes minuta; Tagetes patula; Tagetes sp.; Taraxacum officinale; Tithonia rotundifolia; Tragopogon dubius; Tragopogon pratensis; Tridax procumbens; Urospermum dalechampii; Vernonia sp.; Xanthium strumarium; Zinnia elegans; Zinnia sp. [0111] Convolvulaceae: Calystegia hederacea; Calystegia sepium; Convolvulaceae sp.; Convolvulus arvensis; Convolvulus hirsutus; Convolvulus scammonia; Convolvulus siculus; Convolvulus sp.; Convolvulus tricolor; Dinetus racemosus; Ipomoea aquatica; Ipomoea arachnosperma; Ipomoea batatas; Ipomoea biflora; Ipomoea cairica; Ipomoea hochstetteri; Ipomoea indica; Ipomoea lacunosa; Ipomoea lobata; Ipomoea nil; Ipomoea purpurea; Ipomoea sp.; Ipomoea tricolor; Ipomoea triloba. [0112] Cornaceae: Cornus alba; Cornus canadensis; Cornus nuttallii; Cornus sp. [0113] Cucurbitaceae: Benincasa hispida; Bryonia alba; Citrullus colocynthis; Citrullus lanatus; Cucumis melo; Cucumis sativus; Cucumis sp.; Cucurbita ficifolia; Cucurbita maxima; Cucurbita moschata; Cucurbita pepo; Cucurbita sp.; Cucurbitaceae sp.; Diplocyclos palmatus; Ecballium elaterium; Lagenaria siceraria; Luffa acutangula; Luff a cylindrica; Momordica charantia; Praecitrullus fistulosus; Sechium edule. [0114] Cupressaceae: Chamaecyparis thyoides; Cupressus sp.; Juniperus arizonica; Juniperus virginiana; Platycladus orientalis. Page 20 of 138 [0115] Cyperaceae: Cyperus esculentus; Cyperus rotundus; Cyperus schimperianus. [0116] Dipterocarpaceae: Shorea robusta. [0117] Ebenaceae: Diospyros kaki; Diospyros scabrida. [0118] Elaeagnaceae: Elaeagnus angustifolia; Elaeagnus umbellata. [0119] Equisetaceae: Equisetum palustre. [0120] Ericaceae: Azalea nudiflora; Azalea sp.; Rhododendron sp.; Siphonandra sp. [0121] Euphorbiaceae: Acalypha australis; Acalypha havanensis; Acalypha sp.; Acalypha wilkesiana; Codiaeum sp.; Codiaeum variegatum; Croton niveus; Croton sp.; Euphorbia amygdaloides; Euphorbia burmanni; Euphorbia helenae; Euphorbia helioscopia; Euphorbia hirta; Euphorbia hypericifolia; Euphorbia parviflora; Euphorbia pulcherrima; Euphorbia sp.; Hevea brasiliensis; Hura crepitans; Jatropha gossypiifolia; Jatropha hastata; Jatropha multifida; Jatropha sp.; Manihot esculenta; Manihot sp.; Mercurialis annua; Mercurialis sp.; Ricinus communis. [0122] Fagaceae: Quercus alba; Quercus robur; Quercus sp. Garryaceae: Aucuba japonica. [0123] Gentianaceae: Eustoma grandiflorum; Gentiana sp. [0124] Geraniaceae: Erodium alnifolium; Geranium carolinianum; Geranium dissectum; Geranium lucidum; Geranium molle; Geranium rotundifolium; Geranium sp.; Pelargonium inquinans; Pelargonium sp. [0125] Gesneriaceae: Saintpaulia ionantha. [0126] Goodeniaceae: Goodenia sp.; Scaevola sp. [0127] Heliconiaceae: Heliconia bihai; Heliconia latispatha. [0128] Hydrangeaceae: Deutzia sp.; Hydrangea macrophylla; Hydrangea paniculata; Hydrangea sp.; Philadelphus coronarius; Philadelphus sericanthus. [0129] Iridaceae: Crocosmia x crocosmiiflora; Gladiolus hortulanus; Gladiolus italicus; Gladiolus sp.; Iris sanguine a; Iris x germanica; Ixiaflexuosa. [0130] Juglandaceae: Carya illinoinensis; Juglans regia; Juglans sp. [0131] Lamiaceae: Ajuga sp.; Ballota africana; Clerodendrum chinense; Clerodendrum thomsoniae; Galeopsis speciosa; Galeopsis tetrahit; Glechoma hederacea; Glechoma sp.; Holmskioldia sanguine a; Holmskioldia sp.; Eamium album; Lamium amplexicaule; Eamium purpureum; Eamium sp.; Lavandula sp.; Leonotis ocymifolia; Leucas martinicensis; Marrubium vulgare; Melissa officinalis; Mentha arvensis; Mentha sp.; Mentha spicata; Mentha x piperita; Moluccella laevis; Monarda fistulosa; Nepeta cataria; Ocimum basilicum; Ocimum tenuiflorum; Perilla frutescens; Rosmarinus officinalis; Salvia argentea; Salvia officinalis; Salvia pratensis; Salvia sp.; Salvia splendens; Salvia verticillata; Salvia viridis; Stachys arvensis; Vitex negundo. [0132] Lauraceae: Cassytha sp.; Endlicheria paniculata; Laurus nobilis; Persea americana. Page 21 of 138 [0133] Leguminosae: Acacia greggii; Acacia horrida; Acacia huarango; Acacia karroo; Acacia robusta; Acacia sp.; Alysicarpus longifolius; Amphicarpaea bracteata; Anthyllis vulneraria; Arachis hypogaea; Arachis sp.; Astragalus sinicus; Bauhinia forficata; Bauhinia monandra; Bauhinia sp.; Bauhinia variegata; Bituminaria bituminosa; Canavalia ensiformis; Caragana arborescens; Cassia artemisioides; Ceratonia siliqua; Cercis siliquastrum; Cicer arietinum; Clianthus sp.; Clitoria ternatea; Coronilla valentina; Crotalaria juncea; Crotalaria micans; Crotalaria sp.; Dalbergia sissoo; Dalea mollis; Desmodium khasianum; Dolichos sp.; Erythrina corallodendron; Erythrina poeppigiana; Erythrina sp.; Genista sp.; Gleditsia sp.; Glycine max; Indigofera arrecta; Indigofera holubii; Indigofera tinctoria; Inga sp.; Kennedia coccinea; Eablab purpureus; Laburnum anagyroides; Laburnum sp.; Lathyrus cicera; Lathyrus odoratus; Lathyrus sativus; Lens culinaris; Lespedeza maximowiczii; Lotus corniculatus; Lupinus arboreus; Lupinus argenteus; Lupinus sativus; Macroptilium atropurpureum; Macroptilium lathyroides; Medicago arabica; Medicago arborea; Medicago lupulina; Medicago orbicularis; Medicago polymorpha; Medicago sativa; Medicago sp.; Melilotus albus; Melilotus indicus; Melilotus sp.; Mucuna membranacea; Mucuna pruriens; Neonotonia wightii; Neorautanenia mitis; Onobrychis viciifolia; Ornithopus sp.; Phaseolus acutifolius; Phaseolus coccineus; Phaseolus lunatus; Phaseolus sp.; Phaseolus vulgaris; Pisum sativum; Psophocarpus tetragonolobus; Pueraria montana; Pueraria phaseoloides; Rhynchosia capitata; Rhynchosia caribaea; Robinia hispida; Robinia pseudoacacia; Sesbania cannabina; Sesbania herbacea; Spartium junceum; Styphnolobium japonicum; Teramnus uncinatus; Tipuana tipu; Trifolium alexandrinum; Trifolium aureum; Trifolium dasyurum; Trifolium dubium; Trifolium glome ratum; Trifolium hybridum; Trifolium incarnatum; Trifolium pratense; Trifolium purpureum; Trifolium repens; Trifolium sp.; Trifolium spumosum; Vicia angustifolia; Vicia faba; Vicia pulchella; Vicia sativa; Vicia sp.; Vicia villosa; Vigna aconitifolia; Vigna angularis; Vigna mungo; Vigna radiata; Vigna sp.; Vigna unguiculata; Wisteria floribunda; Wisteria polystachya; Wisteria sinensis. [0134] Liliaceae: Lilium sp. [0135] Linaceae: Reinwardtia tetragyna. [0136] Lythraceae: Cuphea sp.; Lagerstroemia speciosa; Punica granatum. [0137] Magnoliaceae: Magnolia liliiflora; Magnolia sp.; Magnolia stellata. [0138] Malvaceae: Abelmoschus esculentus; Abutilon pictum; Abutilon reflexum; Abutilon sp.; Abutilon theophrasti; Abutilon tubulosum; Alcea rosea; Althaea nudiflora; Byttneria australis; Ceiba pentandra; Corchorus capsularis; Corchorus olitorius; Gossypium barbadense; Gossypium herbaceum; Gossypium hirsutum; Gossypium sp.; Grewia asiatica; Grewia biloba; Helicteres guazumifolia; Hibiscus lunariifolius; Hibiscus mutabilis; Hibiscus rosa-sinensis; Hibiscus sp.; Page 22 of 138 Hibiscus syriacus; Hibiscus trionum; Malva aegyptia; Malva moschata; Malva neglecta; Malva nicaeensis; Malva parviflora; Malva sp.; Malva sylvestris; Malva trimestris; Malvella leprosa; Sida rhombifolia; Sida sp.; Sterculia murex; Tilia americana; Tilia cordata; Tilia platyphyllos; Tilia rubra; Tilia sp.; Tilia tomentosa; Tilia x euchlora; Triumfetta semitriloba; Waltheria indica. [0139] Marantaceae: Calathea sp.; Maranta sp. [0140] Meliaceae: Azadirachta indica; Melia azedarach; Toona ciliata. [0141] Menispermaceae: Tinospora fragosa. [0142] Moraceae: Artocarpus altilis; Ficus carica; Ficus elastica; Ficus religiosa; Ficus sp.; Morus alba; Morus nigra; Morus rubra; Morus sp. [0143] Moringaceae: Moringa oleifera. [0144] Musaceae: Musa acuminata; Musa basjoo; Musa sp.; Musa x paradisiaca. [0145] Myrtaceae: Eucalyptus grandis; Psidium cattleianum; Psidium guajava; Syzygium cumini. [0146] Nothofagaceae: Nothofagus alpina. [0147] Nyctaginaceae: Bougainvillea spectabilis. [0148] Olacaceae: Ximenia americana. [0149] Oleaceae: Forsythia koreana; Forsythia suspensa; Forsythia x intermedia; Fraxinus angustifolia; Fraxinus excelsior; Fraxinus ornus; Fraxinus sp.; Jasminum humile; Jasminum nudiflorum; Jasminum officinale; Jasminum sambac; Jasminum sp.; Ligustrum lucidum; Ligustrum vulgare; Olea europaea; Osmanthus fragrans; Syringa oblata; Syringa vulgaris. [0150] Onagraceae: Chylismia claviformis; Epilobium angustifolium; Fuchsia magellanica; Fuchsia sp.; Fuchsia x hybrida; Gaura sp.; Oenothera biennis; Oenothera laciniata; Oenothera sp.; Oenothera tetraptera. [0151] Orchidaceae: Catasetum sp.; Cymbidium sp.; Orchidaceae sp.; Papilionanthe teres. Oxalidaceae: Oxalis corniculata; Oxalis debilis; Oxalis europaea; Oxalis floribunda; Oxalis sp. [0152] Papaveraceae: Argemone mexicana; Bocconia frutescens; Chelidonium majus; Chelidonium sp.; Dicentra sp.; Eschscholzia sp.; Fumaria officinalis; Papaver aculeatum; Papaver nudicaule; Papaver orientale; Papaver rhoeas; Papaver somniferum. [0153] Passifloraceae: Passiflora caerulea; Passiflora edulis; Passiflora foetida; Passiflora mollissima; Passiflora sp. [0154] Paulo wniaceae: Paulownia fortunei. [0155] Pedaliaceae: Sesamum indicum. [0156] Phyllanthaceae: Phyllanthus amarus; Phyllanthus sp. [0157] Phytolaccaceae: Petiveria alliacea; Phytolacca americana; Phytolacca dioica; Phytolacca esculenta; Phytolacca icosandra. Page 23 of 138 [0158] Pinaceae: Pinus sylvestris; Tsuga canadensis. [0159] Pittosporaceae: Pittosporum tobira. [0160] Plantaginaceae: Angelonia sp.; Antirrhinum majus; Digitalis purpurea; Hippuris vulgaris; Linaria genistifolia; Mecardonia procumbens; Plantago asiatica; Plantago lanceolata; Plantago major; Plantago sp.; Veronica persica; Veronica sp.; Veronica teucrium. [0161] Platanaceae: Platanus orientalis; Platanus sp. [0162] Plumbaginaceae: Limoniastru guyonianum; Limonium sinuatum; Plumbago auriculata; Plumbago sp. [0163] Poaceae: Aegilops sp.; Agropyron desertorum; Aira sp.; Avena fatua; Avena sativa; Avena sp.; Avena sterilis; Bambusa sp.; Bromus catharticus; Bromus sp.; Chondrosum barbatum; Cynodon dactylon; Dactyloctenium aegyptium; Digitaria argillacea; Digitaria ciliaris; Digitaria diversinervis; Digitaria sanguinalis; Eleusine coracana; Elymus hispidus; Elymus repens; Eragrostis sp.; Festuca arundinacea; Festuca sp.; Helictotrichon pratense; Hordeum sp.; Lolium multiflorum; Lolium sp.; Ophiuros exaltatus; Oryza glaberrima; Oryza sativa; Panicum miliaceum; Panicum sp.; Paspalum dilatatum; Pennisetum clandestinum; Pennisetum purpureum; Phleum pratense; Poa annua; Poa pratensis; Poa trivialis; Poaceae sp.; Rottboellia cochinchinensis; Saccharum officinarum; Setaria pumila; Setaria viridis; Sitanion hystrix; Sorghum bicolor; Sorghum halepense; Sorghum sp.; Stenotaphrum secundatum; Triticum sp.; Zea mays; Zeugites sp. [0164] Polemoniaceae: Phlox Carolina; Phlox paniculata; Phlox sp. [0165] Polygonaceae: Emex australis; Fallopia baldschuanica; Fallopia convolvulus; Persicaria hydropiper; Persicaria longiseta; Persicaria maculosa; Persicaria pensylvanica; Polygonum argyrocoleon; Polygonum aviculare; Rumex acetosa; Rumex acetosella; Rumex crispus; Rumex japonicus; Rumex obtusifolius; Rumex sp. [0166] Pontederiaceae: Eichhornia crassipes. [0167] Portulacaceae: Portulaca oleracea. [0168] Primulaceae: Cyclamen graecum; Cyclamen hederifolium; Cyclamen persicum; Cyclamen sp.; Primula denticulata; Primula polyantha; Primula sp.; Primula veris. [0169] Ranunculaceae: Adonis aestivalis; Anemone coronaria; Anemone hortensis; Aquilegia sp.; Clematis paniculata; Clematis sp.; Delphinium sp.; Helleborus sp.; Ranunculus asiaticus; Thalictrum fendleri. [0170] Resedaceae: Reseda odorata. [0171] Rhamnaceae: Frangula dodonei; Helinus integrifolius; Rhamnus alpina; Rhamnus imeretina; Ziziphus jujuba; Ziziphus spina-christi. Page 24 of 138 [0172] Rosaceae: Alchemilla vulgaris; Armeniaca mume; Cerasus lusitanica; Cerasus serrula; Cerasus vulgaris; Chaenomeles japonica; Chaenomeles sinensis; Cotoneaster horizontalis; Cotoneaster microphyllus; Cotoneaster tomentosa; Crataegus laevigata; Crataegus monogyna; Crataegus sanguinea; Cydonia oblonga; Eriobotrya japonica; Filipendula ulmaria; Fragaria moschata; Fragaria vesca; Fragaria virginiana; Fragaria x ananassa; Geum rivale; Malus domestica; Malus floribunda; Malus pumila; Malus sp.; Marcetella maderensis; Padus avium; Potentilla fragarioides; Potentilla fruticosa; Potentilla norvegica; Potentilla tanacetifolia; Prunus amygdalus; Prunus armeniaca; Prunus avium; Prunus cerasifera; Prunus cerasoides; Prunus cerasus; Prunus domestica; Prunus insititia; Prunus lusitanica; Prunus persica; Prunus salicina; Prunus serotina; Prunus sp.; Prunus spinosa; Pyracantha coccinea; Pyracantha koidzumii; Pyracantha sp.; Pyrus communis; Pyrus pyrifolia; Pyrus sp.; Rosa canina; Rosa cymosa; Rosa hybrida; Rosa multiflora; Rosa odorata; Rosa rugosa; Rosa sp.; Rosa x alba; Rosa x centifolia; Rosa x damascena; Rosa x rugosa; Rubus buergeri; Rubus chaerophyllus; Rubus chingii; Rubus fruticosus; Rubus idaeus; Rubus lloydianus; Rubus occidentalis; Rubus sp.; Rubus ulmifolius; Sorbus aucuparia; Sorbus sp.; Spiraea japonica. [0173] Rubiaceae: Coffea arabica; Coffea abbayesii; Coffea affinis; Coffea alleizettii; Coffea ambanjensis; Coffea ambongenis; Coffea andrambovatensis; Coffea ankaranensis; Coffea anthonyi; Coffea arenesiana; Coffea augagneurii; Coffea bakossii; Coffea benghalensis; Coffea bertrandii; Coffea betamponensis; Coffea bissetiae; Coffea boinensis; Coffea boiviniana; Coffea bonnieri; Coffea brassii; Coffea brevipes; Coffea bridsoniae; Coffea buxifolia; Coffea canephora; Coffea carrissoi; Coffea charrieriana; Coffea cochinchinensis; Coffea commersoniana; Coffea congensis; Coffea costatifructa; Coffea coursiana; Coffea dactylifera; Coffea decaryana; Coffea dubardii; Coffea ebracteolata; Coffea eugenioides; Coffea fadenii; Coffea farafanganensis; Coffea floresiana; Coffea fotsoana; Coffea fragilis; Coffea fragrans; Coffea gallienii; Coffea grevei; Coffea heimii; Coffea homollei; Coffea horsfieldiana; Coffea humbertii; Coffea humblotiana; Coffea humilis; Coffea jumellei; Coffea kapakata; Coffea kianjavatensis; Coffea kihansiensis; Coffea kimbozensis; Coffea kivuensis; Coffea labatii; Coffea lancifolia; Coffea lebruniana; Coffea leonimontana; Coffea leroyi; Coffea liaudii; Coffea liberica; Coffea ligustroides; Coffea littoralis; Coffea lulandoensis; Coffea mabesae; Coffea macrocarpa; Coffea madurensis; Coffea magnistipula; Coffea malabarica; Coffea mangoroensis; Coffea mannii; Coffea manombensis; Coffea mapiana; Coffea mauritiana; Coffea mayombensis; Coffea mcphersonii; Coffea melanocarpa; Coffea merguensis; Coffea millotii; Coffea minutiflora; Coffea mogenetii; Coffea mongensis; Coffea montekupensis; Coffea montis-sacri; Coffea moratii; Coffea mufindiensis; Coffea myrtifolia; Coffea namorokensis; Coffea neobridsoniae; Coffea neoleroyi; Coffea perrieri; Page 25 of 138 Coffea pervilleana; Coffea pocsii; Coffea pseudozanguebariae; Coffea pterocarpan; Coffea racemose; Coffea rakotonasoloi; Coffea ratsimamangae; Coffea resinosa; Coffea rhamnifolia; Coffea richardii; Coffea sahafaryensis; Coffea sakarahae; Coffea salvatrix; Coffea sambavensis; Coffea sapinii; Coffea schliebenii; Coffea semsei; Coffea sessiliflora; Coffea stenophylla; Coffea tetragona; Coffea togoensis; Coffea toshii; Coffea travancorensis; Coffea tricalysioides; Coffea tsirananae; Coffea vatovavyensis; Coffea vavateninensis; Coffea vianneyi; Coffea vohemarensis; Coffea wightiana; Coffea zanguebariae; Galium aparine; Galium stellatum; Gardenia jasminoides; Gardenia sp. [0174] Rutaceae: Choisya ternata; Citrus aurantiifolia; Citrus aurantium; Citrus Clementina; Citrus limon; Citrus maxima; Citrus medica; Citrus paradisi; Citrus reticulata; Citrus sinensis; Citrus sp.; Citrus trifoliata; Ruta graveolens; Zanthoxylum rhoifolium. [0175] Salicaceae: Dovyalis caffra; Populus alba; Populus nigra; Populus sp.; Populus tremula; Populus x canadensis; Salix aegyptiaca; Salix alba; Salix babylonica; Salix caprea; Salix chaenomeloides; Salix dephnoides; Salix fragilis; Salix sp.; Salix viminalis. [0176] Sapindaceae: Acer campestre; Acer negundo; Acer platanoides; Acer pseudoplatanus; Acer rubrum; Acer saccharum; Acer sp.; Aesculus glabra; Dodonaea viscosa; Koelreuteria paniculata; Litchi sinensis; Sapindus sp. [0177] Saxifragaceae: Rodgersia podophylla. [0178] Scrophulariaceae: Buddleja davidii; Buddleja madagascariensis; Diascia sp.; Myoporum sp.; Nemesia sp.; Verbascum blattaria. [0179] Simaroubaceae: Ailanthus altissima. [0180] Solanaceae: Acnistus arborescens; Brugmansia arborea; Brugmansia suaveolens; Brugmansia x Candida; Calibrachoa sp.; Capsicum annuum; Capsicum sp.; Cestrum cyaneum; Cestrum elegans; Cestrum strigillatum; Cyphomandra sp.; Datura metel; Datura sp.; Datura stramonium; Lycium chinense; Nicandra physalodes; Nicotiana glauca; Nicotiana sp.; Nicotiana tabacum; Petunia sp.; Petunia x hybrid; Physalis acutifolia; Physalis alkekengi; Physalis angulata; Physalis lagascae; Physalis peruviana; Salpichroa origanifolia; Solanum aethiopicum; Solanum americanum; Solanum capsicoides; Solanum carolinense; Solanum delagoense; Solanum elaeagnifolium; Solanum grandiflorum; Solanum laciniatum; Solanum lycopersicum; Solanum macrocarpon; Solanum mammosum; Solanum melongena; Solanum muricatum; Solanum nigrum; Solanum panduraeforme; Solanum quitoense; Solanum sp.; Solanum tuberosum; Withania somnifera. [0181] Strelitziaceae: Strelitzia reginae. [0182] Theaceae: Camellia japonica; Camellia sinensis; Camellia sp. Page 26 of 138 [0183] Thymelaeaceae: Dais cotinifolia. [0184] Tropaeolaceae: Tropaeolum majus; Tropaeolum sp. [0185] Ulmaceae: Ulmus americana; Ulmus glabra; Ulmus laevis; Ulmus pumila; Ulmus rubra; Ulmus sp. [0186] Urticaceae: Boehmeria nivea; Laportea aestuans; Parietaria judaica; Parietaria officinalis; Pipturus albidus; Urtica dioica; Urtica sp.; Urtica urens. [0187] Verbenaceae: Aloysia citriodora; Duranta erecta; Glandularia phlogiflora; Lantana camara; Lippia alba; Verbena bracteata; Verbena brasiliensis; Verbena hybrida; Verbena officinalis; Verbena sp. [0188] Violaceae: Viola odorata; Viola sp.; Viola tricolor; Viola x wittrockiana. [0189] Vitaceae: Ampelopsis sp.; Parthenocissus quinquefolia; Parthenocissus tricuspidata; Vitis sp.; Vitis vinifera. [0190] Xanthorrhoeaceae: Hemerocallis fulva; Hemerocallis minor. [0191] Zingiberaceae: Curcuma longa; Zingiber mioga. [0192] Zygophyllaceae: Tribulus terrestris. [0193] In particular embodiments, the LC is from a plant in the plant family Cannabaceae, Rubiaceae, and/or Theaceae. [0194] In particular embodiments, the LC is from a plant in the Cannabaceae family, for example, from a cannabis plant including Cannabis sativa, Cannabis indica, and/or Cannabis ruderalis. [0195] There are hundreds of strains of Cannabis sativa including: Amnesia Haze which is a sativa strain that features up to 25 percent THC with long-lasting body-relaxing and clear-headed effects that are beneficial for dealing with mood problems and tension; Sour Diesel offers 19 percent THC and provides users with an invigorating, yet dreamy cerebral effect; Strawberry Cough has a pungent strawberry scent and tendency to make the consumer cough and contains 24 to 26 percent THC; Jack Herer features between 17 and 18 percent THC and causes users to feel an overwhelming feeling of bliss, giving them a clear head that is ready to tackle a creative project; Tangie or Tangerine Dream is 17 percent THC and provides users with a perfect mix of euphoria and relaxation; Super Lemon Haze is an energizing sativa strain that is 18 percent THC which gives users a jolt of energy after use; and Maui Wowie features sweet pineapple flavors and 18 percent THC giving users a motivated, creative feeling. [0196] In particular embodiments, the LC is from a hops plant including a Humulus plant including Humulus lupulus, Humulus japonicus, Humulus americanus, Humulus cordifolius, Humulus neomexicanus, Humulus pubescens, and/or Humulus scandens. [0197] There are several varieties of hops around the world. American varieties include: Ahtanum Page 27 of 138 brand YCR 1 cv is an aroma-type cultivar used for its moderate bittering (Shop, Brooklyn Brew. "Hop Profile: Ahtanum". Brooklyn Brew Shop); Amarillo brand VGXP01 cv is a mid-range alpha acid variety with a unique and distinct aroma discovered growing "wild" (spontaneously) in a hop yard and developed by Virgil Gamache Farms in the late 20th century; Apollo is characterized by its exceptionally high percentage of alpha acids (15.0 – 19.0%), excellent storage stability of alpha acids, low cohumulone value for an alpha variety (24-28%), and resistance to hop powdery mildew strains found in Washington; Azacca has predominately citrus and tropical fruit notes, including mango, papaya, orange, grapefruit, lemon, piney, spicy, pineapple, grassy, tropical fruit, citrus aromas; Calypso is a dual-purpose high alpha hop with aromas of pear, apple and earthy tea; Cascade is an aroma hop developed by USDA-ARS’s breeding program in 1956 from Fuggle and Serebrianker; Centennial is an aroma-type variety bred in 1974 with a genetic composition of ¾ Brewers Gold, 3/32 Fuggle, 1/6 Golding, 1/32 Bavarian and 1/16 Unknown; Chinook is a green bine cultivar (W-421-38) from Washington State and Idaho that is a cross between a Petham Golding and a USDA-selected male (63012M); Citra brand HBC 394 cv is a registered trademark used with HBC 394 cv special aroma hop variety developed by the Hop Breeding Company (Bernstein, Josh M. (June 17, 2010). “New Hops Breeds”. Imbibe Magazine.); Cluster originated from mass selection of the Cluster hop, which is an old American cultivar; Columbus is a high yielding, high alpha acid American bittering hop known by the trade name Tomahawk; Comet is a rare US grown hop, originally bred for its bittering characteristics; Crystal is an American triploid variety developed in 1993 from Hallertau, Cascade, Brewer’s Gold and Early Green; El Dorado is a high alpha hop developed by CLS Farms; Ekuanot is a high oil content hop known for strong aroma including fruitiness, eucalyptus, clove, and tobacco formerly known as Equinox (“Ekuanot®”. BSG CraftBrewing); Eroica has a pale green bine was bred from Brewers Gold with an open pollination; Galena is a cultivar developed in 1968 from Brewer’s Gold by open pollination in Idaho; Glacier is a low-cohumulone American Fuggle descendant;Greensburg is grown in southern Idaho; Horizon is a high alpha cross made in Oregon in 1970; Liberty is a cross between Hallertauer Mittlefrüh (USDA 21397) and downy mildew resistant male (USDA 64035M); Mount Hood is a variety developed from Hallertau used in styles that require only a subtle hop aroma (German/American lagers); Mount Rainier has a complex parentage, including Hallertau, Galena, Fuggle and other hops, and exhibits some noble hop characteristics, but is higher in alpha acid; Mosaic® (Hop Breeding Company, Yakima, WA) Brand HBC 369 cv is a daughter of the YCR 14 cv hop variety and a Nugget derived male; Newport is a high-alpha bittering hop; Nugget has a floral, resiny aroma and flavor; Palisade brand YCR 4 cv hop variety is an aroma hop that is known for its amazing yield and unique aroma; San Juan Ruby Red was discovered growing wild in the Page 28 of 138 San Juan Mountains of Colorado; Santiam is a floral aroma hop with mid-range alpha acid with a pedigree including Tettnang (mother), Hallertau Mittelfrüh (grandmother) and Cascade (great grandmother); Satus is a bittering-type cultivar produced by Yakima Chief Ranches in Washington State (“Satus Hops | Where legends are made”. Beerlegends.com); Simcoe brand YCR 14 cv is an aroma variety known for its versatility and unique characteristics with several different aromas including passion fruit, pine, earthy, and citrus; Sonnet Golding is a low alpha American-grown Golding variety; Sterling is a floral hop which is a cross between Saaz and Mount Hood in character but easier to grow; Summit is useful for barleywines, stouts and IPAs with alpha acids of 17–19% and beta acids of 4.0–6.0%; Tomahawk is the trade name for Columbus; Ultra is a triploid aroma-type cultivar that is a cross between the colchicine-induced tetraploid Hallertau mf (USDA 21397) and the diploid Saazer-derived male genotype (USDA 21237m); Vanguard is an aroma cross developed from Hallertau in 1982; Warrior brand YCR 5 cv hop variety is an alpha hop used for its mild, clean bittering qualities; Willamette is an American development in 1976 of the English Fuggle ("KSWbeer.com: Ahtanum Hops". www.kswbeer.com); Zeus is an aromatic high-alpha hop; and Zythos is a blend of Simcoe, Citra, Palisade and Amarillo, having distinct tropical (pineapple) and citrus tones, with slight pine characteristics. [0198] British hop varieties include: Admiral is a bittering hop used in some English ales; Boadicea is a spicy, light, floral hop suitable for finishing and dry hopping; Bramling Cross is a cross between the Bramling goldings variety and a wild Canadian Manitoban hop; Brewer’s Gold is a bittering hop with a resiny, spicy aroma/flavor with hints of black currant; Bullion is a bittering hop with a resiny/earthy aroma/flavor; Challenger is used in many traditional English Bitters with pleasant and complex marmalade/toffee/citrus flavor, which enhances strong ales; First Gold is the first English commercial grown dwarf hop, released in 1995 and bred by Wye College in Kent; Fuggle is a classic English aroma hop which is known as Styrian Goldings in Europe and is a parent of many New World hops such as Cascade, Centennial and Willamette; Goldings are a group of related clones that harvest at different times such as Cobbs, Amos’ Early Bird, Eastwell, Mathon, East Kent and historical clones such as Bramling, Canterbury, Rodmersham and Petham (“Goldings” British Hop Association, www.britishhops.org.uk/varieties/goldings); Herald is an English aroma and bittering hop; Northdown is a dual purpose hop in England developed in the 1970s; Northern Brewer is a cross between a Canterbury Golding female plant and the male plant OB21 (“Northern Brewer Hops”. www.brew-dudes.com; and “YC Hop Varieties”. www.yakimachief.com); Phoenix is a dual-purpose English hop with a mild aroma and slightly spicy flavor (“Phoenix Hops”. www.brew-dudes.com/phoenix-hops/179); Pilgrim was bred at the Horticulture Research International in Wye, England. Released 2000. Dual purpose with lemon Page 29 of 138 tones; Pilot was previously known as S24; Pioneer is an English hop with distinct bitter lemon flavor; Progress is an English hop developed in the 1960s as a replacement for Fuggle; Target is an English mid-to-high alpha hop bred from Kent Goldings; and Whitbread Golding Variety (WGV) was bred in 1911 from open pollination of Bates Brewer. [0199] German hop varieties include: Hallertauer Magnum is a high alpha acid type cultivar bred from the American variety Galena with a German male hop (75/5/3); Hallertauer Merkur was bred from a cross between Hallertaur Magnum and variety 81/8/13 (“Merkur Hops | Where legends are made”. Beerlegends.com); Hallertauer Taurus is a high to super-high alpha bittering hop (“Hallertauer Taurus” Hopsteiner. Web.archive.org/web/20030514092954/www.hopsteiner.com/ pdf/bracte/HallertauerTaurus.PDF); Hallertauer Tradition was bred in 1991 for resistance to disease; Herkules is a cross between Hallertauer Taurus and a powdery mildew resistant Hüll male breeding line; Huell Melon is an aroma hop variety featuring fruity honeydew melon and apricot aroma (“Annual Report 2013 – Special Crop: Hops”. Bavarian State Research Center for Agriculture (LfL). March 2014. P. 45.; and Lutz, Anton; Kammhuber, Klaus; Seigner, Elisabeth (2012). “New Trend in Hop Breeding at the Hop Research Center Huell”. BrewingScience. 65 (3/4): 24–32); Mandarina Bavaria is an aroma hop variety featuring fruity mandarin orange and citrus aroma (“Annual Report 2013 – Special Crop: Hops” Bavarian State Research Center for Agriculture (LfL). March 2014. P. 45.; and Lutz, Anton; Kammhuber, Klaus; Seigner, Elisabeth (2012). “New Trend in Hop Breeding at the Hop Research Center Huell”. BrewingScience. 65 (3/4): 24–32); Opal has a sweet spice, slightly peppery aroma and flavor combined with a light, clean citrus fruit aroma (“Opal”. Hopslist); Perle is a dual-purpose hop with spicy and slightly floral/fruity; Polaris is an aroma hop variety with high bittering potential and fruity/spicy, fresh aroma reminiscent of mint and menthol (“Annual Report 2012 – Special Crop: Hops”. Bavarian State Research Center for Agriculture (LfL). March 2013; “Annual Report 2013 – Special Crop: Hops”. Bavarian State Research Center for Agriculture (LfL). March 2014. P.45; and Lutz, Anton; Kammhuber, Klaus; Seigner, Elisabeth (2012). “New Trend in Hop Breeding at the Hop Research Center Huell”. BrewingScience. 65 (3/4): 24–32); Saphir shares many characteristics with the Hallertauer Mittelfrüh; Smaragd is a mid-alpha hop with fruity, floral characteristic; and Spalter Select is a disease-resistant Hallertauer and Spalt pale lager variety developed in the early 1990s. [0200] Other European hop varieties include: Aalst is a Belgian variety (Lacambre, G. Traité de la Fabrication des Bières et de la Distillation des Grains, etc. Vol.1.1851); Aramis is a French hop used for bittering and aroma (“Alsace Aramis Hop – Aramis Hops for sale – Comptoir Agricole”); Bor is a hybrid of Saaz and Northern Brewer (“Bor”. Hopsteiner. Page 30 of 138 Web.archive.org/web/20040706065911/ www.hopsteiner.com/pdf/bract/Bor.pdf); Coigneau is a Belgian hop with low bitterness; Iunga is a variety from IUNG Puławy (“Global Hops – Hops Varieties”); Lublin is a Polish grown Saaz, used in Polish lagers; Marynka is a bittering hop with an earthy, licorice quality; Poperinge is a Belgian variety mentioned for its use in Lambic beer in the early 19th century (Lacambre, G. Traité de la Fabrication des Bières et de la Distillation des Grains, etc. Vol. 1. 1851); Premiant is a high-alpha Saaz variant. Gives similar spicy aroma qualities ("Premian". Hopsteiner. web.archive.org/web/20050223031436/ www.hopsteiner.com/ pdfbracte/Premiant.pdf); Sladek is a hybrid of Northern Brewer, Osval’s close No.126 and Czech male components. Similar to Czech Saaz “Sladek”. Hopsteiner. web.archive.org/web/20050223035515/www.hopsteiner.com/pdfbracte/Sladek.pdf); Strisselspalt is a French aroma hop from Alsace, used mostly in pale lagers; Styrian Atlas is a diploid hybrid between Brewers Gold and 3/3 Slovenian wild hop; Styrian Aurora is a diploid hybrid between Northern Brewer and a TG seedling of unknown origin (Taish, Bostjan. “Aurora Data Sheet”); Styrian Bobek is a delicate, spicy aroma hop (Taish, Bostjan. “Bobek Data Sheet”); Styrian Celeia gives a pleasant hoppy aroma similar to other “Super Styria” varieties (Taish, Bostjan. “Celeia Data Sheet”); Styrian Golding is a Slovenian variant used in English ales and Belgian strong ales; Sybilla is a variety from IUNG Puławy which is registered as a bittering hop but has aroma characteristics (“Global Hops – Hops Varieties”); Tardif de Bourgogne is a French hop, used as an aromatic in continental lagers; and Tomyski is a Polish variety used as an aroma hop. [0201] Noble hop varieties include: Hallertau or Hallertauer Mittelfrüh was the original German lager hop; Hersbrucker used in German pale lagers; Saaz used to flavor pale Czech lagers; Tettnanger used in European pale lagers and wheat beers; and Spalt which is has a woody taste. [0202] Australian hop varieties include: Ella is a high alpha variety formerly known as Stella with breeding code 01-220-060 (“Ell”. Hop Products Australia); Enigma is a high alpha variety typically 16–19% which is decedent from the Swiss Tettnang hop (“Hop Products Australia » Enigma™); Feux-Coeur Francais has its genetic roots in the Burgundy region of France; Galaxy is a high alpha dual purpose triploid cultivar with a marked and unique hop aroma, described as a combination of citrus and passionfruit bred by crossing a female tetraploid (J78) with a male derived from Perle (“Hop Products Australia > Products > Australian Varieties > Galaxy”. Hops.com.au); Pride of Ringwood is a hops used by Australian brewer Carlton and United Breweries to bitter all of its beers; Summer is a low alpha Australian aroma variety with breeding code 97-235-026 (“Hop Products Australia > Products > Australian Varieties > Summer”. Hops.com.au); Super Pride is a high alpha version of Pride of Ringwood, bred by crossing a female tetraploid Pride of Ringwood with a male YK¬81¬18 (“"Hop Products Australia > Products Page 31 of 138 > Australian Varieties > Super Pride”. Hops.com.au); Topaz is a high alpha Australian variety bred by crossing a female Tetraploid J78 with a male 29/70/54; and Vic Secret is a hop with breeding code 00-207-013. [0203] New Zealand hop varieties include: Green Bullet is a triploid Alpha Variety bred by open cross-pollination of the New Zealand “Smoothcone” variety (“New Zealand Hops Limited- Supplier of hops, commercial brewing supplies, home brewing supplies, spray free and organic Bio-Gro hops”. Nzhops.co.nz); Hallertau Aroma/Wakatu was released commercially from Hort’s Riwaka Research Centre in 1988 (“New Zealand Hops Limited- Supplier of hops, commercial brewing supplies, home brewing supplies, spray free and organic Bio-Gro hops”. Nzhops.co.nz); Kohatu is a mid-alpha variety with aromas of pine needles and tropical fruit; Motueka was bred by crossing a New Zealand breeding selection (2/3) with Saazer parentage (1/3) (“New Zealand Hops Limited –- Supplier of hops, commercial brewing supplies, home brewing supplies, spray free and organic Bio-Gro hops”. Nzhops.co.nz); Nectaron is a triploid aroma type developed in collaboration with New Zealand’s Plant & Food Research (“NZ Hops reunites with Plant & Food for hop research”. Brews News.2020-10-23; and “NZ hops capturing world attention”. NZ Herald.); Nelson Sauvin is a variety developed in Nelson, New Zealand in 1987 and commercially available since 2000 (Beatson/Ansell/Graham: “Breeding, development, and characteristics of the hop (Humulus lupulus) cultivar ‘Nelson Sauvin’, New Zealand Journal of Crop and Horticultural Science, 2003, Vol.31: 303-309); New Zealand Cascade was bred from crossing an English Fuggle with a male selection believed to have been a crossing of Fuggle with the Russian variety Serebrianka; Pacifica was previously known as the Pacific Hallertau; Pacific Gem is a triploid Alpha type bred from the New Zealand variety “Smoothcone” crossed with Californian Late Cluster x Fuggle (“New Zealand Hops Limited– Supplier of hops, commercial brewing supplies, home brewing supplies, spray free and organic Bio-Gro hops”. Nzhops.co.nz); Pacific Jade is a high alpha bittering hop from New Zealand with a soft bitterness; Rakau is a dual purpose variety typically with alpha acid above 10% and cohumulone less than 25% of alpha acids; Riwaka is a triploid aroma type bred by crossing “Old Line” Saazer with specially developed New Zealand breeding selections; Southern Cross is a mellow bittering hop with high alpha of 11.0–14.0%; Sticklebract is a triploid variety with aroma of pine and citrus; Super Alpha is a triploid variety bred from the New Zealand Smoothcone variety cross open pollinated at the New Zealand Horticultural Research Centre (now known as HortResearch) and released in 1976 (New Zealand Hops Limited - Supplier of hops, commercial brewing supplies, home brewing supplies, spray free and organic Bio-Gro hops”. Nzhops.co.nz); Wai-iti is a low-alpha variety with a strong citrus character of mandarin, lemon and lime zest; and Waimea is a granddaughter of Pacific Jade and bracteolated on dual Page 32 of 138 purpose capability. [0204] A Japanese hop includes Sorachi Ace which is a dual-purpose hop with a lemon, bubblegum, and dill pickle flavor. [0205] An ornamental hop includes Golden hops which is a pale, ornamental variety, Humulus lupulus ‘Aurea’, and is cultivated for garden use. [0206] In particular embodiments, the LC is from the Rubiaceae family and is a Coffea plant including Coffea abbayesii, Coffea affinis, Coffea alleizettii, Coffea ambanjensis, Coffea ambongenis, Coffea andrambovatensis, Coffea ankaranensis, Coffea anthonyi, Coffea arabica, Coffea arenesiana, Coffea augagneurii, Coffea bakossii, Coffea benghalensis, Coffea bertrandii, Coffea betamponensis, Coffea bissetiae, Coffea boinensis, Coffea boiviniana, Coffea bonnieri, Coffea brassii, Coffea brevipes, Coffea bridsoniae, Coffea buxifolia, Coffea canephora, Coffea carrissoi, Coffea charrieriana, Coffea cochinchinensis, Coffea commersoniana, Coffea congensis, Coffea costatifructa, Coffea coursiana, Coffea dactylifera, Coffea decaryana, Coffea dubardii, Coffea bracteolatea, Coffea eugenioides, Coffea fadenii, Coffea farafanganensis, Coffea floresiana, Coffea fotsoana, Coffea fragilis, Coffea fragrans, Coffea gallienii, Coffea grevei, Coffea heimii, Coffea homollei, Coffea horsfieldiana, Coffea humbertii, Coffea humblotiana, Coffea humilis, Coffea jumellei, Coffea kapakata, Coffea kianjavatensis, Coffea kihansiensis, Coffea kimbozensis, Coffea kivuensis, Coffea labatii, Coffea lancifolia, Coffea lebruniana, Coffea leonimontana, Coffea leroyi, Coffea liaudii, Coffea liberica, Coffea ligustroides, Coffea littoralis, Coffea lulandoensis, Coffea mabesae, Coffea macrocarpa, Coffea madurensis, Coffea magnistipula, Coffea malabarica, Coffea mangoroensis, Coffea mannii, Coffea manombensis, Coffea mapiana, Coffea mauritiana, Coffea mayombensis, Coffea mcphersonii, Coffea melanocarpa, Coffea merguensis, Coffea millotii, Coffea minutiflora, Coffea mogenetii, Coffea mongensis, Coffea montekupensis, Coffea montis-sacri, Coffea moratii, Coffea mufindiensis, Coffea myrtifolia, Coffea namorokensis, Coffea neobridsoniae, Coffea neoleroyi, Coffea perrieri, Coffea pervilleana, Coffea pocsii, Coffea pseudozanguebariae, Coffea pterocarpan, Coffea racemose, Coffea rakotonasoloi, Coffea ratsimamangae, Coffea resinosa, Coffea rhamnifolia, Coffea richardii, Coffea sahafaryensis, Coffea sakarahae, Coffea salvatrix, Coffea sambavensis, Coffea sapinii, Coffea schliebenii, Coffea semsei, Coffea sessiliflora, Coffea stenophylla, Coffea tetragona, Coffea togoensis, Coffea toshii, Coffea travancorensis, Coffea tricalysioides, Coffea tsirananae, Coffea vatovavyensis, Coffea vavateninensis, Coffea vianneyi, Coffea vohemarensis, Coffea wightiana, and/or Coffea zanguebariae. [0207] In particular embodiments, a LC is from the Theaceae family and is a tea plant including Camellia sinensis. The variants of Camellia sinensis include Camellia sinensis var. sinensis, Page 33 of 138 Camellia sinensis var. assamica, Camellia sinensis var. pubilimba, or Camellia sinensis var. dehungensis. In particular embodiments, tea varieties include black tea, green tea, white tea, oolong tea, pu-erh tea, and purple tea which are all made from the Camellia sinensis tea plant. Camellia sinensis var. sinensis grows primarily in China and other East Asian countries and has a milder, mellower character, and Camellia sinensis var. assamica grows primarily in India and is generally heartier and more robust. Other varieties include Camellia sinensis var.^pubilimba and^Camellia sinensis.^var.^dehungensis (in T, Bartholomew B. “"18. Theaceae”". Flora of China.^12). [0208] In particular embodiments, a LC is from the Zingiberaceae family and is a turmeric plant including Curcuma longa. [0209] In particular embodiments, a LC is a first LC that is chosen for an intended physiological effect (e.g., the first LC is an active compound or an active ingredient). In particular embodiments, a first LC includes a cannabinoid; α-acids (e.g., humulone, cohumulone, adhumulone, posthumulone, prehumulone, adprehumulone) β-acids (e.g.,lupulone, colupuloe, adlupulone, prelupulone, postlupulone), or flavonoids (e.g., xanthohumol, or xanthan humulone) from a hops plant; tryptophan alkaloids or diterpenes from a coffee plant; resveratrol, or proanthocyanidins from a tea plant; or coenzyme Q10 (ubiquinone or ubiquinol), plastoquinone, plastoquinonol, or other fat-soluble electron transport chain components found in the mitochondria of plants (and all respiring eukaryotic cells). [0210] In particular embodiments, a LC can come from multiple plant types. For example, resveratrol can be found in tea but can also be found in peanuts, grapes, wine, and soy. [0211] As used herein, the term “cannabinoid” is generally understood to include any chemical compound that acts upon a cannabinoid receptor. For instance, cannabinoids may include endocannabinoids (i.e., produced naturally by humans and animals), phytocannabinoids (i.e., found in cannabis and some other plants), and artificial cannabinoids (i.e., manufactured and not naturally occuring). [0212] Examples of cannabinoids include cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabigerol monomethylether (CBGM), cannabigerovarin (CBGV), cannabichromene (CBC), cannabichromevarin (CBCV), cannabidiol monomethylether (CBDM), cannabidiol-C4 (CBD-C4), cannabidivarin (CBDV), cannabidiorcol (CBD-C1), Δ-9- tetrahydrocannabinol (d9-THC), Δ-9- tetrahydrocannabinolic acid A (THCA-A), Δ-9- tetrahydrocannabionolic acid B (THCA-B), Δ-9-tetrahydrocannabinolic acid-C4 (THCA-C4), Δ-9- tetrahydrocannabinol-C4, Δ-9-tetrahydrocannabivarin (THCV), Δ-9-tetrahydrocannabiorcol (THC-C1), Δ-7-cis-iso tetrahydrocannabivarin, Δ-8-tetrahydrocannabinol (d8-THC), cannabicyclol Page 34 of 138 (CBL), cannabicyclovarin (CBLV), cannabielsoin (CBE), cannabinol (CBN), cannabinol methylether (CBNM), cannabinol-C4 (CBN-C4), cannabivarin (CBV), cannabinol-C2 (CBN-C2), cannabiorcol (CBN-C1), cannabinodiol (CBND), cannabinodivarin (CBVD), cannabitriol (CBT), 10-ethoxy-9hydroxy-Δ-6a-tetrahydrocannabinol, 8,9-dihydroxy-Δ-6a- tetrahydrocannabinol, cannabitriolvarin (CBTV), ethoxy-cannabitriolvarin (CBTVE), dehydrocannabifuran (DCBF), cannabifuran (CBF), cannabichromanon (CBCN), cannabicitran (CBT), 10-oxo-Δ-6a- tetrahydrocannabionol (OTHC), Δ-9-cis-tetrahydrocannabinol (cis-THC), 3,4,5,6-tetrahydro-7- hydroxy-α-α-2-trimethyl-9-n-propyl-2, 6-methano-2H-l- benzoxocin-5-methanol (OH-iso-HHCV), cannabiripsol (CBR), trihydroxy-Δ-9- tetrahydrocannabinol (triOH-THC), cannabinol propyl variant (CBNV), cannabidiolic acid (CBDA), cannabitriol (CBO), and tetrahydrocannabivarinic acid (THCVA) and derivatives thereof. Further examples of cannabinoids are discussed in PCT Patent Application Pub. No. WO2017/190249 and U.S. Patent Application Pub. No. US2014/0271940. [0213] The term “derivative” in chemistry refers to a compound that is obtained from a similar compound or a precursor compound by a chemical reaction. [0214] Examples of cannabinoids that can be synthetically produced include: naphthoylindoles, naphthylmethylindoles, naphthoylpyrroles, naphthylmethylindenes, phenylacetylindoles, cyclohexylphenols, tetramethylcyclopropylindoles, adamantoylindoles, indazole carboxamides, and quinolinyl esters. Derivatives of natural cannabinoids can include metabolites of cannabinoids which are disclosed in WO 2015/198078. For example, the metabolite of CBD includes 7-OH- CBD and the metabolite of CBDV includes 7-OH-CBDV. In particular embodiments, examples of cannabinoids include 3-carbamoyl-2-pyridone, and its derivatives and/or analogs disclosed in US 2008/0103139; pyrimidine derivatives and/or analogs disclosed in US 2006/0293354; carenadiol and its derivatives and/or analogs thereof disclosed in US 4,758,597; cannabinoid carboxylic acids and their derivatives and/or analogs disclosed in WO 2013/045115; pyrido[3,2- E][1,2,4]triazolo[4,3-C]pyrimidine and its derivatives and/or analogs disclosed in WO 2008/118414; tetrahydro-pyrazolo[3,4-C] pyridine and its derivatives and/or analogs disclosed in WO 2007/112399; bicyclo[3.1.1]heptan-2-one cannabinoid and its derivatives and/or analogs disclosed in WO 2006/043260; resorcinol and its derivatives and/or analogs disclosed in WO 2005/0123051; dexanabinol compounds and their derivatives and/or analogs disclosed in WO 2004/050011; cannabimimetic lipid amide compounds and their derivatives and/or analogs disclosed in WO 2000/032200; nabilone and its derivatives and/or analogs disclosed in US 2010/0168066; 2-oxoquinolone compounds and their derivatives and/or analogs disclosed in US 2003/0191069; and 3,4-diaryl-4,5-dihydro-(h)-pyrazole-1-carboxamide and its derivatives and/or analogs disclosed in US 2011/0137040. Page 35 of 138 [0215] In particular embodiments, 3-carbamoyl-2-pyridone and its derivatives and/or analogs include methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro- cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; dimethyl 2-[(1-cyclohexylmethyl-5,6-dimethyl- 2-oxo-1,2-dihydropyridine-3-carbonyl)-amino]-succinate; and methyl 2-{[1-(3-methoxycarbonyamino-propyl)-2-oxo-1,2,5,6,7,8,9,10-octahydro- cycloocta[b]pyridine-3-carbonyl]-amino}-2-methyl-propionate. [0216] In particular embodiments, pyrimidine derivatives and/or analogs include a compound having Formula (I) (2-((2,4-dichlorophenyl)amino)-N-((tetrahydro-2H-pyran-4-yl)methyl)-4- (trifluoromethyl)pyrimidine-5-carboxamide), .

Other pyrimidine derivatives and/or analogs include 2-(3-Chlorophenylamino)-4- trifluoromethylpyrimidine-5-carboxylic acid cyclohexylmethyl-amide; 2-Phenylamino-4- trifluoromethylpyrimidine-5-carboxylic acid cyclohexylmethyl-amide; 1-[2-(2,3- Dichlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-1-morphol-in-4-yl-methanone; 1-[2-(2,4- Dichlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-1-morphol-in-4-yl-methanone; and 2-(3- Chlorophenylamino)-4-trifluoromethylpyrimidin-5-carboxylic acid cyclopentylamide. [0217] In particular embodiments, carenadiol and its derivatives and/or analogs include compounds having Formula (II), Page 36 of 138 , wherein R is a lower alkyl having 1 to 9 carbon atoms including isomeric forms such as i-butyl, n- butyl, and t-butyl. In particular embodiments, R is C₅H₁₁ or 1,1-dimethylheptyl. [0218] In particular embodiments, cannabinoid carboxylic acids and their derivatives and/or analogs include compounds having Formula (III), (IV), (V), or (VI), , ,

Page 37 of 138

or , wherein: R¹ is a straight-chain, branched or cyclic hydrocarbon residue with one C atom to 12 C atoms; and X⁺ is NH₄ ⁺, mono-, di- or trivalent metal ions; or primary, secondary, tertiary or quaternary organic ammonium ions with up to 48 C atoms, which may bear still further functional groups. [0219] Examples of multivalent ammonium ions include N,N-dicyclo-hexylamine-H⁺ and N,N- dicyclohexyl-N-ethylamine-H⁺. X⁺ can also be the hydrogen cation of a physiologically active substance with at least one basic nitrogen atom, such as for example morphine, methadone (or an enantiomer thereof) or hydromorphone. [0220] In particular embodiments, pyrido[3,2-E][1,2,4]triazolo[4,3-C]pyrimidine and its derivatives and/or analogs include 5-tert-butyl-8-(2-chlorophenyl)-9-(4-chlorophenyl)pyrido[3,2- e][1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one; 8-(4-bromo-2-chlorophenyl)-5-tert-butyl-9-(4- chlorophenyl)pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one; 5-fert-butyl-9-(4- Page 38 of 138 chlorophenyl)-8-(2-methylphenyl)pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one; 9-(4- bromophenyl)-5-tert-butyl-8-(2-chlorophenyl)pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-3(2H)- one; and 5-tert-butyl-8-(2-chlorophenyl)-9-(4-chlorophenyl)pyrido[3,2-e][l,2,4]triazolo[4,3- c]pyrimidine. [0221] In particular embodiments, tetrahydro-pyrazolo[3,4-C] pyridine and its analogs and/or derivatives include compounds having Formula (VII), (VIII), (IX), (X), or (XI), ,

Page 39 of 138

, , Page 40 of 138

or . [0222] In particular embodiments, bicyclo[3.1.1]heptan-2-one cannabinoids and their derivatives and/or analogs include compounds having Formula (XII), Page 41 of 138

, having a specific stereochemistry wherein C-4 is S, the protons at C-1 and C-5 are cis in relation to one another and the protons at C-4 and C-5 are trans; and wherein: R₁ is (a) O or S; (b) C(R')₂ wherein R' at each occurrence is independently selected from the group consisting of hydrogen, cyano, -OR", -N(R")₂, a saturated or unsaturated, linear or branched C₁- C₆ alkyl, C₁-C₆ alkyl-OR" or C₁-C₆alkyl-N(R")₂ wherein at each occurrence R" is independently selected from the group consisting of hydrogen, C(O)R'", C(O)N(R'")₂, C(S)R'", saturated or unsaturated, linear or branched C₁-C₆ alkyl, C₁-C₆ alkyl-OR'", and C₁-C₆ alkyl-N(R'")₂, wherein at each occurrence R'" is independently selected from the group consisting of hydrogen or saturated or unsaturated, linear, branched or cyclic C_1-C₁₂alkyl; or (c) NR" or N-OR" wherein R" is as previously defined; R₂ and R₃ are each independently (a) -R", -OR", -N(R")₂, -SR", -S(O)(O)NR", wherein at each occurrence R" is as previously defined;(b) -S(O)R^b, -S(O)(O)R^b wherein R^b is selected from the group consisting of hydrogen, saturated or unsaturated, linear or branched C₁-C₆alkyl, C₁-C₆alkyl- OR", and C₁-C₆alkyl-N(R")₂, wherein R" is as previously defined; or (c) -OC(O)OH, -OS(O)(O)OR^e, -OP(O)(OR^e)₂, -OR^d or -OC(O)-R^d chain terminated by -C(O)OH, -S(O)(O)OR^e, or -P(O)(OR^e)₂, wherein R^d is a saturated or unsaturated, linear or branched C₁-C₆ alkyl and R^e is at each occurrence selected from the group consisting of hydrogen and R^d as previously defined; and R₄ is (a) R wherein R is selected from the group consisting of hydrogen, halogen, OR'", OC(O)R'", C(O)OR'", C(O)R'", OC(O)OR'", CN, N(R'")₂, NC(O)R'", NC(O)OR'", C(O)N(R"')₂, NC(O)N(R"')₂, and SR'", wherein at each occurrence R'" is as previously defined; (b) a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl-R wherein R is as previously defined; (c) an aromatic ring which can be further substituted at any position by R wherein R is as previously defined; or (d) a saturated or unsaturated, linear, branched or cyclic C₁-C₁₂ alkyl optionally terminated by an aromatic ring which can be further substituted as defined in (c). [0223] In particular embodiments, resorcinol and its derivatives and/or analogs include Page 42 of 138 compounds having Formula (XIII), , wherein:

R¹ is (a) straight or branched alkyl chain of 7 to 12 carbon atoms; (b) -O-R³, where R³ is a straight or branched alkyl chain of 5 to 9 carbon atoms, optionally substituted by one phenyl group; or (c) -(CH₂)_n-O-R⁴, where n is an integer from 1 to 7, and R⁴ is a straight alkyl chain of 1 to 5 carbon atoms; and R² is a non-cyclic terpenoid including from 10 to 30 carbon atoms. [0224] In particular embodiments, resorcinol and its derivatives and/or analogs include compounds having Formula (XIII), wherein R¹ and R² are as follows: R¹ is a straight alkyl chain of 5 to 8 carbon atoms, optionally substituted with one methyl group; and R² is selected from geranyl optionally substituted with one -OH, and farnesyl optionally substituted with one -OH. [0225] In particular embodiments, resorcinol and its derivatives and/or analogs include compounds having Formula (XIII), wherein: R¹ is (a) straight or branched alkyl chain of 7 to 12 carbon atoms; (b) -O-R³, where R³ is a straight or branched alkyl chain of 5 to 9 carbon atoms, optionally substituted by one phenyl group; or (c) -(CH₂)_n-O-R⁴, where n is an integer from 1 to 7, and R⁴ is a straight alkyl chain of 1 to 5 carbon atoms; and R² is a non-cyclic terpenoid including from 10 to 30 carbon atoms; with the proviso that when R¹ is isononyl, R² is not geranyl. [0226] In particular embodiments, resorcinol and its derivatives and/or analogs include compounds having Formula (XIII), wherein R¹ is (a) a straight or branched alkyl of 7 to 12 carbon atoms; (b) a group -O-R³, where R³ is a straight or branched alkyl of 5 to 9 carbon atoms, or a straight or branched alkyl substituted at the terminal carbon atom by a phenyl group; or (c) a group -(CH₂)_n-O-alkyl, where n is an integer from 1 to 7 and the alkyl group contains 1 to 5 carbon atoms. [0227] In particular embodiments, resorcinol and its derivatives and/or analogs include compounds of Formula (XIII), wherein R² is a non-cyclic terpenoid carbon chain such as geranyl, Page 43 of 138 farnesyl, and related non-cyclic terpenes and their isomers as well as other non-cyclic paraffinic or olefinic carbon chains. [0228] In particular embodiments, resorcinol and its derivatives and/or analogs include compounds of Formula (XIII), wherein R¹ is dimethylheptyl and R² is geranyl. [0229] In particular embodiments, dexanabinol compounds and their derivatives and/or analogs include high enantiomeric purity compounds having Formula (XIV), ,

and having the (3S, 4S) configuration and being in enantiomeric excess of at least 99.90% over the (3R,4R) enantiomer. [0230] In particular embodiments, cannabimimetic lipid amide compounds and their derivatives and/or analogs include compounds having Formula (XV), ,

wherein: X is one of the group consisting of C = O and NH, and Y is the other of that group. Expressed another way, X may be C = O and Y may be NH, or Y may be C = O and X may be NH, but both X and Y may not be the same group. R₁ is H or an alkyl group. In particular embodiments, R₁ is H, CH₃, or (CH₃)₂; R₂ is an alkyl, a substituted alkyl, an alkenyl or an alkynyl group. In particular embodiments, R₂ is Page 44 of 138 CH(R) CH₂Z, CH₂CH(R)Z, or CH(R)(CH₂)nCH₂Z; R being H, CH, CH_3, CHCH, CH₂CF₃, or (CH₃)_2; Z being H, halogen, N₃, NCS, or OH; and n being selected from the group consisting of 0, 1 and 2. R₃ is an alkyl, a substituted alkyl, an aryl, an alkylaryl, an O-alkyl, an O-alkylaryl, a cyclic and a heterocyclic group. O-alkyl and O-alkylaryl refer to groups in which an oxygen atom is interposed between carbon atoms on the anandamide portion and substituent group. Examples of such R₃ groups include cyclohexyl, cyclopentyl, alkylcyclohexyl, alkylcyclopentyl, piperidinyl, morpholinyi and pyridinyl. In particular embodiments, R₃ is n-C₅H₁₀Z', n-C₆H₁₂Z', n-C₇H₁₄Z', or 1 ', 1 '- C(CH₃)₂(CH₂)₅ CH₂Z'; Z' being H, halogens, CN, N₃, NCS, or OH. [0231] In particular embodiments, cannabimimetic lipid amide compounds and their derivatives and/or analogs include compounds having Formula (XVI), ,

wherein: Y is one of the group consisting of C = O and NH and X is the other of that group. R₁ is H or an alkyl group. In particular embodiments, R₁ is H, CH₃, or (CH₃)₂. R₂ is an alkyl, a substituted alkyl, an alkenyl, an alkynyl, an O-alkyl, a cyclic, a polycyclic, or a heterocyclic group. In particular embodiments, R₂ is ,

Page 45 of 138 ; C(CH₃)₂, C≡CH, CH₂OCH₃, CH(R)(CH₂)nCH₂Z, or CH₂CH(R)( CH₂)nZ; R being H, C ₃ or ( C ₃)_2; Z being H, halogens, N₃, NCS, OH, or OAc; and n 0, 1, or 2; and R₃ is an alkyl, a substituted alkyl, an aryl, an alkylaryl, an O-alkyl, an O-alkylaryl, a cyclic, or a heterocyclic group. In particular embodiments R₃ includes cyclohexyl, cyclopentyl, alkylcyclohexyl, alkylcyclopentyl, piperidinyl, morpholinyi and pyridinyl. In particular embodiments, R₃ is n-C₅H₁₀Z', n-C₆H₁₂Z', n-C₇H₁₄Z', or 1',1'-C(CH₃)₂CH₂)₅ CH₂Z'; Z' being H, halogen, CN, N₃, NCS, or OH. [0232] In particular embodiments, nabilone and its derivatives and/or analogs include compounds having Formula (XVII):

wherein: R¹-R³⁶ are independently selected from the group consisting of hydrogen and deuterium. Nabilone derivatives and/or analogs can refer to compounds wherein at least one of R¹-R³⁶ includes deuterium. [0233] In particular embodiments, a first LC from the Humulus plant includes: α-acids (e.g., humulone, cohumulone, adhumulone, posthumulone, prehumulone, adprehumulone) β-acids (e.g., lupulone, colupuloe, adlupulone, prelupulone, postlupulone), from a hops plant;terpenes, Page 46 of 138 sesquiterpenoids, diterpenoids, and triterpenoids, phytoestrogens, and flavonoids (e.g., xanthan humulone or xanthohumol). [0234] In particular embodiments, a first LC from a Coffea plant includes: tryptophan alkaloids, diterpenes, linoleic acid, palmitic acid, triacylglycerols, diterpene esters, triterpene esters, and triterpenes. [0235] In particular embodiments, a first LC from a Camellia plant includes: resveratrol, proanthocyanidins, terpenoid esters, diacylglycerol, sterol esters, and β-amyrin esters. [0236] In particular embodiments, a first LC from a plant includes coenzyme Q10, plastoquinone, plastoquinonol, or other fat-soluble electron transport chain components found in the mitochondria of plants (and all respiring eukaryotic cells). In particular embodiments, ubiquinone and ubiquinol are forms of coenzyme Q10. [0237] Formulations disclosed herein can include more than one LC. At least one of the LC is provided as an active compound or an active ingredient. When more than one LC is used, the additional lipophilic component(s) can also be active compounds or active ingredients, and/or can be provided as carriers. [0238] In particular embodiments, additional lipophilic components include a second lipophilic component. In particular embodiments, additional lipophilic components include a second LC and a third LC. In particular embodiments, additional lipophilic components include a second LC, a third LC, and a fourth LC. In particular embodiments, additional lipophilic components include 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 additional LC. In particular embodiments, additional lipophilic components include a terpene, essential oil, alkaloid, a linoleic acid, a palmitic acid, a triacylglycerol, a terpene ester, a terpenoid ester, a diacylglycerol, a sterol ester, a β-amyrin ester, a carrier oil, or any of the first LC described earlier. [0239] As used herein, a terpene refers to a hydrocarbon or derivative thereof, found as a natural product and biosynthesized by oligomerization of isoprene units (terpenes can also be synthetically produced). A terpene can be acyclic, monocyclic, bicyclic, or multicyclic. Examples include^limonene, pulegone, caryophyllene epoxide, bisabalol and the like. As used herein, the term “terpene” includes corresponding terpenoid or sesquiterpenoid compounds. Over 100 different terpenes have been identified in the^cannabis^plant, and every strain tends toward a unique terpene type and composition. Examples of terpenes include: β-caryophyllene [(lR,4E,9S)- 4,l l,l l-trimethyl-8-methylene-bicyclo(7.2.0)undec-4-ene]; β-caryophyllene oxide; citronellol [3, 7- dimethyl-Δ-octen-l-ol]; α-eudesmol [2-[(2R,4aR)-4a,8- dimethyl-2,3,4,5,6,8a-hexahydro-lH- naphthalen-2-yl]prop-an-2-ol]; β-eudesmol [2-[(2R,4aR,8aS)-4a-methyl-8-methylidene- l,2,3,4,5,6,7,8a-octahydronaphth- alen-2-yl]propan-2-ol]; gamma-eudesmol [2-[(2R,4aR)-4a, 8- Page 47 of 138 dimethyl-2,3,4,5,6,7-hexahydro-lH-naphthalen-2-yl]propan-2-ol]; geraniol [(2E)-3,7-dimethylocta- 2,6-dien-l-ol]; guaiol [2-[(3S,5R,8S)-3,8- dimethyl-l,2,3,4,5,6,7,8-octahydroazulen-5-yl]propan-2- - ol]; α-humulene [(1E,4E,8E)- 2,6,6,9-tetramethylcycloundeca-l,4,8-triene]; β-humulene [(lE,5E)- l,4,4-trimethyl-8-methylidenecycloundeca-1,5-diene]; gamma-humulene [(1Z,6E)-1,8, 8-trimethyl- 5-methy denecycloundeca-1,6-diene]; D-limonene^[(4R)-l-methyl-4-prop-l-en-2-ylcyclohexene]; L-bmonene [(4S)-l-methyl-4-prop-l-en-2-ylcyclohexene]; (-)-linalool [(3R)-3,7-dimethylocta-1.6- dien-3-ol]; (+)-linalool [(3S)-3,7-dimethylocta-l,6-dien-3-ol]; α-myrcene [2-methyl-Δ- methybdeneocta-1 ,7-diene]; β-myrcene [7-methyl-3-methylideneocta-l ,6-diene]; nerol [(2Z)-3,7- dimethylocta-2,6-dien-l-ol]; cis-nerolidol [(6Z)-3,7,l l-trimethyldodeca- l,6,10-trien-3-ol]; trans- nerolidol [(6E)-3,7,l l-trimethyldodeca-l,6,10-trien-3-ol]; α- ocimene [(3E)-3,7-dimethylocta-l,3,7- triene]; β-ocimene [(3E)-3,7-dimethylocta-l,3,6-triene]; p-cymene [l-methyl-4-(l- methylethyl)benzene]; α-phellandrene [2-methyl-5-propan-2-ylcyclohexa-l,3-diene]; β- phellandrene [3-methybdene-Δ-propan-2-ylcyclohexene]; cis-phytol [(Z,7R,l lR)-3,7,l l,15- tetramethylhexadec-2-en-l-ol]; trans-phytol [(E,7R,l lR)-3,7,l l,15-tetramethylhexadec-2-en-l-ol]; (- )-alpha-pinene [(1S,5S)-4.6.6-trimethylbicyclo[3.1.1]hept-3-ene]; (-)-α-pinene [(l S,5S)-6,6- dimethyl-4-methylidenebicyclo[3.1. l]heptane]; (+)-α-pinene [(lR,5R)-4,6,6- trimethylbicyclo[3.1. l]hept-3-ene]; (+)-β-pinene [(lR,5R)-6,6-dimethyl-4-methylidenebicyclo[3.1. l]heptane]; (-)- pulegone [(5S)-5-methyl-2-propan-2-yldenecyclohexan-l-one]; (+)-pulegone [(5R)-5-methyl-2- propan-2-ybdenecyclohexan-l- one]; α-terpinene [l-methyl-4-propan-2-ylcyclohexa-l, 3-diene]; Δ- terpinene [5- methyl-2-propan-2 -ylcy clohexa- 1,3-diene]; ^-terpinene [l-methyl-4-propan-2-ylcy cl ohexa- 1,4-diene]; α-terpineol [2-(4-methylcyclohex-3-en-l-yl)propan-2-ol]; ^-terpineol [1-methy l- 4-propan-2-y lidenecy clohexan-1-ol]; and (+)-valencene [(3R,4aS,5R)-4a,5-dimethyl-3-prop-l-en- 2-yl-2,3,4,5,6,7-hexahydro-lH-naphthalene]. [0240] In particular embodiments, the formulations include one or more terpenes selected from^limonene and/or bisabolol. [0241] In particular embodiments, terpenoids include sesquiterpenoids, diterpenoids, or triterpenoids. In particular embodiments, a sesquiterpenoid includes isohumulone. In particular embodiments, terpenes include monoterpenes, sesquiterpenes, diterpenes, or triterpenes. In particular embodiments, the monoterpene includes limonene, myrcene, geraniol, linalool, terpineol, α-pinene, or β-pinene. In particular embodiments, the sesquiterpene includes humulene, caryophyllene, or bisabolol. In particular embodiments, the triterpene includes squalene. In particular embodiments, the terpene ester includes a diterpene ester or a triterpene ester. [0242] In particular embodiments, an essential oil includes α-pinene, β-pinene, myrcene, Page 48 of 138 limonene, α-humulene, β-farnesene, β-caryophyllene, α-selinene, β-selinene, and/or γ- muurolene. [0243] In particular embodiments, an alkaloid includes lupuline. [0244] In particular embodiments, an additional lipophilic component includes an oil carrier. Oil carriers can include medium chain triglycerides (MCT) and/or long chain triglycerides. Oil carriers can also include borage oil, castor oil, coconut oil, cottonseed oil, soybean oil, safflower oil, sunflower oil, castor oil, corn oil, olive oil, palm oil, peanut oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, sesame oil, triolein, trilinolein, and trilinolenin. [0245] In certain embodiments, the oil carrier is^olive oil and/or sesame oil. In other embodiments, the oil carrier includes medium-chain triglycerides (MCT) fractionated from coconut oil, hemp oil, sunflower oil,^olive oil, corn oil, or sesame oil, including mixtures thereof. [0246] In particular embodiments, additional lipophilic components or combinations of additional lipophilic components are in the formulation at amounts ranging from 0.01% to 20% w/w. In particular embodiments, a formulation includes a terpene or a combination of terpenes in an amount of 0.01% w/w, 0.5% w/w, 0.75% w/w, 1% w/w, 2% w/w, 3% w/w, 4% w/w, 5% w/w, 6% w/w, 7% w/w, 8% w/w, 9% w/w, 10% w/w, 11% w/w, 12% w/w, 13% w/w, 14% w/w, 15% w/w, 16% w/w, 17% w/w, 18% w/w, 19% w/w, or 20% w/w. In certain embodiments, additional lipophilic components or combinations of additional lipophilic components are in the formulation at an amount of at least 0.5% w/w, at least 0.75% w/w, at least 1% w/w, at least 2% w/w, at least 3% w/w, at least 4% w/w, at least 5% w/w, at least 6% w/w, at least 7% w/w, at least 8% w/w, at least 9% w/w, at least 10% w/w, at least 11% w/w, at least 12% w/w, at least 13% w/w, at least 14% w/w, at least 15% w/w, at least 16% w/w, at least 17% w/w, at least 18% w/w, at least 19% w/w, or at least 20% w/w. [0247] In particular embodiments, a ratio of first LC to additional lipophilic component includes: 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 5:4, 3:8, 9:2, 2:3, or 1:1. [0248] In certain examples, LC within a formulation are selected from the same plant type. For example, a formulation can include two LC from a common plant type, three LC from a common plant type, four LC from a common plant type, five LC from a common plant type, or six LC from a common plant type. These embodiments provide formulations with a high concentration of ingredients from a common plant type. One certain example includes CBD and humulene. Other examples include a cannabinoid (e.g., CBD) in combination with α-tocopherol, β-tocopherol, Ɣ- tocopherol, and/or Δ-tocopherol). In these combinations, the tocopherols can provide a useful Page 49 of 138 antioxidant function, preventing or reducing degradation of active components within a formulation. Other embodiments may combine particular components from different plant types, for example CBD from a cannabis plant and theanine from a tea plant. [0249] (iv) Formulations. Formulations include aqueous or dry formulations as disclosed herein prepared for a particular use. During preparation for a use (i.e., formulation), the nature of an aqueous or dry formulation may change so that it no longer meets the structural definitions or features provided herein. For example, LC in an aqueous formulation may become substantially unevenly dispersed during a formulation process. The liquid portion of an aqueous media or liquid composition may evaporate during a formulation process, such that only LC and other components remain, leading to a dry formulation. Alternatively, the liquid portion of an aqueous media may be purposefully removed to produce powdered or dehydrated versions of the LC with glycosides and surfactant(s). Other changes, such as will be understood by one of ordinary skill in the formulation arts, may also occur. [0250] Examples of formulations include beverages and beverage kits, consumer products, drops, gels, patches, films, sprays, foams, aerosols, sublingual capsules, tablets, suppositories, capsules, pessaries, tinctures, strips, lozenges, creams, lotions, balms, topicals, ointments, syrups, pastes, liquids, powders, solids, gas, inhalants, or rings, to name a few. [0251] (v) Beverages or Beverage Kits. In particular embodiments, formulations of the present disclosure can be formulated into a beverage or a beverage kit. A beverage is a liquid intended for consumption. A beverage kit includes a container including LC and an aqueous formulation disclosed herein in a form to be added to a liquid for drinking. The form can be liquid, a dried powder, granules, syrups, concentrates, and the like. The kit can include the container including the LC, aqueous formulation, and optionally can include a beverage that the contents of the container can be added to before drinking. [0252] Examples of beverages include coffee, tea, beer, juice, milk (both dairy and non-dairy), water, liquor, punch, a shake, soda, cocoa beverages, energy drink, drinkable yogurt, fermented beverages, cider, and wine. [0253] In particular embodiments, beverages and/or beverage kits include flavoring agents, sweeteners, nutritional additives, preservatives, pH modifiers, coloring agents, taste-masking agents, viscosity modifiers, and thickeners. [0254] Methods for making beverage products are described by Woodroof and Phillips,^Beverages: Carbonated & Noncarbonated, AVI Publishing Co. (rev.ed.1981); by Thorner and Herzberg,^Non-alcoholic Food Service Beverage Handbook, AVI Publishing Co. (2nd ed. 1978); and by U.S. Patent 4,737,375. Methods for making beverages include hot packing or Page 50 of 138 aseptic packaging operations. [0255] (vi) Food Products. In particular embodiments, formulations of the present disclosure can be formulated into a food product. Food products generally are those that are chewed before swallowing. [0256] In particular embodiments,^food products^are made by inclusion or infusion of LC- containing formulations of the present disclosure into a foodstuff. In particular embodiments, food products^are made by combining LC and formulations of the present disclosure with other ingredients to make an^edible food product,^including butters and oils. Exemplary oils include coconut oil, grape seed oil, olive oil, palm oil, papaya seed oil, peanut oil, sesame oil, sprouted wheat oil, wheat germ oil, or any combination thereof. [0257] The LC and formulations of the present disclosure can be added to the food product at any stage of its preparation. For example, the formulations can be mixed with the food product’s ingredients so that it is distributed throughout the food product and the product may be cooked, or the formulations can be added to the final food product. In particular embodiments, the formulations of the present disclosure can be applied to the surface of the food product, e.g., as a glaze, icing, or coating. [0258] In particular embodiments, food products include flavoring agents, sweeteners, nutritional additives, preservatives, pH modifiers, coloring agents, taste-masking agents, viscosity modifiers, and thickeners. [0259] (vii) Oral Formulations. In particular embodiments, formulations of the present disclosure can be formulated into an oral formulation. Oral formulations referred to herein are formulations that are delivered by the mouth that are not conventional beverages or food products and are not subject to a regulatory approval process. [0260] Examples of oral formulations include syrups, gels, chewables, tinctures, and oils. [0261] In particular embodiments, oral formulations can include preservatives, pH modifiers, coloring agents, taste-masking agents, viscosity modifiers, and thickeners. [0262] Oral formulations can be manufactured using processes that are well known to those of skill in the art. Excipients include diluents, binders, disintegrants, dispersants, lubricants, glidants, stabilizers, surfactants and colorants. [0263] Oral formulations can include additional active compounds or active ingredients and can be formulated with any compounds suitable for administration as an oral formulation. In particular embodiments, the oral formulation can include components that do not impair the desired action of the oral formulation and/or components that supplement the desired action of the oral formulation. Page 51 of 138 [0264] (viii) Mucosal Formulations. In particular embodiments, formulations of the present disclosure can be formulated into a mucosal formulation. [0265] Examples of mucosal formulations include nebulizers, ointments, creams, lotions, foams, sprays, mousses, pastes, gels, liquid droplets, and dissolvable films. Mucosal formulations referred to herein refer to formulations delivered through moist cavities such as the lining of the mouth (sublingual and buccal), bladder, rectal, genital, or nasal cavity. Mucosal formulations administered buccally can be formulated into sprays, gels, pastes, dissolvable tablets or dissolvable strips. Mucosal formulations administered sublingually can be formulated into lozenges, sprays, gels, pastes, dissolvable tablets or dissolvable strips. Mucosal formulations administered bronchially or pulmonary can be formulated into an aerosol, pressurized atomizers, inhalers of dry powder, or dissolved in volatile liquids. Mucosal formulations administered rectally can be formulated into suppositories, ointments, creams, suspensions, solutions, lotions, pastes, gels, sprays, foams or oils. Mucosal formulations administered vaginally can be formulated into suppositories, ointments, creams, suspensions, solutions, lotions, pastes, gels, sprays, foams or oils. Mucosal formulations administered nasally can be formulated into ointments, suspensions, solutions, lotions, pastes, gels, sprays or mists. [0266] In particular embodiments, mucosal formulations can include preservatives, pH modifiers, coloring agents, taste-masking agents, film-forming polymers, penetration enhancers, viscosity modifiers, lubricants, and thickeners. [0267] In particular embodiments, mucosal formulations include liquid droplets administered sublingually. In particular embodiments, mucosal formulations include nebulizers for administration nasally. In particular embodiments, mucosal formulations include a spray for administration nasally. In particular embodiments, mucosal formulations include a suppository. [0268] In particular embodiments, mucosal formulations include a nebulizer. Nebulizers are broadly known to those of skill in the art and the invention is not limited to any specific type of nebulizer. Examples of suitable nebulizers and/or delivery devices are described in: U.S. Pat. Nos. 7,036,500; 7,029,656; 7,013,894; 6,994,083; 6,962,151; 6,929,003; 6,854,662; 6,748,945; 6,732,731; 6,729,327; 6,598,602; 5,853,002; 5,549,102; 5,435,282; 5,036,840; 7,077,126; 7,059,320; 6,983,747; 6,679,251; 6,606,990; 6,514,177; 513,727; 6,513,519; 6,464,388; 6,176,237; 6,085,741; 6,000,394; 5,957,389; 5,740,966; 5,596,982; 5,461,695; 5,458,136; 5,312,046; 5,309,900; 5,280,784; and U.S. Publication Nos.: 20060102172; 20060065267; 20060054166; 20060048772; 20060011196; 20050224076; 20050056274; 20050039741; 20040250816; 20030037788; 20030037785; 20020005196 and 20010054421 and the like. The disclosures of which are incorporated by reference in their entireties. Page 52 of 138 [0269] (ix) Consumer Products. In particular embodiments, formulations of the present disclosure can be formulated onto a consumer product such that the LC or functional remnants thereof are found on or near the surface of the consumer product. In certain examples, the addition of a liquid to the surface of the consumer product results in the release of the LC into the liquid. [0270] In particular embodiments, a consumer product includes any product that comes into contact with an ingestible liquid or other ingestible or inhalable substrate. Examples of such products include liquid-holding receptacles (e.g., cups or bowls), utensils (e.g., spoons, forks, knives), peripheral cooking objects (e.g., coffee filters), wrappers (e.g., food or tobacco wrappers), etc. The consumer product can be made of glass, paper, plastic, ceramics, stoneware, styrofoam, cardboard, metal, or combinations thereof. [0271] In particular embodiments, the formulations can be applied to the surface of or incorporated into the consumer product by any method known in the art including by printing, solvent-based methods, adsorption, absorption, heat-based methods, and/or mechanochemical activation-based methods. In particular embodiments, the formulations can be applied to the surface of a consumer product by spray drying, film deposition, extrusion-based printing, dip coating, ink-jet printing, bead coating, or any other method known in the art. The formulations can be deposited on the surface of the consumer product in any shape or orientation desired including stripes, amorphous blobs, circles, words, or logos. In particular embodiments, a colorant is included in the formulations such that the human eye can see the shape and/or orientation of the formulation on the consumer product. Once the formulation on or within the consumer product comes into contact with a liquid or other medium (e.g., heated air), the formulation can be released from the consumer product surface such that it will be able to be dispersed ingested or inhaled. [0272] In particular embodiments, coating formulations on consumer products can further include mechanical modifiers, plasticizers, disintegrants, film-forming polymers, thinners, thickeners, preservatives, pH modifiers, taste-masking agents, viscosity modifiers, and/or lubricants. [0273] Mechanical modifiers are used to improve the processing flowability and physical properties of a formulation and can include magnesium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil, polyethylene glycol, sugars, mannitol, sorbitol, lactose, whey and yeast, microcrystalline cellulose, povidone, carbopol, crospovidone, croscarmellose sodium, gellan gum, silicone dioxide, pectin, gelatin. carrageenan, carnauba wax, carob gum, agar, mannan, sodium alginate, and shellac. [0274] In particular embodiments, edible plasticizers include glycerol, triacetin, sorbitan, corn starch and citric acids, guar gum, and propylene glycol. [0275] An exemplary disintegrant includes a milled lactose powder which can allow the Page 53 of 138 formulation to release a LC at a desired rate. [0276] In particular embodiments, a thinner includes food grade ethanol, other alcohol, or water. In particular embodiments, thickeners include starch. Exemplary starches include pea starch, potato starch, corn starch, microcrystalline cellulose, wheat starch, rice starch, and combinations thereof. [0277] (x) Common Considerations & Components for Drinkable, Ingestible, and/or Inhalable Products & Formulations. Flavoring agents useful herein include any material or mixture of materials operable to enhance the taste of a drinkable formulation. Any orally acceptable natural or synthetic flavoring agents can be used, such as essential oils, various flavoring aldehydes, flavoring oils, esters, alcohols, similar materials, as well as sweeteners such as sodium saccharin, xylitol, D-mannose, and combinations thereof. Essential oils can include: Ylang Ylang (Cananga odorata); Yarrow (Achillea millefolium); Violet (Viola odorata); Vetiver (Vetiveria zizanoides); Vanilla (Vanilla plantifolia); Tuberose (Polianthes tuberosa); Thyme (Thymus vulgaris L.); Tea Tree (Melaleuca altemifolia); Tangerine (Citrus reticulata); Spruce, Black (Picea mariana); Spruce (Tsuga Canadensis); Spikenard (Nardostachys jatamansi); Spearmint (Mentha spicata); Sandalwood (Santalum spicatum); Rosewood (Aniba rosaeodora); Rosemary Verbenone (Rosmarinus officinalis); Rosemary (Rosmarinus officinalis); Rose (Rosa damascena); Rose Geranium (Pelargonium roseum); Ravensara (Ravensara aromatica); Plai (Zingiber cassumunar) Pine Needle (Pinus sylvestris L.); Petitgrain (Citrus aurantium); Peppermint (Mentha piperita); Pepper, Black (Piper nigrum L.); Patchouli (Pogostemon cablin); Palo Santo (Bursera graveolens); Palmarosa (Cymbopogon martini); Osmanthus (Osmanthus fragrans); Oregano (Origanum vulgare); Orange, Sweet (Citrus sinensis); Oak Moss (Evemia prunastri); Nutmeg (Myristica fragrans) Niaouli (Melaleuca viridifloria); Neroli (aka Orange Blossom) (Citrus aurantium); Myrtle (Myrtus communis); Myrrh (Commiphora myrrha); Mimosa (Acacia decurrens); Melissa (Melissa officinalis L ); Marjoram, Sweet (Origanum majorana); Manuka (Leptospermum scoparium); Mandarin, Red (Citrus deliciosa); Mandarin (Citrus deliciosa); Lotus, White (Nelumbo nucifera); Lotus, Pink (Nelumbo nucifera); Lotus, Blue (Nelumbo nucifera); Lime (Citms aurantifolia); Lily (Lilum aurantum); Lemongrass (Cymbopogon citratus); Lemon (Citrus limonum); Lavender (Lavandula angustifolium); Lavandin (Lavandula hybrida grosso); Kanuka (Kunzea ericoides); Juniper Berry (Juniperus cummunis); Jasmine (Jasminum officinale); Jasmine Abs (Jasminum sambac); Helichr sum (Helichrysum italicum); Grapefruit, White (Citrus x paradisi); Grapefruit, Pink (Citrus paradisi); Ginger (Zingiber officinalis); Geranium (Pelargonium graveolens); Geranium, Bourbon (Pelargonium graveolens, 'Herit); Gardenia (Gardenia jasminoides); Galbanum (Ferula galbaniflua); Frankincense (Boswellia carterii); Frangipani Page 54 of 138 (Plumeria alba); Fir Needle White (Abies alba); Fir Needle Siberia (Abies sibenca); Fir Needle Canada (Abies balsamea); Fennel, Sweet (Foeniculum vulgare); Eucalyptus Smithii. Eucalyptus Radiata, Eucalyptus Globulus, Eucalyptus Citriodora, Eucalyptus Blue Mallee (Eucalyptus polybractea); Elemi (Canarium luzonicum); Dill (Anethum graveolens); Cypress (Cupressus sempervirens); Cumin (Cuminum cyminum); Coriander (Coriandum sativum); Cocoa (Theobroma cacao); Clove (Eugenia caryophylatta); Clary Sage (Salvia sclarea); Cistus (aka Labdanum) (Cistus ladaniferus L.); Cinnamon (Cinnamomum zeylanicum); Chamomile, Roman (Anthemis nobilis); Chamomile, Blue (Matricaria chamomilla); Celery Seed (Apium graveolins); Cedarwood, Western Red (Thuja plicata); Cedarwood, Blood (Juniperus virginiana); Cedarwood Atlas (Cedrus atlantica); Carrot Seed (Daucus carota); Cardamon (Elettaria cardamomum); Caraway Seed (Carum carvi); Cajeput (Melaleuca cajuputi); Cade (Juniperus oxy cedrus); Birch, White (Betula alba); Birch, Sweet (Betula lenta); Bergamot (Citrus bergamia); Bay Laurel (Lauras nobilis); Basil (Ocimum basilicum); Basil, Holy (Ocimum sanctum); Basil (Ocimum basilicum); Balsam Poplar (Populus balsamifera); Balsam Peru (Myroxylon balsamum); Angelica (Angelica archangelica L.); and combinations thereof. Flavoring agents include, for example, vanillin, sage, marjoram, parsley oil, spearmint oil, cinnamon oil, oil of wintergreen (methylsalicylate), peppermint oil, clove oil, bay oil, anise oil, eucalyptus oil, citrus oils, fruit oils, and essences including those derived from lemon, orange, lime, grapefruit, apricot, banana, grape, apple, strawberry, cherry, pineapple, etc., bean- and nut-derived flavors such as coffee, cocoa, cola, peanut, almond, etc., adsorbed and encapsulated flavoring agents, and mixtures thereof. Flavoring agents also include ingredients that provide fragrance and/or other sensory effect in the mouth, including cooling or warming effects. Such ingredients include menthol, menthyl acetate, menthyl lactate, camphor, eucalyptus oil, eucalyptol, anethole, eugenol, cassia, oxanone, [α] -irisone, propenyl guaiethol, thymol, linalool, benzaldehyde, cinnamaldehyde, N-ethyl-p-menthan-3-carboxamme, N,2,3-trimethyl-2- isopropylbutanamide, 3-l-menthoxypropane-l,2-diol, cinnamaldehyde glycerol acetal (CGA), methane glycerol acetal (MGA) and mixtures thereof. In particular embodiments, the formulation includes a lipophilic flavoring agent including menthol, vanillin or an essential oil (e.g., orange oil, lemon oil, clove oil, peppermint oil, spearmint oil or aniseed oil). In particular embodiments, flavoring agents can be present in the formulation at amounts ranging from 1 to 10 mg/ml, 10 to 50 mg/ml, 50 to 100 mg/'ml, 100 to 250 mg/ml, 250 to 500 mg/ml, 500 to 750 mg/ml, or 750 to 1000 mg/ml. [0278] In particular embodiments, flavoring agents include lemon juice concentrate, tangerine flavor, tangerine concentrate, and/or apple juice concentrate. In particular embodiments, flavoring agents include jasmine, rooibos, and/or peppermint tea. Page 55 of 138 [0279] Sweeteners include maltose, sucrose, glucose, fructose, invert sugars and mixtures thereof. These sugars can be incorporated into the formulations in solid or liquid form. Fructose can be obtained or provided as liquid fructose, high fructose corn syrup (HFCS), dry fructose or fructose syrup. High fructose corn syrup is commercially available as HFCS-42, HFCS-55 and HFCS-90, which include 42%, 55% and 90%, respectively, by weight of the sugar solids therein of fructose. In particular embodiments, sweeteners can be provided to some extent by other components of the formulations, such as by fruit juice, flavorants, and so forth. Sweeteners can be employed in the process of the present disclosure in amounts ranging from 0.01% to 20%, from 6% to 14%, sugar solids by weight of the formulations. [0280] Optional artificial or noncaloric sweeteners can be used alone or in combination with carbohydrate sweeteners in beverages or beverage kits. They include, for example, saccharin, cyclamates, acetosulfam, sucralose, L-aspartyl-L-phenyalanine lower alkyl ester sweeteners (e.g., aspartame). L-aspartyl-D-alanine amides disclosed in U.S. Pat. No.4,411,930 to Brennan et al., L-aspartyl-D-serine amides disclosed in U.S. Pat. No. 4,399,163 to Brennan et al., L- aspartyl-L-1-hydroxymethyl-alkaneamide sweeteners disclosed in U.S. Pat. No. 4,338,346 to Brand, L-aspartyl-1-hydroxyethylakaneamide sweeteners disclosed in U.S. Pat. No.4,423,029 to Rizzi, L-aspartyl-D-phenylglycine ester and amide sweeteners disclosed in European Patent Application 168,112 to J. M. Janusz, published Jan.15, 1986, and the like. Artificial or noncaloric sweeteners, if used, are typically employed in an amount ranging from 0.01% to 1%, from 0.05% to 0.10% by weight of the beverage portion of the beverage or beverage kit. [0281] Nutritional additives include essential oils, vitamins, minerals, and amino acids. Vitamins include Vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B12, vitamin C, vitamin E, vitamin D, niacin (vitamin PP), biotin (vitamin H), menadione (vitamin K), folic acid, and pyridoxine (B6). Minerals include iron, zinc, calcium, phosphorus, potassium, magnesium, and fluoride. Amino acids include lysine, histidine, isoleucine, leucine, methionine, phenylalanine, threonine, tryptophan, and valine. Exemplary nutritional additives can be found in Roberts et al., Nutraceuticals: The Complete Encyclopedia of Supplements, Herbs, Vitamins, and Healing Foods (American Nutraceutical Association, 2001); in Physicians' Desk Reference for Nutritional Supplements, 1st Ed. (2001); and in The Physicians' Desk Reference for Herbal Medicines, 1st Ed. (2001), which are incorporated by reference. [0282] Taste-masking agents include sodium bicarbonate, ion-exchange resins, cyclodextrin inclusion compounds, adsorbates, and the like. [0283] (xi) Ocular Formulations. In particular embodiments, formulations of the present disclosure can be formulated into an ocular formulation. Page 56 of 138 [0284] Ocular formulations include aqueous formulations, suspensions (e.g., eye drops), viscous or semi-viscous gels, or other types of solid or semisolid compositions (e.g., ointments) or sustained release devices or mechanisms that are placed in or around the eye. Examples of ocular formulations include eye drops and ointments. [0285] In particular embodiments, an ointment is an oil-based or oil-and-water-based semi-solid or viscous formulation with a melting or softening point near body temperature. In particular embodiments, eye drops are a liquid formulation that can be applied to the eye as droplets. In particular embodiments, a gel is a jelly-like viscous formulation that includes a matrix of interacting molecules that confer viscosity, and a liquid (e.g., suspension) that is dispersed within the matrix. [0286] Ocularly administrable formulations can also be provided with tear substitutes. "Tear substitutes" refer to molecules or compositions which lubricate or "wet," approximate the consistency of endogenous tears, aid in natural tear build-up, or otherwise provide temporary relief of eyes upon ocular administration. A variety of tear substitutes are known in the art and include: monomeric polyols, such as, glycerol, propylene glycol, and ethylene glycol; polymeric polyols such as polyethylene glycol; cellulose esters such hydroxypropylmethyl cellulose, carboxymethyl cellulose sodium and hydroxy propylcellulose; dextrans such as dextran 70; water soluble proteins such as gelatin; vinyl polymers, such as polyvinyl alcohol, polyvinylpyrrolidone, and povidone; and carbomers, such as carbomer 934P, carbomer 941, carbomer 940 and carbomer 974P. Many such tear substitutes are commercially available, which include cellulose esters such as Bion® Tears (Alcon Research, Ltd., Fort Worth, Texas, U.S.A.), Celluvisc® (Allergan, Inc., Irvine, California, U.S.A.), Genteal® (Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, U.S.A.), OccuCoat® (Barnes-Hind, Inc. Clearwater, Florida, U.S.A.), Refresh® (Allergan, Inc., Irvine, California, U.S.A.), Systane® (Novartis AG, Basel, Switzerland), Systane Ultra® (Novartis AG, Basel, Switzerland), Refresh Endura® (Allergan, Inc., Irvine, California, U.S.A.), Refresh Liquigel® (Allergan, Inc., Irvine, California, U.S.A.), Teargen II™ (McKesson), Tears Naturale® (Alcon (Puerto Rico), Inc., Humacao, Puerto Rico), Tears Naturale® II (Alcon (Puerto Rico), Inc., Humacao, Puerto Rico), Tears Naturale Free® (Alcon (Puerto Rico), Inc., Fort Worth, Texas, U.S.A.), and TheraTears® (Advanced Vision Research, Inc., Ann Arbor, Michigan, U.S.A.); and polyvinyl alcohols such as Akwa Tears® (Akorn, Inc., Lake Forest, Illinois, U.S.A.), HypoTears® (Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, U.S.A.), Moisture Eyes® (Bausch & Lomb Incorporated, Rochester, New York, U.S.A.), Murine Tears® (Medtech Products, Inc., Irvington, New York, U.S.A.), Visine Tears® (Johnson & Johnson, New Brunswick, New Jersey, U.S.A.), and Soothe® (Bausch & Lomb Incorporated, Rochester, New York, U.S.A.). Tear substitutes may also include paraffins, such as Page 57 of 138 the commercially available Lacri-Lube® (Allergan, Inc., Irvine, California, U.S.A.) ointments. Other commercially available ointments that are used as tear substitutes include Lubrifresh PM™ (Bausch & Lomb Incorporated), Moisture Eyes® PM (Bausch & Lomb Incorporated, Rochester, New York, U.S.A.) and Refresh P.M.® (Allergan, Inc., Irvine, California, U.S.A.). [0287] Additional potential excipients for ocularly administrable formulations include solubilizing agents, stabilizing agents, surfactants, demulcents, viscosity modifiers, diluents, inert carriers, preservatives, binders, and/or disintegrants. Further examples of excipients include certain inert proteins such as albumins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as aspartic acid (which may alternatively be referred to as aspartate), glutamic acid (which may alternatively be referred to as glutamate), lysine, arginine, glycine, and histidine; fatty acids and phospholipids such as alkyl sulfonates and caprylate; surfactants such as sodium dodecyl sulphate and polysorbate; nonionic surfactants such as such as TWEEN® (Tween-Croda Americas, LLC, Wilmington, DE, PLURONICS® (Pluronic-BASF Corp., Mount Olive, NJ), or a polyethylene glycol (PEG) designated 200, 300, 400, or 600; a Carbowax designated 1000, 1500, 4000, 6000, and 10000; carbohydrates such as glucose, sucrose, mannose, maltose, trehalose, and dextrins, including cyclodextrins; polyols such as mannitol and sorbitol; chelating agents such as EDTA; and salt-forming counter-ions such as sodium. [0288] Eye drops may include a sterile formulation such as physiological saline, buffering solution, etc., or by combining powder compositions to be dissolved before use. Other vehicles may be chosen, as is known in the art: balance salt solution, saline solution, water soluble polyethers such as polyethylene glycol, polyvinyls, such as polyvinyl alcohol and povidone, cellulose derivatives such as methylcellulose and hydroxypropyl methylcellulose, petroleum derivatives such as mineral oil and white petrolatum, animal fats such as lanolin, polymers of acrylic acid such as carboxypolymethylene gel, vegetable fats such as peanut oil and polysaccharides such as dextrans, and glycosaminoglycans such as sodium hyaluronate. If desired, additives ordinarily used in the eye drops can be added. Such additives include isotonizing agents (e.g., sodium chloride, etc.), buffer agent (e.g., boric acid, sodium monohydrogen phosphate, sodium dihydrogen phosphate, etc.), preservatives (e.g., benzalkonium chloride, benzethonium chloride, chlorobutanol, etc.), thickeners (e.g., saccharide such as lactose, mannitol, maltose, etc.; e.g., hyaluronic acid or its salt such as sodium hyaluronate, potassium hyaluronate, etc.; e.g., mucopolysaccharide such as chondroitin sulfate, etc.; e.g., sodium polyacrylate, carboxyvinyl polymer, crosslinked polyacrylate, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose or other agents known to those skilled in the art). Page 58 of 138 [0289] For eye drops, the formulations can include concentrations of the first LC ranging from 0.0001 to 10.0 w/v %, 0.005 to 10.0 w/v %, 0.01 to 10.0 w/v %, 0.05 to 10.0 w/v %, 0.1 to 10.0 w/v %, 0.5 to 10.0 w/v %, 1.0 to 10.0 w/v %, 20 to 10.0 w/v %, 3.0 to 10.0 w/v %, 4.0 to 10.0 w/v %, or 5.0 to 10.0 w/v %. The administration may be administered several times a day per eye, one to ten times, one to four times, or once a day. The size of the drop administered may be in the range of 10-100 μl, 10-90 μl, 10-80 μl, 10-70 μl, 10-60 μl, 10-50 μl, 10-40 μl, 10-30 μl, 20-100 μl, 20-90 μl, 20-80 μl, 20-70 μl, 20-60 μl, 20-50 μl, 20-40 μl, or 20-30 μl. [0290] (xii) Topical Formulations. In particular embodiments, formulations of the present disclosure can be formulated into a topical formulation. Topical formulations are formulations that are applied directly to a body surface, such as skin. Topical formulations can be in the form of foams, sprays, mousses, patches, powders, pastes, medicated plasters, creams, ointments, lotions, or gels. [0291] Penetration enhancers increase dermal penetration and include 2-(2- ethoxyethoxy)ethanol and dimethyl isosorbide in the range of 5-30% (w/w). Other non-limiting examples of penetration enhancers include C8-C22 fatty acids such as isostearic acid, octanoic acid, and oleic acid; C8-C22 fatty alcohols such as oleyl alcohol and lauryl alcohol; lower alkyl esters of C8-C22 fatty acids such as ethyl oleate, isopropyl myristate, butyl stearate, and methyl laurate; di(lower)alkyl esters of C6-C8 diacids such as diisopropyl adipate; monoglycerides of C8- C22 fatty acids such as glyceryl monolaurate; tetrahydrofurfuryl alcohol polyethylene glycol ether; polyethylene glycol; propylene glycol; 2-(2-ethoxyethoxy)ethanol; diethylene glycol monomethyl ether; alkylaryl ethers of polyethylene oxide; polyethylene oxide monomethyl ethers; polyethylene oxide dimethyl ethers; dimethyl sulfoxide; glycerol; ethyl acetate; acetoacetic ester; N- alkylpyrrolidone; terpenes; macrocyclic enhancers such as macrocyclic ketones, for example, 3- methylcyclopentadecanone, 9-cycloheptadecen-l-one, cyclohexadecanone, and cyclopentadecanone; macrocyclic esters such as pentadecalactone. Examples of suitable agents to enhance dermal penetration are disclosed at Int J Pharm. 2013 Apr. 15; 447(1-2):12-21 (incorporated herein by reference). [0292] In particular embodiments, the topical formulation includes water. In particular embodiments, the topical formulation is substantially or totally free of water. In particular embodiments, the water content of the topical formulation is 0 to 80% water. [0293] Other components commonly used in topical formulations include: antioxidants (e.g., α- tocopherol, β-tocopherol, Ɣ-tocopherol, Δ-tocopherol, butylated hydroxytoluene, butylated hydroxyanisole), stabilizers, chelating agents, softeners, lubricants, emollients, pigments, fragrances, skin soothing agents, skin healing agents and skin conditioning agents. Skin healing Page 59 of 138 and skin conditioning agents include glycerol, allantoin, and bisabolol. [0294] (xiii) Pharmaceutical Formulations. In particular embodiments, formulations of the present disclosure can be formulated into a pharmaceutical formulation. Pharmaceutical formulations include any formulation (e.g., formulations described above) when the formulation is subject to government approval by a regulatory agency, such as the U.S. FDA. [0295] (xiv) Common Considerations for all Products and Formulations. The following passages present considerations that are applicable to a variety of formulation types. One of ordinary skill in the art can interpret and apply these sections to formulation types described above as appropriate. [0296] Formulations for beverages and beverage kits can include additional surfactants and/or water. [0297] In particular embodiments, formulations can be diluted and then concentrated. In particular embodiments, formulations can be concentrated into a liquid or solid (e.g., spray-dried particles). [0298] In particular embodiments, formulations can include water soluble active compounds. In particular embodiments, water soluble active compounds include water soluble vitamins, water soluble minerals, water soluble enzymes, and substances with a negative logP. In particular embodiments, water soluble vitamins include ascorbic acid (vitamin C), thiamin, riboflavin, niacin, nicotinamide mononucleotide, pantethine, vitamin B6 (pyridoxine, pyridoxal, and pyridoxamine), folacin, folate, vitamin B12, biotin, choline, and pantothenic acid. In particular embodiments, water soluble minerals include calcium, phosphorus, potassium, sodium, chloride, magnesium, iron, zinc, iodine, sulfur, cobalt, copper, fluoride, manganese, and selenium. In particular embodiments, water soluble enzymes include bromelain, papain, lactase, beta-amylase, cellulase, lipase, and proteases. In particular embodiments, substances with a negative logP include caffeine, theanine, theobromine, theophylline, chlorogenic acids, taurine, glucuronolactone, glucose, gamma amino butyric acid (GABA), fructose, glucose, sucrose, ribose, xylitol, inositol, aspartame, rebaudioside, soluble fiber, whey protein, ethanol, carnitine, carnosine, creatine, glycerylphosphorylcholine, beta-glucan, polyphenols, amino acids, 5-HTP, glucosamine, chondroitin, collagen, hyaluronic acid, pyrroloquinoline quinone (PQQ), glutathione, fructooligosaccharides, galactooligosaccharides, and probiotic organisms. [0299] Suitable preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, Onamer M, or other agents known to those skilled in the art. In particular embodiments, a suitable preservative includes any food-grade preservative. Food-grade preservatives include antioxidant preservatives and antimicrobial preservatives. Antioxidant preservatives include ascorbyl Page 60 of 138 palmitate, ascorbic acid, butylated hydroxyanisole (BHA) butylated hydroxytoluene (BHT), citric acid, rosmarinic acid, sulfites, tertiary butylhydroquinone (TBHQ), tocopherols, and salts and mixtures thereof. Antimicrobial preservatives include acetic acid, benzoic acid, potassium sorbate, natamycin, nisin, nitrates, nitrites, propionic acid, rosmarinic acid, sorbic acid, sulfites, sodium hexametaphosphate, sulfur dioxide, and salts and mixtures thereof. In particular embodiments, preservatives include antibiotics, antimicrobials, antifungals, and antivirals. In particular embodiments, the preservative is a water-phase preservative. Water-phase preservatives include etheylenediaminetetraacetic acid (EDTA), citric acid, potassium sorbate, and sodium benzoate. In particular embodiments, preservatives may be employed at a level from 0.004% to 0.02%, from 0.001% to 0.01%, from 0.001% to 0.008%, or 0.005% to 0.006%, from 0.02% to 0.3%, from 0.04% to 0.2%, or 0.1% to 0.2% by weight of a formulation. [0300] Suitable pH modifiers include citric acid, tartaric acid, phosphoric acid, hydrochloric acid, maleic acid, sodium hydroxide, disodium hydrogen phosphate, sodium acetate, sodium bicarbonate, sodium phosphate tribasic, dipotassium hydrogen phosphate, acetic acid, lactic acid, fumaric acid, adipic acid, sulfuric acid, salts thereof, and combinations thereof. In particular embodiments, the pH of the formulation will be controlled. In particular embodiments, the formulation has a pH from 2 to 9. In particular embodiments, the formulation has a pH from 6.5 to 7.5. In particular embodiments, the formulation has a pH of 7. Acidity can be adjusted to and maintained within the requisite range by known and conventional methods, e.g, the use of acid buffers. Typically, acidity is a balance of maximum acidity for microbial inhibition and optimum acidity for formulation characteristics (e.g., flavor or activity). In particular embodiments, the pH modifier includes buffer to maintain a physiologically compatible pH range. Buffers include acetate, bicarbonate, citrate, and phosphate. [0301] Coloring agents include red, black and yellow iron oxides and FD&C dyes such as FD&C Blue No. 2, FD&C Red No. 40. In particular embodiments coloring agents used in food include carotene, curcumin, riboflavin, carmine, turmeric, annatto, cochineal, betanin, saffron, paprika, elderberry, brilliant blue, indigotine, fast green, allura red, erythrosine, tartrazine, sunset yellow, and caramel. [0302] Viscosity modifiers include cellulose or cellulose derivatives such as ethylcellulose, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), carboxymethylcellulose, sodium hydroxypropyl methylcellulose (HPMC), methylcellulose, methylethylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, polyvinylpolypyrrolidone (crospovidone), Carbopol (carbomer), and sodium hyaluronate (hyaluronic acid), Aerosil, cetostearyl alcohol, Gelucires 33/01, 39/01 and 43/01, glyceryl behenate, glyceryl palmitostearate, Softisans 100, 142, 378 and Page 61 of 138 649, stearyl alcohol carbomer, xanthan gum, maltodextrin, acacia, tragacanth, povidone and polyvinyl alcohol. [0303] Lubricants include calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, or mixtures thereof. Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof. [0304] Thickeners include xanthan gum, carboxymethylcellulose, propylene glycol alginate, gellan gum, guar gum, pectin, tragacanth gum, gum acacia, locust bean gum, as well as mixtures of these thickeners. [0305] In particular embodiments, formulations may include a sterile unit dose type containing no preservatives, in multidose form, and/or packaged with preservatives to prevent microbial contamination during use. [0306] Formulations can contain an amount of first LC selected from 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7 mg, 7.5 mg, 8 mg, 8.5 mg, 9 mg, 9.5 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, 70 mg, 71 mg, 72 mg, 73 mg, 74 mg, 75 mg, 76 mg, 77 mg, 78 mg, 79 mg, 80 mg, 81 mg, 82 mg, 83 mg, 84 mg, 85 mg, 86 mg, 87 mg, 88 mg, 89 mg, 90 mg, 91 mg, 92 mg, 93 mg, 94 mg, 95 mg, 96 mg, 97 mg, 98 mg, 99 mg, 100 mg, or more than 100 mg. [0307] In particular embodiments, formulations can contain a concentration of first LC ranging from 0.0001 to 10.0 w/v %, 0.005 to 10.0 w/v %, 0.01 to 10.0 w/v %, 0.05 to 10.0 w/v %, 0.1 to 10.0 w/v %, 0.5 to 10.0 w/v %, 1.0 to 10.0 w/v %, 20 to 10.0 w/v %, 3.0 to 10.0 w/v %, 4.0 to 10.0 w/v %, or 5.0 to 10.0 w/v %. These formulations may be applied several times a day, one to six times, one to four times, one to two times, or once a day. [0308] (xv) Administration. Formulations of the present disclosure can be administered to subjects (humans, veterinary animals (dogs, cats, reptiles, birds, etc.) livestock (horses, cattle, goats, pigs, chickens, etc.) and research animals (monkeys, rats, mice, fish, etc.). In particular embodiments, an effective amount is administered to the subject. [0309] An "effective amount" is the amount of a formulation necessary to result in a desired Page 62 of 138 physiological change in the subject. [0310] For administration, effective amounts (also referred to herein as doses) can be initially estimated based on results from in vitro assays and/or animal model studies. Such information can be used to more accurately determine useful doses in subjects of interest. The actual dose amount administered to a particular subject can be determined by the subject, a physician, veterinarian or researcher taking into account parameters such as physical and physiological factors including target, body weight, severity of a condition, gender, age, symptoms to be treated, previous or concurrent therapeutic interventions, desirable effects, route of administration, and period of administration. [0311] The formulations of the present disclosure may be administered several times per day, one to four times per day, one to three times per day, one to two times per day, or once per day. Each administration can include one dose or several doses. The formulation can be administered as several units per administration, one to four units, one to three units, one to two units, or one units per administration. Units can be any of the administrable formulations described above including: dry powder, foams, gels, granules, inhalers, liquids, lotions, lozenges, mists, oils, ointments, pastes, pills, powder, pressurized atomizers, solutions, sprays, strips, suspensions, syrups, tablets, troches, or wafers. If the formulation is a drop, the formulation can be administered as several drops per administration, one to four drops, one to three drops, one to two drops, or one drop per administration. If the formulation is a spray, the formulation can be administered as several sprays per administration, one to four sprays, one to three sprays, one to two sprays, or one spray per administration. If the formulation is a capsule, the formulation can be administered as several capsules per administration, one to four capsules, one to three capsules, one to two capsules, or one capsule per administration. If the formulation is a tablet, the formulation can be administered as several tablets per administration, one to four tablets, one to three tablets, one to two tablets, or one tablet per administration. [0312] Effective amounts of LC (e.g., LAC or rLAC) can include 0.1 µg/kg to 5 mg/kg body weight, 0.5 µg/kg to 2 mg/kg, or 1 mg/kg to 4 mg/kg. Effective amounts to administer can include greater than 0.1 µg/kg, greater than 0.6 µg/kg, greater than 1 mg/kg, greater than 2 mg/kg, greater than 3 mg/kg, greater than 4 mg/kg, or greater than 5 mg/kg of body weight. [0313] The Exemplary Embodiments and Example below are included to demonstrate particular embodiments of the disclosure. Those of ordinary skill in the art should recognize in light of the present disclosure that many changes can be made to the specific embodiments disclosed herein and still obtain a like or similar result without departing from the spirit and scope of the disclosure. [0314] (xvi) Exemplary Embodiments. Page 63 of 138 1. A formulation including a glycoside, a surfactant, and a lipophilic component (LC). 2. The formulation of embodiment 1, including at least two glycosides. 3. The formulation of embodiment 1 or 2, wherein the LC is a lipophilic active component (LAC) or a regulated LAC (rLAC). 4. The formulation of any of embodiments 1-3, wherein the formulation is an aqueous formulation. 5. The formulation of embodiment 4, wherein the aqueous formulation includes 10% to 99%, 10% to 70%, 20% to 60%, 30% to 50%, 20% to 40%, 10 to 30%, 50% to 99%, 50% to 80%, 60% to 70%, 70% to 99%, 80% to 99%, or 90% to 99.99% moisture. 6. The formulation of any of embodiments 1-5, wherein the formulation includes a stabilized emulsion. 7. The formulation of any of embodiments 1-6, wherein the formulation has two to five times more LC than a glycoside within the formulation. 8. The formulation of any of embodiments 1-6, wherein the formulation has five to ten times more LC than an individual glycoside within the formulation. 9. The formulation of any of embodiments 1-7, wherein the formulation has two times more LC than a glycoside within the formulation. 10. The formulation of any of embodiments 1-9, wherein the formulation has two times more LC than a combination of glycosides within the formulation. 11. The formulation of any of embodiments 1-10, wherein the formulation has more than 5% LC by weight of the formulation. 12. The formulation of any of embodiments 1-10, wherein the formulation has 5%-10% LC by weight of the formulation. 13. The formulation of any of embodiments 1-12, wherein a glycoside within the formulation includes a steviol-type glycoside. 14. The formulation of any of embodiments 1-13, wherein a glycoside within the formulation includes a curcurbitane-type glycoside. 15. The formulation of any of embodiments 2-14, wherein at least one of the at least two glycosides includes a steviol-type glycoside. 16. The formulation of any of embodiments 2-15, wherein at least one of the at least two glycosides includes a curcurbitane-type glycoside. 17. The formulation of any of embodiments 2-16, wherein at least one of the at least two glycosides includes a steviol-type glycoside and at least one of the at least two glycosides includes a curcurbitane-type glycoside. 18. The formulation of any of embodiments 1-17, wherein a glycoside within the formulation Page 64 of 138 includes a diterpenoid-type glycoside. 19. The formulation of any of embodiments 1-18, wherein a glycoside within the formulation includes a triterpenoid-type glycoside. 20. The formulation of any of embodiments 2-19, wherein at least one of the at least two glycosides includes a diterpenoid-type glycoside. 21. The formulation of any of embodiments 2-20, wherein at least one of the at least two glycosides includes a triterpenoid-type glycoside. 22. The formulation of any of embodiments 2-21, wherein at least one of the at least two glycosides includes a diterpenoid-type glycoside and at least one of the at least two glycosides includes a triterpenoid-type glycoside. 23. The formulation of any of embodiments 1-22, wherein a glycoside within the formulation includes a rebaudioside glycoside. 24. The formulation of any of embodiments 1-23, wherein a glycoside includes a mogroside-type glycoside. 25. The formulation of any of embodiments 2-24, wherein at least one of the at least two glycosides includes a rebaudioside glycoside. 26. The formulation of any of embodiments 2-25, wherein at least one of the at least two glycosides includes a mogroside-type glycoside. 27. The formulation of any of embodiments 2-26, wherein at least one of the at least two glycosides includes a rebaudioside glycoside and at least one of the at least two glycosides includes a mogroside-type glycoside. 28. The formulation of any of embodiments 1-27, wherein a glycoside within the formulation includes amyrin, furostan, Q521 quillaja constituent, glycyrrhizic acid, escin, tea saponin, or bidesmosidic saponin from quillaja. 29. The formulation of any of embodiments 2-28, wherein at least one of the at least two glycosides includes amyrin, furostan, Q521 quillaja constituent, glycyrrhizic acid, escin, tea saponin, or bidesmosidic saponin from quillaja. 30. The formulation of any of embodiments 1-29, wherein a surfactant within the formulation includes a sucrose ester. 31. The formulation of any of embodiments 1-30, wherein a surfactant within the formulation includes a sorbitan ester. 32. The formulation of any of embodiments 1-31, wherein a surfactant within the formulation includes a saponin. 33. The formulation of embodiment 32, wherein the glycoside does not include a saponin if the Page 65 of 138 surfactant is a saponin. 34. The formulation of any of embodiments 1-33, wherein a surfactant within the formulation includes a non-protein-based surfactant. 35. The formulation of any of embodiments 1-34, wherein a surfactant within the formulation includes an ionic surfactant. 36. The formulation of any of embodiments 1-35, wherein a surfactant within the formulation includes an anionic surfactant. 37. The formulation of any of embodiments 1-36, wherein a surfactant within the formulation includes a zwitterionic surfactant. 38. The formulation of any of embodiments 1-37, wherein a surfactant within the formulation includes a sorbitan fatty acid ester, polyethylene glycol sorbitan fatty acid ester, polyethylene- polypropylene glycol, saturated polyglycolized glyceride, polyethylene glycol, quillaia, polyethylene glycol stearate, polyethylene glycol hydrogenated castor oil, diethylene glycol monoethyl ether, propylene glycol laurate , D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS), polyvinyl pyrrolidone, iota carrageenan, hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC), microcrystalline cellulose (MCC), lecithin, sucrose laurate, sucrose palmitate, sucrose stearate, gamma-cyclodextrin, β-cyclodextrin pectin, whey protein, caseinate, Xanthan gum, locust bean gum, gellan gum, acacia gum, guar gum, Tragacanth gum, polyethylene glycol hydroxystearate polyoxyl-10-oleyl ether, or polyethylene glycol glyceride. 39. The formulation of any of embodiments 1-38, wherein a surfactant within the formulation includes polysorbate 80. 40. The formulation of any of embodiments 1-39, wherein a surfactant within the formulation includes sorbitan monooleate. 41. The formulation of any of embodiments 1-40, wherein a surfactant within the formulation includes polysorbate 80 and sorbitan monooleate. 42. The formulation of any of embodiments 1-41, wherein the LC is derived from a plant. 43. The formulation of embodiment 42, wherein the plant is a Cannabaceae plant. 44. The formulation of embodiment 43, wherein the Cannabaceae plant is a cannabis plant. 45. The formulation of embodiment 44, wherein the cannabis plant is Cannabis sativa, Cannabis indica, or Cannabis ruderalis. 46. The formulation of any of embodiments 1-45, wherein the LC is a cannabinoid. 47. The formulation of embodiment 46, wherein the cannabinoid includes tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin Page 66 of 138 (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBT), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), and/or mixtures thereof. 48. The formulation of embodiments 46 or 47, wherein the cannabinoid includes CBD. 49. The formulation of any of embodiments 46-48, wherein the cannabinoid includes CBD and THC. 50. The formulation of any of embodiments 46-49, wherein the cannabinoid includes CBD and THC at a ratio of 1:1 (% w/w). 51. The formulation of any of embodiments 1-50, wherein the LC includes a synthetic and/or artificial cannabinoid. 52. The formulation of embodiment 43, wherein the Cannabaceae plant is a Humulus plant. 53. The formulation of embodiment 52, wherein the Humulus plant is Humulus lupulus, Humulus americanus, Humulus cordifolius, Humulus neomexicanus, Humulus pubescens, or Humulus scandens. 54. The formulation of embodiment 52 or 53, wherein the Humulus plant is Humulus lupulus. 55. The formulation of embodiments 42, wherein the plant is a Rubiaceae plant. 56. The formulation of embodiment 55, wherein the Rubiaceae plant is a Coffea plant. 57. The formulation of embodiment 56, wherein the Coffea plant is Coffea abbayesii, Coffea affinis, Coffea alleizettii, Coffea ambanjensis, Coffea ambongenis, Coffea andrambovatensis, Coffea ankaranensis, Coffea anthonyi, Coffea arabica, Coffea arenesiana, Coffea augagneurii, Coffea bakossii, Coffea benghalensis, Coffea bertrandii, Coffea betamponensis, Coffea bissetiae, Coffea boinensis, Coffea boiviniana, Coffea bonnieri, Coffea brassii, Coffea brevipes, Coffea bridsoniae, Coffea buxifolia, Coffea canephora, Coffea carrissoi, Coffea charrieriana, Coffea cochinchinensis, Coffea commersoniana, Coffea congensis, Coffea costatifructa, Coffea coursiana, Coffea dactylifera, Coffea decaryana, Coffea dubardii, Coffea ebracteolata, Coffea eugenioides, Coffea fadenii, Coffea farafanganensis, Coffea floresiana, Coffea fotsoana, Coffea fragilis, Coffea fragrans, Coffea gallienii, Coffea grevei, Coffea heimii, Coffea homollei, Coffea horsfieldiana, Coffea humbertii, Coffea humblotiana, Coffea humilis, Coffea jumellei, Coffea kapakata, Coffea kianjavatensis, Coffea kihansiensis, Coffea kimbozensis, Coffea kivuensis, Coffea labatii, Coffea lancifolia, Coffea lebruniana, Coffea leonimontana, Coffea leroyi, Coffea liaudii, Coffea liberica, Coffea ligustroides, Coffea littoralis, Coffea lulandoensis, Coffea mabesae, Coffea macrocarpa, Coffea madurensis, Coffea magnistipula, Coffea malabarica, Coffea mangoroensis, Coffea mannii, Coffea manombensis, Coffea mapiana, Coffea mauritiana, Coffea Page 67 of 138 mayombensis, Coffea mcphersonii, Coffea melanocarpa, Coffea merguensis, Coffea millotii, Coffea minutiflora, Coffea mogenetii, Coffea mongensis, Coffea montekupensis, Coffea montis- sacri, Coffea moratii, Coffea mufindiensis, Coffea myrtifolia, Coffea namorokensis, Coffea neobridsoniae, Coffea neoleroyi, Coffea perrieri, Coffea pervilleana, Coffea pocsii, Coffea pseudozanguebariae, Coffea pterocarpan, Coffea racemose, Coffea rakotonasoloi, Coffea ratsimamangae, Coffea resinosa, Coffea rhamnifolia, Coffea richardii, Coffea sahafaryensis, Coffea sakarahae, Coffea salvatrix, Coffea sambavensis, Coffea sapinii, Coffea schliebenii, Coffea semsei, Coffea sessiliflora, Coffea stenophylla, Coffea tetragona, Coffea togoensis, Coffea toshii, Coffea travancorensis, Coffea tricalysioides, Coffea tsirananae, Coffea vatovavyensis, Coffea vavateninensis, Coffea vianneyi, Coffea vohemarensis, Coffea wightiana, or Coffea zanguebariae. 58. The formulation of embodiment 56 or 57, wherein the Coffea plant is Coffea arabica. 59. The formulation of embodiment 42, wherein the plant is a Theaceae plant. 60. The formulation of embodiment 59, wherein the Theaceae plant is a Camellia plant. 61. The formulation of embodiment 60, wherein the Camellia plant is Camellia sinensis var. sinensis, Camellia sinensis var. assamica, Camellia sinensis var. pubilimba, or Camellia sinensis var. dehungensis. 62. The formulation of embodiment 60 or 61, wherein the Camellia plant is Camellia sinensis var. sinensi. 63. The formulation of any of embodiments 1-62, formulated as a beverage. 64. The formulation of embodiment 63, wherein the beverage is beer, coffee, or tea. 65. The formulation of embodiment 63 or 64, wherein the beverage is tea. 66. The formulation of any of embodiments 63-65, wherein the beverage is soda. 67. The formulation of any of embodiments 63-66, wherein the beverage is a juice-flavored drink. 68. The formulation of any of embodiments 63-67, wherein the beverage is carbonated water. 69. The formulation of embodiment 1, including 30-40 g LC, 2-6 g surfactant, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 70. The formulation of embodiment 1, including 35 g LC, 4 g surfactant, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 71. The formulation of embodiment 1, including 35.85 g LC, 3.96 g surfactant, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 Page 68 of 138 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 72. The formulation of embodiment 1 or 2, including 30-40 g LC, 2-6 g surfactant, 3-7 g rebaudioside A, 4-8 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 73. The formulation of embodiment 1 or 2, including 35 g LC, 4 g surfactant, 5 g rebaudioside A, 6 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 74. The formulation of embodiment 1 or 2, including 35.85 g LC, 3.96 g surfactant, 4.70 g rebaudioside A, 6.26 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 75. The formulation of embodiment 1 or 2, including 30-40 g LC, 2-6 g surfactant, 3-7 g glycoside, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 76. The formulation of embodiment 1 or 2, including 35 g LC, 4 g surfactant, 5 g glycoside, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 77. The formulation of embodiment 1 or 2, including 35.85 g LC, 3.96 g surfactant, 4.70 g glycoside, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 78. The formulation of embodiment 1 or 2, including 30-40 g LC, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 79. The formulation of embodiment 1 or 2, including 35 g LC, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 80. The formulation of embodiment 1 or 2, including 35.85 g LC, 3.96 g saponin, 4.70 g Page 69 of 138 rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 81. The formulation of embodiment 1, including 30-40 g cannabidiol, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 82. The formulation of embodiment 1, including 35 g cannabidiol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 83. The formulation of embodiment 1, including 35.85 g cannabidiol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 84. The formulation of embodiment 1 or 2, including 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 85. The formulation of embodiment 1 or 2, including 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 86. The formulation of embodiment 1 or 2, including 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 87. The formulation of embodiment 1, including 30-40 g cannabidiol, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 – 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, and 580 – 630 g water. 88. The formulation of embodiment 1, including 35 g cannabidiol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, and 610 or 611 g water. 89. The formulation of embodiment 1, including 35.85 g cannabidiol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium Page 70 of 138 benzoate, 0.24 g potassium sorbate, and 611.50 g water. 90. The formulation of embodiment 1 or 2, including 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, and 580 – 630 g water. 91. The formulation of embodiment 1 or 2, including 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, and 610 or 611 g water. 92. The formulation of embodiment 1 or 2, including 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, and 611.50 g water. 93. The formulation of embodiment 1, including 30-40 g cannabidiol, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g triethyl citrate. 94. The formulation of embodiment 1, including 35 g cannabidiol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g triethyl citrate. 95. The formulation of embodiment 1, including 35.85 g cannabidiol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g triethyl citrate. 96. The formulation of embodiment 1 or 2, including 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g triethyl citrate. 97. The formulation of embodiment 1 or 2, including 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g triethyl citrate. 98. The formulation of embodiment 1 or 2, including 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g triethyl citrate. 99. The formulation of embodiment 1, including 30-40 g tetrahydrocannabinol, 2-6 g saponin, 7- Page 71 of 138 15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 100. The formulation of embodiment 1, including 35 g tetrahydrocannabinol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 101. The formulation of embodiment 1, including 35.85 g tetrahydrocannabinol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 102. The formulation of embodiment 1 or 2, including 30-40 g tetrahydrocannabinol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 103. The formulation of embodiment 1 or 2, including 35 g tetrahydrocannabinol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 104. The formulation of embodiment 1 or 2, including 35.85 g tetrahydrocannabinol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 105. The formulation of embodiment 1, including 30-40 g cannabigerol, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 106. The formulation of embodiment 1, including 35 g cannabigerol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 107. The formulation of embodiment 1, including 35.85 g cannabigerol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. Page 72 of 138 108. The formulation of embodiment 1 or 2, including 30-40 g cannabigerol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 109. The formulation of embodiment 1 or 2, including 35 g cannabigerol4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally , 4 g sucrose acetate isobutyrate. 110. The formulation of embodiment 1 or 2, including 35.85 g cannabigerol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 111. The formulation of embodiment 1 or 2, including 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside M, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 112. The formulation of embodiment 1 or 2, including 35 g cannabidiol, 4 g saponin, 5 g rebaudioside M, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 113. The formulation of embodiment 1 or 2, including 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside M, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 114. The formulation of embodiment 1 or 2, including 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g isomogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 115. The formulation of embodiment 1 or 2, including 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g isomogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 116. The formulation of embodiment 1 or 2, including 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g isomogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g Page 73 of 138 ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 117. The formulation of embodiment 1, including 30-40 g curcumin, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 118. The formulation of embodiment 1, including 35 g curcumin, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 119. The formulation of embodiment 1, including 35.85 g curcumin, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 120. The formulation of embodiment 1 or 2, including 30-40 g curcumin, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 121. The formulation of embodiment 1 or 2, including 35 g curcumin, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 122. The formulation of embodiment 1 or 2, including 35.85 g curcumin, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 123. The formulation of embodiment 1, including 30-40 g melatonin, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 124. The formulation of embodiment 1, including 35 g melatonin, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 125. The formulation of embodiment 1, including 35.85 g melatonin, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium Page 74 of 138 benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 126. The formulation of embodiment 1 or 2, including 30-40 g melatonin, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 127. The formulation of embodiment 1 or 2, including 35 g melatonin, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 128. The formulation of embodiment 1 or 2, including 35.85 g melatonin, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 129. The formulation of embodiment 1, including 30-40 g cannabidiol, 2-6 g saponin, 7-15 g glycoside, and 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 130. The formulation of embodiment 1, including 35 g cannabidiol, 4 g saponin, 11 g glycoside, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 131. The formulation of embodiment 1, including 35.85 g cannabidiol, 3.96 g saponin, 10.96 g glycoside, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 132. The formulation of embodiment 1 or 2, including 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 133. The formulation of embodiment 1 or 2, including 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, and 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 134. The formulation of embodiment 1 or 2, including 35.85 g cannabidiol3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 611.50 g water, and optionally , 4.93 g sucrose acetate isobutyrate. 135. The formulation of embodiment 1, including 30-40 g cannabidiol, 0.02-0.06 g saponin, 0.07- 0.15 g glycoside, 0.002 – 0.006 g tocopherol, 0.0006 - 0.0010 g ascorbyl palmitate, 0.0060 – 0.010 g ascorbic acid, 0.1 – 0.3 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 4 - 8 g sucrose, 580 – 630 g water, and optionally 0.03-0.07 g sucrose acetate isobutyrate. 136. The formulation of embodiment 1, including 35 g cannabidiol, 0.04 g saponin, 0.11 g Page 75 of 138 glycoside, 0.004 g tocopherol, 0.0008 g ascorbyl palmitate, 0.008 g ascorbic acid, 0.2 g sodium benzoate, 0.2 g potassium sorbate, 6 g sucrose, 610 or 611 g water, and optionally 0.04 g sucrose acetate isobutyrate. 137. The formulation of embodiment 1, including 35.85 g cannabidiol, 0.0396 g saponin, 0.1096 g glycoside, 0.0041 g tocopherol, 0.0008 g ascorbyl palmitate, 0.0080 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 6.12 g sucrose, 611.50 g water, and optionally 0.0493 g sucrose acetate isobutyrate. 138. The formulation of embodiment 1 or 2, including 30-40 g cannabidiol, 0.02-0.06 g saponin, 0.03-0.07 g rebaudioside A, 0.04-0.08 g mogroside V, 0.002 – 0.006 g tocopherol, 0.0006 - 0.0010 g ascorbyl palmitate, 0.0060 – 0.010 g ascorbic acid, 0.1 – 0.3 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 4 - 8 g sucrose, 580 – 630 g water, and optionally 0.03-0.07 g sucrose acetate isobutyrate. 139. The formulation of embodiment 1 or 2, including 35 g cannabidiol, 0.04 g saponin, 0.05 g rebaudioside A, 0.06 g mogroside V, 0.004 g tocopherol, 0.0008 g ascorbyl palmitate, 0.008 g ascorbic acid, 0.2 g sodium benzoate, 0.2 g potassium sorbate, 6 g sucrose, 610 or 611 g water, and optionally 0.04 g sucrose acetate isobutyrate,. 140. The formulation of embodiment 1 or 2, including 35.85 g cannabidiol, 0.0396 g saponin, 0.0470 g rebaudioside A, 0.0626 g mogroside V, 0.0041 g tocopherol, 0.0008 g ascorbyl palmitate, 0.0080 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 6.12 g sucrose, 611.50 g water, and optionally 0.0493 g sucrose acetate isobutyrate. 141. The formulation of embodiment 1, including 8 - 12 g cannabidiol, 14 - 18 g all-rac-alpha- tocopherol, 0.5-4 g glycoside, 0.05 – 0.2 g ascorbyl palmitate, 1 - 3 g tween 80, 2 - 5 g span 80, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 65 - 70 g water. 142. The formulation of embodiment 1, including 10 g cannabidiol, 16 g all-rac-alpha-tocopherol, 2 g glycoside, 0.10 g ascorbyl palmitate, 2 g tween 80, 3 or 4 g span 80, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 67 g water. 143. The formulation of embodiment 1, including 10 g cannabidiol, 16 g all-rac-alpha-tocopherol, 1.43 g glycoside, 0.10 g ascorbyl palmitate, 1.98 g tween 80, 3.52 g span 80, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 66.9 g water. 144. The formulation of embodiment 1 or 2, including 8 - 12 g cannabidiol, 14 - 18 g all-rac-alpha- tocopherol, 0.25 – 2 g rebaudioside A, 0.25 – 2 g mogroside V, 0.05 – 0.2 g ascorbyl palmitate, 1 - 3 g tween 80, 2 - 5 g span 80, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 65 - 70 g water. 145. The formulation of embodiment 1 or 2, including 10 g cannabidiol, 16 g all-rac-alpha- Page 76 of 138 tocopherol, 1 g rebaudioside A, 1 g mogroside V, 0.10 g ascorbyl palmitate, 2 g tween 80, 3 or 4 g span 80, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 67 g water. 146. The formulation of embodiment 1 or 2, including 10 g cannabidiol, 16 g all-rac-alpha- tocopherol, 0.61 g rebaudioside A, 0.82 g mogroside V, 0.10 g ascorbyl palmitate, 1.98 g tween 80, 3.52 g span 80, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 66.9 g water. 147. The formulation of embodiment 1, including 5 – 7 g ubiquinone, 0.25 – 2 g saponin, 0.5-4 g glycoside, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 90 – 95 g water. 148. The formulation of embodiment 1, including 6 g ubiquinone, 1 g saponin, 2 g glycoside, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 92 g water. 149. The formulation of embodiment 1, including 5.99 g ubiquinone, 0.78 g saponin, 1.43 glycoside, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 91.73 g water. 150. The formulation of embodiment 1 or 2, including 5 – 7 g ubiquinone, 0.25 – 2 g saponin, 0.25 – 2 g rebaudioside A, 0.25 – 2 g mogroside V, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 90 – 95 g water. 151. The formulation of embodiment 1 or 2, including 6 g ubiquinone, 1 g saponin, 1 g rebaudioside A, 1 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 92 g water. 152. The formulation of embodiment 1 or 2, including 5.99 g ubiquinone, 0.78 g saponin, 0.61 g rebaudioside A, 0.82 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 91.73 g water. 153. The formulation of embodiment 1 or 2, including 5 – 7 g ubiquinol, 0.25 – 2 g saponin, 0.25 – 2 g rebaudioside A, 0.25 – 2 g mogroside V, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 90 – 95 g water. 154. The formulation of embodiment 1 or 2, including 6 g ubiquinol, 1 g saponin, 1 g rebaudioside A, 1 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 92 g water. 155. The formulation of embodiment 1 or 2, including 5.99 g ubiquinol, 0.78 g saponin, 0.61 g rebaudioside A, 0.82 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 91.73 g water. 156. The formulation of embodiment 1 or 2, including 1-3 g cannabinol, 1-3 g sunflower oil, 0.1- 0.5 g saponin, 01.-0.3 g rebaudioside A, 0.1-0.5 g mogroside V, 0.01-0.02 g sodium benzoate, 0.01-0.02 g potassium sorbate, and 13-18 g water. 157. The formulation of embodiment 1 or 2, including 2 g cannabinol, 2 g sunflower oil, 0.3 g saponin, 0.2 g rebaudioside A, 0.3 g mogroside V, 0.01 g sodium benzoate, 0.01 g potassium Page 77 of 138 sorbate, and 15 g water. 158. The formulation of embodiment 1 or 2, including 1.60 g cannabinol, 1.6 g sunflower oil, 0.38 g saponin, 0.19 g rebaudioside A, 0.25 g mogroside V, 0.01 g sodium benzoate, 0.01 g potassium sorbate, and 16.04 g water. 159. The formulation of embodiment 1 or 2, including 30-40 g cannabidiol, 2-6 g vitamin E TPGS, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 – 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.1 – 0.3 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 4 – 8 g sucrose, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 160. The formulation of embodiment 1 or 2, including 35 g cannabidiol, 4 g vitamin E TPGS, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.2 g sodium benzoate, 0.2 g potassium sorbate, 6 g sucrose, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 161. The formulation of embodiment 1 or 2, including 35.85 g cannabidiol, 3.96 g vitamin E TPGS, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 6.12 g sucrose, 611.50 g water and optionally 4.93 g sucrose acetate isobutyrate. 162. The formulation of embodiment 1 or 2, including 4-6 g cannabidiol, 2-5 g saponin from Yucca, 0.25-2 g rebaudioside A, 0.25-2 g mogroside V, 0.01-0.10 g sodium benzoate, 0.01-0.10 g potassium sorbate, and 80-100 g water. 163. The formulation of embodiment 1 or 2, including 5 g cannabidiol, 3 g saponin from Yucca, 0.5 g rebaudioside A, 0.5 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 90 g water. 164. The formulation of embodiment 1 or 2, including 5.82 g cannabidiol, 3.01 g saponin from Yucca, 0.43 g rebaudioside A, 0.57 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 90.11 g water. 165. The formulation of embodiment 1 or 2, including 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g rebaudioside C, 0.2 – 0.6 g tocopherol, 0.60 – 1.0 g ascorbic acid, 0.1 – 0.3 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 4 – 8 g sucrose, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 166. The formulation of embodiment 1 or 2, including 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g rebaudioside C, 0.4 g tocopherol, 0.80 g ascorbic acid, 0.2 g sodium benzoate, 0.2 g potassium sorbate, 6 g sucrose, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 167. The formulation of embodiment 1 or 2, including 35.85 g cannabidiol, 3.96 g saponin, 4.70 g Page 78 of 138 rebaudioside A, 6.26 g rebaudioside C, 0.41 g tocopherol, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 6.12 g sucrose, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 168. The formulation of any of embodiments 1-167, formulated as a topical composition. 169. The formulation of embodiment 168, wherein the topical composition is a lotion, cream or gel. 170. The formulation of embodiment 168 or 169, wherein the topical composition is a spray. 171. A product including a mixture of any of embodiments 1-168 and other embodiments of 1-152 where each embodiment is separately manufactured and then combined. 172. A product including a mixture of any of embodiments 1-169 and suspended particles 10 microns or less in diameter. 173. A beverage kit including the formulation of any of embodiments 1-167, a beverage, and instructions to combine the formulation and the beverage into a vessel suitable for drinking. 174. The beverage kit of embodiment 173, wherein the beverage is beer, coffee, or tea. 175. The beverage kit of embodiment 173 or 174, wherein the beverage is tea. 176. The beverage kit of any of embodiments 173-175, wherein the beverage is soda. 177. The beverage kit of any of embodiments 173-176, wherein the beverage is a juice-flavored drink. 178. The beverage kit of any of embodiments 173-177, wherein the beverage is carbonated water. 179. A kit for forming a formulation having a stabilized emulsion, the kit including a glycoside, a surfactant, and a lipophilic component (LC). 180. The kit of embodiment 179, including at least two glycosides. 181. The kit of embodiment 179 or 180, wherein the LC is a lipophilic active component (LAC) or a regulated LAC (rLAC). 182. The kit of any of embodiments 179-181, including instructions to form an aqueous formulation. 183. The kit of any of embodiments 179-182, including an aqueous media. 184. The kit of embodiment 167 or 168, wherein the aqueous formulation includes 10% to 99%, 10% to 70%, 20% to 60%, 30% to 50%, 20% to 40%, 10 to 30%, 50% to 99%, 50% to 80%, 60% to 70%, 70% to 99%, 80% to 99%, or 90% to 99.99% moisture. 185. The kit of any of embodiments 179-183, wherein the kit has two to five times more LC than a glycoside within the kit. 186. The kit of any of embodiments 179-183, wherein the kit has five to ten times more LC than Page 79 of 138 an individual glycoside within the kit. 187. The kit of any of embodiments 179-186, wherein the kit has two times more LC than a glycoside within the kit. 188. The kit of any of embodiments 180-187, wherein the kit has two times more LC than a combination of glycosides within the kit. 189. The kit of any of embodiments 179-188, wherein the formed aqueous formulation has more than 5% LC by weight of the aqueous formulation. 190. The kit of any of embodiments 179-188, wherein the formed aqueous formulation has more than 5%-10% LC by weight of the aqueous formulation. 191. The kit of any of embodiments 179-189, wherein a glycoside within the kit includes a steviol- type glycoside. 192. The kit of any of embodiments 179-191, wherein a glycoside within the kit includes a curcurbitane-type glycoside. 193. The kit of any of embodiments 180-192, wherein at least one of the at least two glycosides includes a steviol-type glycoside. 194. The kit of any of embodiments 180-193, wherein at least one of the at least two glycosides includes a curcurbitane-type glycoside. 195. The kit of any of embodiments 180-199, wherein at least one of the at least two glycosides includes a steviol-type glycoside and at least one of the at least two glycosides includes a curcurbitane-type glycoside. 196. The kit of any of embodiments 179-195, wherein a glycoside within the kit includes a diterpenoid-type glycoside. 197. The kit of any of embodiments 179-196, wherein a glycoside within the kit includes a triterpenoid-type glycoside. 198. The kit of any of embodiments 180-197, wherein at least one of the at least two glycosides includes a diterpenoid-type glycoside. 199. The kit of any of embodiments 180-198, wherein at least one of the at least two glycosides includes a triterpenoid-type glycoside. 200. The kit of any of embodiments 180-199, wherein at least one of the at least two glycosides includes a diterpenoid-type glycoside and at least one of the at least two glycosides includes a triterpenoid-type glycoside. 201. The kit of any of embodiments 179-200, wherein a glycoside within the kit includes a rebaudioside glycoside. 202. The kit of any of embodiments 179-201, wherein a glycoside within the kit includes a Page 80 of 138 mogroside-type glycoside. 203. The kit of any of embodiments 180-202, wherein at least one of the at least two glycosides includes a rebaudioside glycoside. 204. The kit of any of embodiments 180-203, wherein at least one of the at least two glycosides includes a mogroside-type glycoside. 205. The kit of any of embodiments 180-204, wherein at least one of the at least two glycosides includes a rebaudioside glycoside and at least one of the at least two glycosides includes a mogroside-type glycoside. 206. The kit of any of embodiments 179-205, wherein a glycoside within the kit includes amyrin, furostan, Q521 quillaja constituent, glycyrrhizic acid, escin, tea saponin, or bidesmosidic saponin from quillaja. 207. The kit of any of embodiments 180-206, wherein at least one of the at least two glycosides includes amyrin, furostan, Q521 quillaja constituent, glycyrrhizic acid, escin, tea saponin, or bidesmosidic saponin from quillaja. 208. The kit of any of embodiments 179-207, wherein a surfactant within the kit includes a sucrose ester. 209. The kit of any of embodiments 179-208, wherein a surfactant within the kit includes a sorbitan ester. 210. The kit of any of embodiments 179-209, wherein a surfactant within the kit includes a saponin. 211. The kit of embodiment 210, wherein the glycoside does not include a saponin if the surfactant is a saponin. 212. The kit of any of embodiments 179-211, wherein a surfactant within the kit includes a non- protein-based surfactant. 213. The kit of any of embodiments 179-212, wherein a surfactant within the kit includes a protein-based surfactant that does not consist of soy protein isolate. 214. The kit of any of embodiments 179-213, wherein a surfactant within the kit includes an ionic surfactant. 215. The kit of any of embodiments 179-214, wherein a surfactant within the kit includes an anionic surfactant. 216. The kit of any of embodiments 179-215, wherein a surfactant within the kit includes a zwitterionic surfactant. 217. The kit of any of embodiments 179-216, wherein a surfactant within the kit includes a sorbitan fatty acid ester, polyethylene glycol sorbitan fatty acid ester, polyethylene-polypropylene glycol, Page 81 of 138 saturated polyglycolized glyceride, polyethylene glycol, quillaia, polyethylene glycol stearate, polyethylene glycol hydrogenated castor oil, diethylene glycol monoethyl ether, propylene glycol laurate , D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS), polyvinyl pyrrolidone, iota carrageenan, hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC), microcrystalline cellulose (MCC), lecithin, sucrose laurate, sucrose palmitate, sucrose stearate, gamma-cyclodextrin, β-cyclodextrin pectin, whey protein, caseinate, Xanthan gum, locust bean gum, gellan gum, acacia gum, guar gum, Tragacanth gum, polyethylene glycol hydroxystearate polyoxyl-10-oleyl ether, or polyethylene glycol glyceride. 218. The kit of any of embodiments 179-217, wherein a surfactant within the kit includes polysorbate 80. 219. The kit of any of embodiments 179-218, wherein a surfactant within the kit includes sorbitan monooleate. 220. The kit of any of embodiments 179-219, wherein a surfactant within the kit includes polysorbate 80 and sorbitan monooleate. 221. The kit of any of embodiments 179-220, wherein the LC is derived from a plant. 222. The kit of embodiment 221, wherein the plant is a Cannabaceae plant. 223. The kit of embodiment 222, wherein the Cannabaceae plant is a cannabis plant. 224. The kit of embodiment 223, wherein the cannabis plant is Cannabis sativa, Cannabis indica, or Cannabis ruderalis. 225. The kit of any of embodiments 179-224, wherein the LC is a cannabinoid. 226. The kit of embodiment 225, wherein the cannabinoid includes tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBT), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), and/or mixtures thereof. 227. The kit of embodiment 225 or 223, wherein the cannabinoid includes CBD. 228. The kit of any of embodiments 225-223, wherein the cannabinoid includes CBD and THC. 229. The kit of any of embodiments 225-223, wherein the cannabinoid includes CBD and THC at a ratio of 1:1 (% w/w). 230. The kit of any of embodiments 179-229, wherein the LC includes a synthetic and/or artificial cannabinoid. 231. The kit of embodiment 222, wherein the Cannabaceae plant is a Humulus plant. Page 82 of 138 232. The kit of embodiment 231, wherein the Humulus plant is Humulus lupulus, Humulus americanus, Humulus cordifolius, Humulus neomexicanus, Humulus pubescens, or Humulus scandens. 233. The kit of embodiment 231 or 232, wherein the Humulus plant is Humulus lupulus. 234. The kit of embodiment 221, wherein the plant is a Rubiaceae plant. 235. The kit of embodiment 234, wherein the Rubiaceae plant is a Coffea plant. 236. The kit of embodiment 235, wherein the Coffea plant is Coffea abbayesii, Coffea affinis, Coffea alleizettii, Coffea ambanjensis, Coffea ambongenis, Coffea andrambovatensis, Coffea ankaranensis, Coffea anthonyi, Coffea arabica, Coffea arenesiana, Coffea augagneurii, Coffea bakossii, Coffea benghalensis, Coffea bertrandii, Coffea betamponensis, Coffea bissetiae, Coffea boinensis, Coffea boiviniana, Coffea bonnieri, Coffea brassii, Coffea brevipes, Coffea bridsoniae, Coffea buxifolia, Coffea canephora, Coffea carrissoi, Coffea charrieriana, Coffea cochinchinensis, Coffea commersoniana, Coffea congensis, Coffea costatifructa, Coffea coursiana, Coffea dactylifera, Coffea decaryana, Coffea dubardii, Coffea ebracteolata, Coffea eugenioides, Coffea fadenii, Coffea farafanganensis, Coffea floresiana, Coffea fotsoana, Coffea fragilis, Coffea fragrans, Coffea gallienii, Coffea grevei, Coffea heimii, Coffea homollei, Coffea horsfieldiana, Coffea humbertii, Coffea humblotiana, Coffea humilis, Coffea jumellei, Coffea kapakata, Coffea kianjavatensis, Coffea kihansiensis, Coffea kimbozensis, Coffea kivuensis, Coffea labatii, Coffea lancifolia, Coffea lebruniana, Coffea leonimontana, Coffea leroyi, Coffea liaudii, Coffea liberica, Coffea ligustroides, Coffea littoralis, Coffea lulandoensis, Coffea mabesae, Coffea macrocarpa, Coffea madurensis, Coffea magnistipula, Coffea malabarica, Coffea mangoroensis, Coffea mannii, Coffea manombensis, Coffea mapiana, Coffea mauritiana, Coffea mayombensis, Coffea mcphersonii, Coffea melanocarpa, Coffea merguensis, Coffea millotii, Coffea minutiflora, Coffea mogenetii, Coffea mongensis, Coffea montekupensis, Coffea montis-sacri, Coffea moratii, Coffea mufindiensis, Coffea myrtifolia, Coffea namorokensis, Coffea neobridsoniae, Coffea neoleroyi, Coffea perrieri, Coffea pervilleana, Coffea pocsii, Coffea pseudozanguebariae, Coffea pterocarpan, Coffea racemose, Coffea rakotonasoloi, Coffea ratsimamangae, Coffea resinosa, Coffea rhamnifolia, Coffea richardii, Coffea sahafaryensis, Coffea sakarahae, Coffea salvatrix, Coffea sambavensis, Coffea sapinii, Coffea schliebenii, Coffea semsei, Coffea sessiliflora, Coffea stenophylla, Coffea tetragona, Coffea togoensis, Coffea toshii, Coffea travancorensis, Coffea tricalysioides, Coffea tsirananae, Coffea vatovavyensis, Coffea vavateninensis, Coffea vianneyi, Coffea vohemarensis, Coffea wightiana, or Coffea zanguebariae. 237. The kit of embodiment 235 or 236, wherein the Coffea plant is Coffea arabica. 238. The kit of embodiment 221, wherein the plant is a Theaceae plant. Page 83 of 138 239. The kit of embodiment 238, wherein the Theaceae plant is a Camellia plant. 240. The kit of embodiment 239, wherein the Camellia plant is Camellia sinensis var. sinensis, Camellia sinensis var. assamica, Camellia sinensis var. pubilimba, or Camellia sinensis var. dehungensis. 241. The kit of embodiment 239 or 249, wherein the Camellia plant is Camellia sinensis var. sinensi. 242. The kit of any of embodiments 183-241, wherein the aqueous media includes a beverage. 243. The kit of embodiment 242, wherein the beverage is beer, coffee, or tea. 244. The kit of embodiment 242 or 243, wherein the beverage is tea. 245. The kit of embodiment 242, wherein the beverage is soda. 246. The kit of any of embodiments 242-245, wherein the beverage is a juice-flavored drink. 247. The kit of embodiment 242, wherein the beverage is carbonated water. 248. The kit of embodiment 179, including 30-40 g LC, 2-6 g surfactant, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 249.5. The kit of embodiment 179, including 35 g LC, 4 g surfactant, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 250.6. The kit of embodiment 179, including 35.85 g LC, 3.96 g surfactant, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 251. The kit of embodiment 179 or 165, including 30-40 g LC, 2-6 g surfactant, 3-7 g rebaudioside A, 4-8 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 252. The kit of embodiment 179 or 165, including 35 g LC, 4 g surfactant, 5 g rebaudioside A, 6 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 253. The kit of embodiment 179 or 165, including 35.85 g LC, 3.96 g surfactant, 4.70 g rebaudioside A, 6.26 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. Page 84 of 138 254. The kit of embodiment 179 or 165, including 30-40 g LC, 2-6 g surfactant, 3-7 g glycoside, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 255. The kit of embodiment 179 or 165, including 35 g LC, 4 g surfactant, 5 g glycoside, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 256. The kit of embodiment 179 or 165, 35.85 g LC, 3.96 g surfactant, 4.70 g glycoside, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 257. The kit of embodiment 179 or 165, including 30-40 g LC, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 258. The kit of embodiment 179 or 165, including 35 g LC, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 259. The kit of embodiment 179 or 165, including 35.85 g LC, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 260. The kit of embodiment 179, including 30-40 g cannabidiol, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 261. The kit of embodiment 179, including 35 g cannabidiol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 262. The kit of embodiment 179, including 35.85 g cannabidiol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. Page 85 of 138 263. The kit of embodiment 179 or 165, including 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 264. The kit of embodiment 179 or 165, including 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 265. The kit of embodiment 179 or 165, including 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 266. The kit of embodiment 179, including 30-40 g cannabidiol, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, and 580 – 630 g water. 267. The kit of embodiment 179, including 35 g cannabidiol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, and 610 or 611 g water. 268. The kit of embodiment 179, including 35.85 g cannabidiol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, and 611.50 g water. 269. The kit of embodiment 179 or 165, including 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, and 580 – 630 g water. 270. The kit of embodiment 179 or 165, including 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, and 610 or 611 g water. 271. The kit of embodiment 179 or 165, including 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, and 611.50 g water. 272. The kit of embodiment 179, including 30-40 g cannabidiol, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g triethyl Page 86 of 138 citrate. 273. The kit of embodiment 179, including 35 g cannabidiol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g triethyl citrate. 274. The kit of embodiment 179, including 35.85 g cannabidiol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g triethyl citrate. 275. The kit of embodiment 179 or 165, including 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g triethyl citrate. 276. The kit of embodiment 179 or 165, including 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g triethyl citrate. 277. The kit of embodiment 179 or 165, including 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g triethyl citrate. 278. The kit of embodiment 179, including 30-40 g tetrahydrocannabinol, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 279. The kit of embodiment 179, including 35 g tetrahydrocannabinol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 280. The kit of embodiment 179, including 35.85 g tetrahydrocannabinol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 281. The kit of embodiment 179 or 180, including 30-40 g tetrahydrocannabinol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 282. The kit of embodiment 179 or 180, including 35 g tetrahydrocannabinol, 4 g saponin, 5 g Page 87 of 138 rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 283. The kit of embodiment 179 or 180, including 35.85 g tetrahydrocannabinol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 284. The kit of embodiment 179 or 180, including 30-40 g cannabigerol, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 285. The kit of embodiment 179 or 180, including 35 g cannabigerol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 286. The kit of embodiment 179 or 180, including 35.85 g cannabigerol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 287. The kit of embodiment 179 or 180, including 30-40 g cannabigerol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 288. The kit of embodiment 179 or 180, including 35 g cannabigerol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 289. The kit of embodiment 179 or 180, including 35.85 g cannabigerol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 290. The kit of embodiment 179 or 180, including 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside M, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. Page 88 of 138 291. The kit of embodiment 179 or 180, including 35 g cannabidiol, 4 g saponin, 5 g rebaudioside M, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 292. The kit of embodiment 179 or 180, including 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside M, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 293. The kit of embodiment 179 or 180, including 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g isomogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 294. The kit of embodiment 179 or 180, including 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g isomogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 295. The kit of embodiment 179 or 180, including 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g isomogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 296. The kit of embodiment 179 or 180, including 30-40 g curcumin, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 297. The kit of embodiment 179 or 180, including 35 g curcumin, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 298. The kit of embodiment 179 or 180, including 35.85 g curcumin, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 299. The kit of embodiment 179 or 180, including 30-40 g curcumin, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 Page 89 of 138 g water, and optionally 3-7 g sucrose acetate isobutyrate. 300. The kit of embodiment 179 or 180, including 35 g curcumin, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 301. The kit of embodiment 179 or 180, including 35.85 g curcumin, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 302. The kit of embodiment 179 or 180, including 30-40 g melatonin, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 303. The kit of embodiment 179 or 180, including 35 g melatonin, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 304. The kit of embodiment 179 or 180, including 35.85 g melatonin, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 305. The kit of embodiment 179 or 180, including 30-40 g melatonin, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 306. The kit of embodiment 179 or 180, including 35 g melatonin, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 307. The kit of embodiment 179 or 180, including 35.85 g melatonin, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 308. The kit of embodiment 179 or 180, including 30-40 g cannabidiol, 2-6 g saponin, 7-15 g glycoside, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. Page 90 of 138 309. The kit of embodiment 179 or 180, including 35 g cannabidiol, 4 g saponin, 11 g glycoside, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 310. The kit of embodiment 179 or 180, including 35.85 g cannabidiol, 3.96 g saponin, 10.96 g glycoside, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 311. The kit of embodiment 179 or 180, including 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 312. The kit of embodiment 179 or 180, including 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 313. The kit of embodiment 179 or 180, including 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 314. The kit of embodiment 179 or 180, including 30-40 g cannabidiol, 0.02-0.06 g saponin, 0.07- 0.15 g glycoside, 0.002 – 0.006 g tocopherol, 0.0006 - 0.0010 g ascorbyl palmitate, 0.0060 – 0.010 g ascorbic acid, 0.1 – 0.3 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 4 - 8 g sucrose, 580 – 630 g water, and optionally 0.03-0.07 g sucrose acetate isobutyrate. 315. The kit of embodiment 179 or 180, including 35 g cannabidiol, 0.04 g saponin, 0.11 g glycoside, 0.004 g tocopherol, 0.0008 g ascorbyl palmitate, 0.008 g ascorbic acid, 0.2 g sodium benzoate, 0.2 g potassium sorbate, 6 g sucrose, 610 or 611 g water, and optionally 0.04 g sucrose acetate isobutyrate. 316. The kit of embodiment 179 or 180, including 35.85 g cannabidiol, 0.0396 g saponin, 0.1096 g glycoside, 0.0041 g tocopherol, 0.0008 g ascorbyl palmitate, 0.0080 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 6.12 g sucrose, 611.50 g water, and optionally 0.0493 g sucrose acetate isobutyrate. 317. The kit of embodiment 179 or 180, including 30-40 g cannabidiol, 0.02-0.06 g saponin, 0.03- 0.07 g rebaudioside A, 0.04-0.08 g mogroside V, 0.002 – 0.006 g tocopherol, 0.0006 - 0.0010 g ascorbyl palmitate, 0.0060 – 0.010 g ascorbic acid, 0.1 – 0.3 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 4 - 8 g sucrose, 580 – 630 g water, and optionally 0.03-0.07 g sucrose acetate isobutyrate. 318. The kit of embodiment 179 or 180, including 35 g cannabidiol, 0.04 g saponin, 0.05 g rebaudioside A, 0.06 g mogroside V, 0.004 g tocopherol, 0.0008 g ascorbyl palmitate, 0.008 g ascorbic acid, 0.2 g sodium benzoate, 0.2 g potassium sorbate, 6 g sucrose, 610 or 611 g water, and optionally 0.04 g sucrose acetate isobutyrate. 319. The kit of embodiment 179 or 180, including 35.85 g cannabidiol, 0.0396 g saponin, 0.0470 Page 91 of 138 g rebaudioside A, 0.0626 g mogroside V, 0.0041 g tocopherol, 0.0008 g ascorbyl palmitate, 0.0080 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 6.12 g sucrose, 611.50 g water, and optionally 0.0493 g sucrose acetate isobutyrate. 320. The kit of embodiment 179 or 180, including 8 - 12 g cannabidiol, 14 - 18 g all-rac-alpha- tocopherol, 0.5-4 g glycoside, 0.05 – 0.2 g ascorbyl palmitate, 1 - 3 g tween 80, 2 - 5 g span 80, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 65 - 70 g water. 321. The kit of embodiment 179 or 180, including 10 g cannabidiol, 16 g all-rac-alpha-tocopherol, 2 g glycoside, 0.10 g ascorbyl palmitate, 2 g tween 80, 3 or 4 g span 80, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 67 g water. 322. The kit of embodiment 179 or 180, including 10 g cannabidiol, 16 g all-rac-alpha-tocopherol, 1.43 g glycoside, 0.10 g ascorbyl palmitate, 1.98 g tween 80, 3.52 g span 80, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 66.9 g water. 323. The kit of embodiment 179 or 180, including 8 - 12 g cannabidiol, 14 - 18 g all-rac-alpha- tocopherol, 0.25 – 2 g rebaudioside A, 0.25 – 2 g mogroside V, 0.05 – 0.2 g ascorbyl palmitate, 1 - 3 g tween 80, 2 - 5 g span 80, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 65 - 70 g water. 324. The kit of embodiment 179 or 180, including 10 g cannabidiol, 16 g all-rac-alpha-tocopherol, 1 g rebaudioside A, 1 g mogroside V, 0.10 g ascorbyl palmitate, 2 g tween 80, 3 or 4 g span 80, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 67 g water. 325. The kit of embodiment 179 or 180, including 10 g cannabidiol, 16 g all-rac-alpha-tocopherol, 0.61 g rebaudioside A, 0.82 g mogroside V, 0.10 g ascorbyl palmitate, 1.98 g tween 80, 3.52 g span 80, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 66.9 g water. 326. The kit of embodiment 179 or 180, including 5 – 7 g ubiquinone, 0.25 – 2 g saponin, 0.5-4 g glycoside, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 90 – 95 g water. 327. The kit of embodiment 179 or 180, including 6 g ubiquinone, 1 g saponin, 2 g glycoside, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 92 g water. 328. The kit of embodiment 179 or 180, including 5.99 g ubiquinone, 0.78 g saponin, 1.43 glycoside, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 91.73 g water. 329. The kit of embodiment 179 or 180, including 5 – 7 g ubiquinone, 0.25 – 2 g saponin, 0.25 – 2 g rebaudioside A, 0.25 – 2 g mogroside V, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 90 – 95 g water. 330. The kit of embodiment 179 or 180, including 6 g ubiquinone, 1 g saponin, 1 g rebaudioside A, 1 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 92 g water. 331. The kit of embodiment 179 or 180, including 5.99 g ubiquinone, 0.78 g saponin, 0.61 g Page 92 of 138 rebaudioside A, 0.82 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 91.73 g water. 332. The kit of embodiment 179 or 180, including 5 – 7 g ubiquinol, 0.25 – 2 g saponin, 0.25 – 2 g rebaudioside A, 0.25 – 2 g mogroside V, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 90 – 95 g water. 333. The kit of embodiment 179 or 180, including 6 g ubiquinol, 1 g saponin, 1 g rebaudioside A, 1 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 92 g water. 334. The kit of embodiment 179 or 180, including 5.99 g ubiquinol, 0.78 g saponin, 0.61 g rebaudioside A, 0.82 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 91.73 g water. 335. The kit of embodiment 179 or 180, including 1-3 g cannabinol, 1-3 g sunflower oil, 0.1-0.5 g saponin, 01.-0.3 g rebaudioside A, 0.1-0.5 g mogroside V, 0.01-0.02 g sodium benzoate, 0.01- 0.02 g potassium sorbate, and 13-18 g water. 336. The kit of embodiment 179 or 180, including 2 g cannabinol, 2 g sunflower oil, 0.3 g saponin, 0.2 g rebaudioside A, 0.3 g mogroside V, 0.01 g sodium benzoate, 0.01 g potassium sorbate, and 15 g water. 337. The kit of embodiment 179 or 180, including 1.60 g cannabinol, 1.6 g sunflower oil, 0.38 g saponin, 0.19 g rebaudioside A, 0.25 g mogroside V, 0.01 g sodium benzoate, 0.01 g potassium sorbate, and 16.04 g water. 338. The kit of embodiment 179 or 180, including 30-40 g cannabidiol, 2-6 g vitamin E TPGS, 3- 7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 – 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.1 – 0.3 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 4 – 8 g sucrose, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 339. The kit of embodiment 179 or 180, including 35 g cannabidiol, 4 g vitamin E TPGS, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.2 g sodium benzoate, 0.2 g potassium sorbate, 6 g sucrose, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 340. The kit of embodiment 179 or 180, including 35.85 g cannabidiol, 3.96 g vitamin E TPGS, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 6.12 g sucrose, 611.50 g water and optionally 4.93 g sucrose acetate isobutyrate. 341. The kit of embodiment 179 or 180, including 4-6 g cannabidiol, 2-5 g saponin from Yucca, 0.25-2 g rebaudioside A, 0.25-2 g mogroside V, 0.01-0.10 g sodium benzoate, 0.01-0.10 g potassium sorbate, and 80-100 g water. Page 93 of 138 342. The kit of embodiment 179 or 180, including 5 g cannabidiol, 3 g saponin from Yucca, 0.5 g rebaudioside A, 0.5 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 90 g water. 343. The kit of embodiment 179 or 180, including 5.82 g cannabidiol, 3.01 g saponin from Yucca, 0.43 g rebaudioside A, 0.57 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 90.11 g water. 344. The kit of embodiment 179 or 180, including 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g rebaudioside C, 0.2 – 0.6 g tocopherol, 0.60 – 1.0 g ascorbic acid, 0.1 – 0.3 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 4 – 8 g sucrose, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 345. The kit of embodiment 179 or 180, including 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g rebaudioside C, 0.4 g tocopherol, 0.80 g ascorbic acid, 0.2 g sodium benzoate, 0.2 g potassium sorbate, 6 g sucrose, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 346. The kit of embodiment 179 or 180, including 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g rebaudioside C, 0.41 g tocopherol, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 6.12 g sucrose, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 347. A method of forming a composition including adding a glycoside, a surfactant, and a lipophilic component (LC) to a media. 348. The method of embodiment 347, wherein the composition includes at least two glycosides. 349. The method of embodiment 347 or 348, wherein the LC is a lipophilic active component (LAC) or a regulated LAC (rLAC). 350. The method of any of embodiments 347-349, wherein the composition is a stabilized emulsion. 351. The method of any of embodiments 347-350, wherein the media is an aqueous media. 352. The method of any of embodiments 347-351, wherein the composition includes 1% to 9%, 2% to 6%, 3% to 5%, 5% to 50%, 2% to 40%, 8 to 30%, 10% to 99%, 10% to 70%, 20% to 60%, 30% to 50%, 20% to 40%, 10 to 30%, 50% to 99%, 50% to 80%, 60% to 70%, 70% to 99%, 80% to 99%, or 90% to 99.99% moisture. 353. The method of any of embodiments 347-352, wherein the composition has two to five times more LC than glycoside within the composition. 354. The method of any of embodiments 347-352, wherein the composition has five to ten more times more LC than an individual glycoside within the composition. Page 94 of 138 355. The method of any of embodiments 347-353, wherein the composition has two times more LC than glycoside within the composition. 356. The method of any of embodiments 347-355, wherein the composition has two times more LC than the combination of two glycosides within the composition. 357. The method of any of embodiments 347-356, wherein the composition has more than 5% LC by weight of the composition. 358. The method of any of embodiments 347-356, wherein the aqueous formulation has more than 5%-10% LC by weight of the composition. 359. The method of any of embodiments 347-358, wherein a glycoside within the method includes a steviol-type glycoside. 360. The method of any of embodiments 347-359, wherein a glycoside within the method includes a curcurbitane-type glycoside. 361. The method of any of embodiments 348-360, wherein at least one of the at least two glycosides includes a steviol-type glycoside. 362. The method of any of embodiments 348-361, wherein at least one of the at least two glycosides includes a curcurbitane-type glycoside.

363. The method of any of embodiments 348-362, wherein at least one of the at least two glycosides includes a steviol-type glycoside and at least one of the at least two glycosides includes a curcurbitane-type glycoside. 364. The method of any of embodiments 347-363, wherein a glycoside within the method includes a diterpenoid-type glycoside. 365. The method of any of embodiments 347-364, wherein a glycoside within the method includes a triterpenoid-type glycoside. 366. The method of any of embodiments 348-365, wherein at least one of the at least two glycosides includes a diterpenoid-type glycoside.

367. The method of any of embodiments 348-366, wherein at least one of the at least two glycosides includes a triterpenoid-type glycoside. 368. The method of any of embodiments 348-367, wherein at least one of the at least two glycosides includes a diterpenoid-type glycoside and at least one of the at least two glycosides includes a triterpenoid-type glycoside. 369. The method of any of embodiments 347-368, wherein a glycoside within the method includes a rebaudioside glycoside. 370. The method of any of embodiments 347-369, wherein a glycoside within the method includes a mogroside-type glycoside. Page 95 of 138 371. The method of any of embodiments 348-370, wherein at least one of the at least two glycosides includes a rebaudioside glycoside. 372. The method of any of embodiments 348-371, wherein at least one of the at least two glycosides includes a mogroside-type glycoside. 373. The method of any of embodiments 348-372, wherein at least one of the at least two glycosides includes a rebaudioside glycoside and at least one of the at least two glycosides includes a mogroside-type glycoside. 374. The method of any of embodiments 347-373, wherein a glycoside within the method includes amyrin, furostan, Q521 quillaja constituent, glycyrrhizic acid, escin, tea saponin, or bidesmosidic saponin from quillaja. 375. The method of any of embodiments 348-374, wherein at least one of the at least two glycosides includes amyrin, furostan, Q521 quillaja constituent, glycyrrhizic acid, escin, tea saponin, or bidesmosidic saponin from quillaja. 376. The method of any of embodiments 347-375, wherein a surfactant within the method includes a sucrose ester. 377. The method of any of embodiments 347-376, wherein a surfactant within the method includes a sorbitan ester. 378. The method of any of embodiments 347-377, wherein a surfactant within the method includes a saponin. 379. The method of embodiment 378, wherein the glycoside does not include a saponin if the surfactant is a saponin. 380. The method of any of embodiments 347-379, wherein a surfactant within the method includes a non-protein-based surfactant. 381. The method of any of embodiments 347-380, wherein a surfactant within the method includes a protein-based surfactant that does not consist of soy protein isolate. 382. The method of any of embodiments 347-381, wherein a surfactant within the method includes an ionic surfactant. 383. The method of any of embodiments 347-382, wherein a surfactant within the method includes an anionic surfactant. 384. The method of any of embodiments 347-383, wherein a surfactant within the method includes a zwitterionic surfactant. 385. The method of any of embodiments 347-384, wherein a surfactant within the method includes a sorbitan fatty acid ester, polyethylene glycol sorbitan fatty acid ester, polyethylene- polypropylene glycol, saturated polyglycolized glyceride, polyethylene glycol, quillaia, Page 96 of 138 polyethylene glycol stearate, polyethylene glycol hydrogenated castor oil, diethylene glycol monoethyl ether, propylene glycol laurate , D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS), polyvinyl pyrrolidone, iota carrageenan, hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC), microcrystalline cellulose (MCC), lecithin, sucrose laurate, sucrose palmitate, sucrose stearate, gamma-cyclodextrin, β-cyclodextrin pectin, whey protein, caseinate, Xanthan gum, locust bean gum, gellan gum, acacia gum, guar gum, Tragacanth gum, polyethylene glycol hydroxystearate polyoxyl-10-oleyl ether, or polyethylene glycol glyceride. 386. The method of any of embodiments 347-385, wherein a surfactant within the method includes polysorbate 80. 387. The method of any of embodiments 347-386, wherein a surfactant within the method includes sorbitan monooleate. 388. The method of any of embodiments 347-387, wherein a surfactant within the method includes polysorbate 80 and sorbitan monooleate. 389. The method of any of embodiments 347-388, wherein the LC is derived from a plant. 390. The method of embodiment 389, wherein the plant is a Cannabaceae plant. 391. The method of embodiment 390, wherein the Cannabaceae plant is a cannabis plant. 392. The method of embodiment 391, wherein the cannabis plant is Cannabis sativa, Cannabis indica, or Cannabis ruderalis. 393. The method of any of embodiments 347-392, wherein the LC is a cannabinoid. 394. The method of embodiment 393, wherein the cannabinoid includes tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBT), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), and/or mixtures thereof. 395. The method of embodiment 393 or 394, wherein the cannabinoid includes CBD. 396. The method of any of embodiments 393-395, wherein the cannabinoid includes CBD and THC. 397. The method of any of embodiments 393-396, wherein the cannabinoid includes CBD and THC at a ratio of 1:1 (% w/w). 398. The method of any of embodiments 347-397, wherein the LC includes a synthetic and/or artificial cannabinoid. 399. The method of embodiment 390, wherein the Cannabaceae plant is a Humulus plant. Page 97 of 138 400. The method of embodiment 399, wherein the Humulus plant is Humulus lupulus, Humulus americanus, Humulus cordifolius, Humulus neomexicanus, Humulus pubescens, or Humulus scandens. 401. The method of embodiment 399 or 400, wherein the Humulus plant is Humulus lupulus. 402. The method of embodiment 389, wherein the plant is a Rubiaceae plant. 403. The method of embodiment 402, wherein the Rubiaceae plant is a Coffea plant. 404. The method of embodiment 403, wherein the Coffea plant is Coffea abbayesii, Coffea affinis, Coffea alleizettii, Coffea ambanjensis, Coffea ambongenis, Coffea andrambovatensis, Coffea ankaranensis, Coffea anthonyi, Coffea arabica, Coffea arenesiana, Coffea augagneurii, Coffea bakossii, Coffea benghalensis, Coffea bertrandii, Coffea betamponensis, Coffea bissetiae, Coffea boinensis, Coffea boiviniana, Coffea bonnieri, Coffea brassii, Coffea brevipes, Coffea bridsoniae, Coffea buxifolia, Coffea canephora, Coffea carrissoi, Coffea charrieriana, Coffea cochinchinensis, Coffea commersoniana, Coffea congensis, Coffea costatifructa, Coffea coursiana, Coffea dactylifera, Coffea decaryana, Coffea dubardii, Coffea ebracteolata, Coffea eugenioides, Coffea fadenii, Coffea farafanganensis, Coffea floresiana, Coffea fotsoana, Coffea fragilis, Coffea fragrans, Coffea gallienii, Coffea grevei, Coffea heimii, Coffea homollei, Coffea horsfieldiana, Coffea humbertii, Coffea humblotiana, Coffea humilis, Coffea jumellei, Coffea kapakata, Coffea kianjavatensis, Coffea kihansiensis, Coffea kimbozensis, Coffea kivuensis, Coffea labatii, Coffea lancifolia, Coffea lebruniana, Coffea leonimontana, Coffea leroyi, Coffea liaudii, Coffea liberica, Coffea ligustroides, Coffea littoralis, Coffea lulandoensis, Coffea mabesae, Coffea macrocarpa, Coffea madurensis, Coffea magnistipula, Coffea malabarica, Coffea mangoroensis, Coffea mannii, Coffea manombensis, Coffea mapiana, Coffea mauritiana, Coffea mayombensis, Coffea mcphersonii, Coffea melanocarpa, Coffea merguensis, Coffea millotii, Coffea minutiflora, Coffea mogenetii, Coffea mongensis, Coffea montekupensis, Coffea montis-sacri, Coffea moratii, Coffea mufindiensis, Coffea myrtifolia, Coffea namorokensis, Coffea neobridsoniae, Coffea neoleroyi, Coffea perrieri, Coffea pervilleana, Coffea pocsii, Coffea pseudozanguebariae, Coffea pterocarpan, Coffea racemose, Coffea rakotonasoloi, Coffea ratsimamangae, Coffea resinosa, Coffea rhamnifolia, Coffea richardii, Coffea sahafaryensis, Coffea sakarahae, Coffea salvatrix, Coffea sambavensis, Coffea sapinii, Coffea schliebenii, Coffea semsei, Coffea sessiliflora, Coffea stenophylla, Coffea tetragona, Coffea togoensis, Coffea toshii, Coffea travancorensis, Coffea tricalysioides, Coffea tsirananae, Coffea vatovavyensis, Coffea vavateninensis, Coffea vianneyi, Coffea vohemarensis, Coffea wightiana, or Coffea zanguebariae. 405. The method of embodiment 403 or 404, wherein the Coffea plant is Coffea arabica. 406. The method of any of embodiments 389, wherein the plant is a Theaceae plant. Page 98 of 138 407. The method of any of embodiments 406, wherein the Theaceae plant is a Camellia plant. 408. The method of any of embodiments 407, wherein the Camellia plant is Camellia sinensis var. sinensis, Camellia sinensis var. assamica, Camellia sinensis var. pubilimba, or Camellia sinensis var. dehungensis. 409. The method of embodiment 407 or 408, wherein the Camellia plant is Camellia sinensis var. sinensi. 410. The method of any of embodiments 347-409, formulated as a beverage. 411. The method of embodiment 410, wherein the beverage is beer, coffee, or tea. 412. The method of embodiment 410 or 411, wherein the beverage is tea. 413. The method of any of embodiments 410-412, wherein the beverage is soda. 414. The method of any of embodiments 410-413, wherein the beverage is a juice-flavored drink. 415. The method of any of embodiments 410-414, wherein the beverage is carbonated water. 416. The method of embodiment 347, wherein the method includes adding 30-40 g LC, 2-6 g surfactant, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 417. The method of embodiment 347, wherein the method includes adding 35 g LC, 4 g surfactant, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 418. The method of embodiment 347, wherein the method includes adding 35.85 g LC, 3.96 g surfactant, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 419. The method of embodiment 347 or 348, wherein the method includes adding 35 g LC, 4 g surfactant, 5 g rebaudioside A, 6 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 420. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g LC, 3.96 g surfactant, 4.70 g rebaudioside A, 6.26 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 421. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g LC, 2- 6 g surfactant, 3-7 g glycoside, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl Page 99 of 138 palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 422. The method of embodiment 347 or 348, wherein the method includes adding 35 g LC, 4 g surfactant, 5 g glycoside, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 423. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g LC, 3.96 g surfactant, 4.70 g glycoside, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 424. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g LC, 2- 6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 425. The method of embodiment 347 or 348, wherein the method includes adding 35 g LC, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 426. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g LC, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 427. The method of embodiment 347, wherein the method includes adding 30-40 g cannabidiol, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 428. The method of embodiment 347, wherein the method includes adding 35 g cannabidiol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 429. The method of embodiment 347, wherein the method includes adding 35.85 g cannabidiol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. Page 100 of 138 430. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 431. The method of embodiment 347 or 348, wherein the method includes adding 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 432. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 433. The method of embodiment 347, wherein the method includes adding 30-40 g cannabidiol, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, and 580 – 630 g water. 434. The method of embodiment 347, wherein the method includes adding 35 g cannabidiol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, and 610 or 611 g water. 435. The method of embodiment 347, wherein the method includes adding 35.85 g cannabidiol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, and 611.50 g water. 436. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, and 580 – 630 g water. 437. The method of embodiment 347 or 348, wherein the method includes adding 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, and 610 or 611 g water. 438. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, and 611.50 g water. Page 101 of 138 439. The method of embodiment 347, wherein the method includes adding 30-40 g cannabidiol, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g triethyl citrate. 440. The method of embodiment 347, wherein the method includes adding 35 g cannabidiol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g triethyl citrate. 441. The method of embodiment 347, wherein the method includes adding 35.85 g cannabidiol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g triethyl citrate. 442. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g triethyl citrate. 443. The method of embodiment 347 or 348, wherein the method includes adding 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g triethyl citrate. 444. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g triethyl citrate. 445. The method of embodiment 347, wherein the method includes adding 30-40 g tetrahydrocannabinol, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 446. The method of embodiment 347, wherein the method includes adding 35 g tetrahydrocannabinol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 447. The method of embodiment 347, wherein the method includes adding 35.85 g tetrahydrocannabinol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g Page 102 of 138 water, and optionally 4.93 g sucrose acetate isobutyrate. 448. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g tetrahydrocannabinol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 449. The method of embodiment 347 or 348, wherein the method includes adding 35 g tetrahydrocannabinol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 450. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g tetrahydrocannabinol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 451. The method of embodiment 347, wherein the method includes adding 30-40 g cannabigerol, 2-6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 452. The method of embodiment 347, wherein the method includes adding 35 g cannabigerol, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 453. The method of embodiment 347, wherein the method includes adding 35.85 g cannabigerol, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 454. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g cannabigerol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 455. The method of embodiment 347 or 348, wherein the method includes adding 35 g cannabigerol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. Page 103 of 138 456. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g cannabigerol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 457. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside M, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 458. The method of embodiment 347 or 348, wherein the method includes adding 35 g cannabidiol, 4 g saponin, 5 g rebaudioside M, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 459. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside M, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 460. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g isomogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 461. The method of embodiment 347 or 348, wherein the method includes adding 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g isomogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 462. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g isomogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 463. The method of embodiment 347, wherein the method includes adding 30-40 g curcumin, 2- 6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 464. The method of embodiment 347, wherein the method includes adding 35 g curcumin, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g Page 104 of 138 sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 465. The method of embodiment 347, wherein the method includes adding 35.85 g curcumin, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 466. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g curcumin, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 467. The method of embodiment 347 or 348, wherein the method includes adding 35 g curcumin, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 468. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g curcumin, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 469. The method of embodiment 347, wherein the method includes adding 30-40 g melatonin, 2- 6 g saponin, 7-15 g glycoside, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 470. The method of embodiment 347, wherein the method includes adding 35 g melatonin, 4 g saponin, 11 g glycoside, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 471. The method of embodiment 347, wherein the method includes adding 35.85 g melatonin, 3.96 g saponin, 10.96 g glycoside, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 472. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g melatonin, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 - 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.10 – 0.26 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. Page 105 of 138 473. The method of embodiment 347 or 348, wherein the method includes adding 35 g melatonin, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.2 g potassium sorbate, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 474. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g melatonin, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 475. The method of embodiment 347, wherein the method includes adding 30-40 g cannabidiol, 2-6 g saponin, 7-15 g glycoside, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 476. The method of embodiment 347, wherein the method includes adding 35 g cannabidiol, 4 g saponin, 11 g glycoside, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 477. The method of embodiment 347, wherein the method includes adding 35.85 g cannabidiol, 3.96 g saponin, 10.96 g glycoside, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 478. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g mogroside V, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 479. The method of embodiment 347 or 348, wherein the method includes adding 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g mogroside V, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 480. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g mogroside V, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 481. The method of embodiment 347, wherein the method includes adding 30-40 g cannabidiol, 0.02-0.06 g saponin, 0.07-0.15 g glycoside, 0.002 – 0.006 g tocopherol, 0.0006 - 0.0010 g ascorbyl palmitate, 0.0060 – 0.010 g ascorbic acid, 0.1 – 0.3 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 4 - 8 g sucrose, 580 – 630 g water, and optionally 0.03-0.07 g sucrose acetate isobutyrate. 482. The method of embodiment 347, wherein the method includes adding 35 g cannabidiol, 0.04 g saponin, 0.11 g glycoside, 0.004 g tocopherol, 0.0008 g ascorbyl palmitate, 0.008 g ascorbic acid, 0.2 g sodium benzoate, 0.2 g potassium sorbate, 6 g sucrose, 610 or 611 g water, and optionally 0.04 g sucrose acetate isobutyrate. Page 106 of 138 483. The method of embodiment 347, wherein the method includes adding 35.85 g cannabidiol, 0.0396 g saponin, 0.1096 g glycoside, 0.0041 g tocopherol, 0.0008 g ascorbyl palmitate, 0.0080 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 6.12 g sucrose, 611.50 g water, and optionally 0.0493 g sucrose acetate isobutyrate. 484. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g cannabidiol, 0.02-0.06 g saponin, 0.03-0.07 g rebaudioside A, 0.04-0.08 g mogroside V, 0.002 – 0.006 g tocopherol, 0.0006 - 0.0010 g ascorbyl palmitate, 0.0060 – 0.010 g ascorbic acid, 0.1 – 0.3 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 4 - 8 g sucrose, 580 – 630 g water, and optionally 0.03-0.07 g sucrose acetate isobutyrate. 485. The method of embodiment 347 or 348, wherein the method includes adding 35 g cannabidiol, 0.04 g saponin, 0.05 g rebaudioside A, 0.06 g mogroside V, 0.004 g tocopherol, 0.0008 g ascorbyl palmitate, 0.008 g ascorbic acid, 0.2 g sodium benzoate, 0.2 g potassium sorbate, 6 g sucrose, 610 or 611 g water, and optionally 0.04 g sucrose acetate isobutyrate. 486. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g cannabidiol, 0.0396 g saponin, 0.0470 g rebaudioside A, 0.0626 g mogroside V, 0.0041 g tocopherol, 0.0008 g ascorbyl palmitate, 0.0080 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 6.12 g sucrose, 611.50 g water, and optionally 0.0493 g sucrose acetate isobutyrate. 487. The method of embodiment 347, wherein the method includes adding 8 - 12 g cannabidiol, 14 - 18 g all-rac-alpha-tocopherol, 0.5-4 g glycoside, 0.05 – 0.2 g ascorbyl palmitate, 1 - 3 g tween 80, 2 - 5 g span 80, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 65 - 70 g water. 488. The method of embodiment 347, wherein the method includes adding 10 g cannabidiol, 16 g all-rac-alpha-tocopherol, 2 g glycoside, 0.10 g ascorbyl palmitate, 2 g tween 80, 3 or 4 g span 80, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 67 g water. 489. The method of embodiment 347, wherein the method includes adding 10 g cannabidiol, 16 g all-rac-alpha-tocopherol, 1.43 g glycoside, 0.10 g ascorbyl palmitate, 1.98 g tween 80, 3.52 g span 80, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 66.9 g water. 490. The method of embodiment 347 or 348, wherein the method includes adding 8 - 12 g cannabidiol, 14 - 18 g all-rac-alpha-tocopherol, 0.25 – 2 g rebaudioside A, 0.25 – 2 g mogroside V, 0.05 – 0.2 g ascorbyl palmitate, 1 - 3 g tween 80, 2 - 5 g span 80, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 65 - 70 g water. 491. The method of embodiment 347 or 348, wherein the method includes adding 10 g cannabidiol, 16 g all-rac-alpha-tocopherol, 1 g rebaudioside A, 1 g mogroside V, 0.10 g ascorbyl Page 107 of 138 palmitate, 2 g tween 80, 3 or 4 g span 80, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 67 g water. 492. The method of embodiment 347 or 348, wherein the method includes adding 10 g cannabidiol, 16 g all-rac-alpha-tocopherol, 0.61 g rebaudioside A, 0.82 g mogroside V, 0.10 g ascorbyl palmitate, 1.98 g tween 80, 3.52 g span 80, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 66.9 g water. 493. The method of embodiment 347, wherein the method includes adding 5 – 7 g ubiquinone, 0.25 – 2 g saponin, 0.5-4 g glycoside, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 90 – 95 g water. 494. The method of embodiment 347, wherein the method includes adding 6 g ubiquinone, 1 g saponin, 2 g glycoside, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 92 g water. 495. The method of embodiment 347, wherein the method includes adding 5.99 g ubiquinone, 0.78 g saponin, 1.43 glycoside, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 91.73 g water. 496. The method of embodiment 347 or 348, wherein the method includes adding 5 – 7 g ubiquinone, 0.25 – 2 g saponin, 0.25 – 2 g rebaudioside A, 0.25 – 2 g mogroside V, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 90 – 95 g water. 497. The method of embodiment 347 or 348, wherein the method includes adding 6 g ubiquinone, 1 g saponin, 1 g rebaudioside A, 1 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 92 g water. 498. The method of embodiment 347 or 348, wherein the method includes adding 5.99 g ubiquinone, 0.78 g saponin, 0.61 g rebaudioside A, 0.82 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 91.73 g water. 499. The method of embodiment 347 or 348, wherein the method includes adding 5 – 7 g ubiquinol, 0.25 – 2 g saponin, 0.25 – 2 g rebaudioside A, 0.25 – 2 g mogroside V, 0.01 – 0.05 g sodium benzoate, 0.02 – 0.06 g potassium sorbate, and 90 – 95 g water. 500. The method of embodiment 347 or 348, wherein the method includes adding 6 g ubiquinol, 1 g saponin, 1 g rebaudioside A, 1 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 92 g water. 501. The method of embodiment 347 or 348, wherein the method includes adding 5.99 g ubiquinol, 0.78 g saponin, 0.61 g rebaudioside A, 0.82 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 91.73 g water. 502. The method of embodiment 347 or 348, wherein the method includes adding 1-3 g cannabinol, 1-3 g sunflower oil, 0.1-0.5 g saponin, 01.-0.3 g rebaudioside A, 0.1-0.5 g mogroside Page 108 of 138 V, 0.01-0.02 g sodium benzoate, 0.01-0.02 g potassium sorbate, and 13-18 g water. 503. The method of embodiment 347 or 348, wherein the method includes adding 2 g cannabinol, 2 g sunflower oil, 0.3 g saponin, 0.2 g rebaudioside A, 0.3 g mogroside V, 0.01 g sodium benzoate, 0.01 g potassium sorbate, and 15 g water. 504. The method of embodiment 347 or 348, wherein the method includes adding 1.60 g cannabinol, 1.6 g sunflower oil, 0.38 g saponin, 0.19 g rebaudioside A, 0.25 g mogroside V, 0.01 g sodium benzoate, 0.01 g potassium sorbate, and 16.04 g water. 505. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g cannabidiol, 2-6 g vitamin E TPGS, 3-7 g rebaudioside A, 4-8 g mogroside V, 0.2 – 0.6 g tocopherol, 0.06 – 0.10 g ascorbyl palmitate, 0.60 – 1.0 g ascorbic acid, 0.1 – 0.3 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 4 – 8 g sucrose, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. 506. The method of embodiment 347 or 348, wherein the method includes adding 35 g cannabidiol, 4 g vitamin E TPGS, 5 g rebaudioside A, 6 g mogroside V, 0.4 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.2 g sodium benzoate, 0.2 g potassium sorbate, 6 g sucrose, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 507. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g cannabidiol, 3.96 g vitamin E TPGS, 4.70 g rebaudioside A, 6.26 g mogroside V, 0.41 g tocopherol, 0.08 g ascorbyl palmitate, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 6.12 g sucrose, 611.50 g water and optionally 4.93 g sucrose acetate isobutyrate. 508. The method of embodiment 347 or 348, wherein the method includes adding 4-6 g cannabidiol, 2-5 g saponin from Yucca, 0.25-2 g rebaudioside A, 0.25-2 g mogroside V, 0.01-0.10 g sodium benzoate, 0.01-0.10 g potassium sorbate, and 80-100 g water. 509. The method of embodiment 347 or 348, wherein the method includes adding 5 g cannabidiol, 3 g saponin from Yucca, 0.5 g rebaudioside A, 0.5 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 90 g water. 510. The method of embodiment 347 or 348, wherein the method includes adding 5.82 g cannabidiol, 3.01 g saponin from Yucca, 0.43 g rebaudioside A, 0.57 g mogroside V, 0.03 g sodium benzoate, 0.04 g potassium sorbate, and 90.11 g water. 511. The method of embodiment 347 or 348, wherein the method includes adding 30-40 g cannabidiol, 2-6 g saponin, 3-7 g rebaudioside A, 4-8 g rebaudioside C, 0.2 – 0.6 g tocopherol, 0.60 – 1.0 g ascorbic acid, 0.1 – 0.3 g sodium benzoate, 0.1 – 0.3 g potassium sorbate, 4 – 8 g sucrose, 580 – 630 g water, and optionally 3-7 g sucrose acetate isobutyrate. Page 109 of 138 512. The method of embodiment 347 or 348, wherein the method includes adding 35 g cannabidiol, 4 g saponin, 5 g rebaudioside A, 6 g rebaudioside C, 0.4 g tocopherol, 0.80 g ascorbic acid, 0.2 g sodium benzoate, 0.2 g potassium sorbate, 6 g sucrose, 610 or 611 g water, and optionally 4 g sucrose acetate isobutyrate. 513. The method of embodiment 347 or 348, wherein the method includes adding 35.85 g cannabidiol, 3.96 g saponin, 4.70 g rebaudioside A, 6.26 g rebaudioside C, 0.41 g tocopherol, 0.80 g ascorbic acid, 0.18 g sodium benzoate, 0.24 g potassium sorbate, 6.12 g sucrose, 611.50 g water, and optionally 4.93 g sucrose acetate isobutyrate. 514. A formulation, kit, or method of any of embodiments 1-513 that includes a protein LC. [0315] (xvii) Exemplary Formulations. [0316] Table 1. Exemplary Formulation 1. 30-40 g LC 35 g LC 35.85 g LC 3-7 sucrose acetate 4 sucrose acetate 493 sucrose acetate

[0317] Table 2. Exemplary Formulation 2. 30-40 g LC 35 g LC 35.85 g LC

Page 110 of 138 0.06 – 0.10 g ascorbyl 0.08 g ascorbyl palmitate 0.08 g ascorbyl palmitate palmitate

30-40 g LC 35 g LC 35.85 g LC 3-7 g sucrose acetate 4 g sucrose acetate 4.93 g sucrose acetate

[0319] Table 4. Exemplary Formulation 4. 30-40 g cannabidiol 35 g cannabidiol 35.85 g cannabidiol

Page 111 of 138 0 – 0.26 g sodium benzoate 0.18 g sodium benzoate 0.18 g sodium benzoate – 0.3 g potassium sorbate 0.2 g potassium sorbate 0.24 g potassium sorbate

0-40 g cannabidiol 35 g cannabidiol 35.85 g cannabidiol -6 g saponin 4 g saponin 3.96 g saponin

a e . xempary ormua on . 0-40 g cannabidiol 35 g cannabidiol 35.85 g cannabidiol

[0322] Table 7. Exemplary Formulation 7. 30-40 g tetrahydrocannabinol 35 g tetrahydrocannabinol 35.85 g tetrahydrocannabinol 3-7 g sucrose acetate 4 g sucrose acetate 4.93 g sucrose acetate

a e . e pay o ua o . 30-40 g cannabigerol 35 g cannabigerol 35.85 g cannabigerol

Page 113 of 138 [0324] Table 9. Exemplary Formulation 9. 30-40 g cannabidiol 35 g cannabidiol 35.85 g cannabidiol 3-7 g sucrose acetate 4 g sucrose acetate 4.93 g sucrose acetate

a e . e pay o ua o . 30-40 g cannabidiol 35 g cannabidiol 35.85 g cannabidiol

Page 114 of 138 [0326] Table 11. Exemplary Formulation 11. 30-40 g curcumin 35 g curcumin 35.85 g curcumin 3-7 g sucrose acetate 4 g sucrose acetate 4.93 g sucrose acetate

. p y . 30-40 g melatonin 35 g melatonin 35.85 g melatonin

[0328] Table 13. Exemplary Formulation 13. Page 115 of 138 30-40 g cannabidiol 35 g cannabidiol 35.85 g cannabidiol 3-7 g sucrose acetate 5 g sucrose acetate 4.93 g sucrose acetate

30-40 g cannabidiol 35 g cannabidiol 35.85 g cannabidiol 3-7 g sucrose acetate 4 g sucrose acetate 4.93 g sucrose acetate

[0330] Table 15. Exemplary Formulation 15. 8 – 12 g cannabidiol 10 g cannabidiol 10 g cannabidiol l

Page 116 of 138 2 – 5 g span 80 3 or 4 g span 80 3.52 g span 80 0.01 – 0.05 g sodium 0.03 g sodium benzoate 0.03 g sodium benzoate

5 – 7 g ubiquinone 6 g ubiquinone 5.99 g ubiquinone 0.25 – 2 g saponin 1 g saponin 0.78 g saponin

a e . xempary ormua on . 5 – 7 g ubiquinone 6 g ubiquinone 5.99 g ubiquinone

[0333] Table 9. Exemplary Formulation 9. 30-40 g cannabinol 35 g cannabinol 35.85 g cannabinol

Page 117 of 138 2-6 g saponin 4 g saponin 3.96 g saponin 3-7 g rebaudioside A 5 g rebaudioside A 4.70 g rebaudioside A

30-40 g cannabidiol 35 g cannabidiol 35.85 g cannabidiol 37 r t t 4 r t t 493 r t t

[0335] Table 14. Exemplary Formulation 14. 30-40 g cannabidiol 35 g cannabidiol 35.85 g cannabidiol

Page 118 of 138 3-7 g rebaudioside A 5 g rebaudioside A 4.70 g rebaudioside A 4-8 g mogroside V 6 g mogroside V 6.26 g mogroside V

30-40 g cannabidiol 35 g cannabidiol 35.85 g cannabidiol 3-7 sucrose acetate 4 sucrose acetate 493 sucrose acetate

[0337] Table 22. Exemplary Formulation 22. 5 – 7 g ubiquinol 6 g ubiquinol 5.99 g ubiquinol

Page 119 of 138 benzoate 0.02 – 0.06 g potassium 0.04 g potassium sorbate 0.04 g potassium sorbate

1-3 g cannabinol 2 g cannabinol 1.60 g cannabinol 1-3 g sunflower oil 2 g sunflower oil 1.6 g sunflower oil

. p y . 30-40 g cannabidiol 35 g cannabidiol 35.85 g cannabidiol

[0340] Table 25. Exemplary Formulation 25. Page 120 of 138 4-6 g cannabidiol 5 g cannabidiol 5.82 g cannabidiol 2-5 g saponin from Yucca 3 g saponin from Yucca 3.01 g saponin from Yucca

30-40 g cannabidiol 35 g cannabidiol 35.85 g cannabidiol 3-7 g sucrose acetate 4 g sucrose acetate 493 g sucrose acetate

[0342] (xviii) Closing Paragraphs. Unless otherwise indicated, the practice of the present disclosure can employ conventional techniques of chemistry, organic chemistry, and biochemistry. These methods are described in, for example, Harcourt et al., Holt McDougal Modern Chemistry: Student Edition (2018); J. Karty, Organic Chemistry Principles and Mechanisms (2014); Nelson et al., Lehninger Principles of Biochemistry 5^th edition (2008); Skoog et al., Fundamentals of Analytical Chemistry (8^th Edition); Atkins et al., Atkins’ Physical Chemistry (11^th Edition). [0343] As will be understood by one of ordinary skill in the art, each embodiment disclosed herein can comprise, consist essentially of or consist of its particular stated element, step, ingredient or component. Thus, the terms “include” or “including” should be interpreted to recite: “comprise, Page 121 of 138 consist of, or consist essentially of.” The transition term “comprise” or “comprises” means has, but is not limited to, and allows for the inclusion of unspecified elements, steps, ingredients, or components, even in major amounts. The transitional phrase “consisting of” excludes any element, step, ingredient or component not specified. The transition phrase “consisting essentially of” limits the scope of the embodiment to the specified elements, steps, ingredients or components and to those that do not materially affect the embodiment. A material effect would cause a statistically significant reduction in the ability to obtain a claimed effect according to a relevant parameter described in the current disclosure. [0344] Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. When further clarity is required, the term “about” has the meaning reasonably ascribed to it by a person skilled in the art when used in conjunction with a stated numerical value or range, i.e., denoting somewhat more or somewhat less than the stated value or range, to within a range of ±20% of the stated value; ±19% of the stated value; ±18% of the stated value; ±17% of the stated value; ±16% of the stated value; ±15% of the stated value; ±14% of the stated value; ±13% of the stated value; ±12% of the stated value; ±11% of the stated value; ±10% of the stated value; ±9% of the stated value; ±8% of the stated value; ±7% of the stated value; ±6% of the stated value; ±5% of the stated value; ±4% of the stated value; ±3% of the stated value; ±2% of the stated value; or ±1% of the stated value. [0345] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. [0346] The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of Page 122 of 138 referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention. [0347] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims. [0348] Certain embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context. [0349] Furthermore, numerous references have been made to patents, printed publications, journal articles and other written text throughout this specification (referenced materials herein). Each of the referenced materials are individually incorporated herein by reference in their entirety for their referenced teaching. [0350] In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described. [0351] The particulars shown herein are by way of example and for purposes of illustrative Page 123 of 138 discussion of the preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of various embodiments of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for the fundamental understanding of the invention, the description taken with the drawings and/or examples making apparent to those skilled in the art how the several forms of the invention may be embodied in practice. [0352] Definitions and explanations used in the present disclosure are meant and intended to be controlling in any future construction unless clearly and unambiguously modified in the examples or when application of the meaning renders any construction meaningless or essentially meaningless. In cases where the construction of the term would render it meaningless or essentially meaningless, the definition should be taken from Webster’s Dictionary, 3^rd Edition or a dictionary known to those of ordinary skill in the art. Page 124 of 138

Claims

CLAIMS What is claimed is: 1. A formulation comprising a glycoside, a surfactant, and a lipophilic component (LC), wherein the glycoside is not a saponin if the surfactant is a saponin.

2. The formulation of claim 1, further comprising at least two glycosides.

3. The formulation of claim 1, wherein the formulation is an aqueous formulation.

4. The formulation of claim 1, wherein the formulation is a dry formulation.

5. The formulation of claim 4, wherein the dry formulation is a pill, tablet, mucoadhesive tablet, or capsule.

6. The formulation of claim 1, wherein the formulation comprises a stabilized emulsion.

7. The formulation of claim 1, wherein the formulation has two to five times more LC than the glycoside within the formulation.

8. The formulation of claim 2, wherein the formulation has five to ten times more LC than an individual glycoside within the formulation.

9. The formulation of claim 1, wherein the formulation has two times more LC than the glycoside within the formulation.

10. The formulation of claim 2, wherein the formulation has two times more LC than a combination of two glycosides within the formulation.

11. The formulation of claim 1, wherein the formulation has more than 5% LC by weight of the formulation.

12. The formulation of claim 1, wherein the formulation has more than 5%-10% LC by weight of the formulation.

13. The formulation of claim 1, wherein the glycoside comprises a steviol-type glycoside.

14. The formulation of claim 1, wherein the glycoside comprises a curcurbitane-type glycoside.

15. The formulation of claim 2, wherein at least one of the at least two glycosides comprises a steviol-type glycoside.

16. The formulation of claim 2, wherein at least one of the at least two glycosides comprises a curcurbitane-type glycoside.

17. The formulation of claim 2, wherein at least one of the at least two glycosides comprises a steviol-type glycoside and at least one of the at least two glycosides comprises a curcurbitane- type glycoside.

18. The formulation of claim 1, wherein the glycoside comprises a diterpenoid-type glycoside.

19. The formulation of claim 1, wherein the glycoside comprises a triterpenoid-type glycoside.

20. The formulation of claim 2, wherein at least one of the at least two glycosides comprises a Page 125 of 138 diterpenoid-type glycoside.

21. The formulation of claim 2, wherein at least one of the at least two glycosides comprises a triterpenoid-type glycoside.

22. The formulation of claim 2, wherein at least one of the at least two glycosides comprises a diterpenoid-type glycoside and at least one of the at least two glycosides comprises a triterpenoid- type glycoside.

23. The formulation of claim 1, wherein the glycoside comprises a rebaudioside glycoside.

24. The formulation of claim 1, wherein the glycoside comprises a mogroside-type glycoside.

25. The formulation of claim 2, wherein at least one of the at least two glycosides comprises a rebaudioside glycoside.

26. The formulation of claim 2, wherein at least one of the at least two glycosides comprises a mogroside-type glycoside.

27. The formulation of claim 2, wherein at least one of the at least two glycosides comprises a rebaudioside glycoside and at least one of the at least two glycosides comprises a mogroside- type glycoside.

28. The formulation of claim 1, wherein the glycoside comprises amyrin, furostan, Q521 quillaja constituent, glycyrrhizic acid, escin, tea saponin, or bidesmosidic saponin from quillaja.

29. The formulation of claim 2, wherein at least one of the at least two glycosides comprises amyrin, furostan, Q521 quillaja constituent, glycyrrhizic acid, escin, tea saponin, or bidesmosidic saponin from quillaja.

30. The formulation of claim 1, wherein the surfactant comprises a sucrose ester.

31. The formulation of claim 1, wherein the surfactant comprises a sorbitan ester.

32. The formulation of claim 1, wherein the surfactant comprises a saponin.

33. The formulation of claim 1, wherein the surfactant comprises a non-protein-based surfactant.

34. The formulation of claim 1, wherein the surfactant comprises a protein-based surfactant that does not consist of soy protein isolate.

35. The formulation of claim 1, wherein the surfactant comprises an ionic surfactant.

36. The formulation of claim 1, wherein the surfactant comprises an anionic surfactant.

37. The formulation of claim 1, wherein the surfactant comprises a zwitterionic surfactant.

38. The formulation of claim 1, wherein the surfactant comprise a sorbitan fatty acid ester, polyethylene glycol sorbitan fatty acid ester, polyethylene-polypropylene glycol, saturated polyglycolized glyceride, polyethylene glycol, quillaia, polyethylene glycol stearate, polyethylene glycol hydrogenated castor oil, diethylene glycol monoethyl ether, propylene glycol laurate , D-α- Tocopherol polyethylene glycol 1000 succinate (TPGS), polyvinyl pyrrolidone, iota carrageenan, Page 126 of 138 hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC), microcrystalline cellulose (MCC), lecithin, sucrose laurate, sucrose palmitate, sucrose stearate, gamma- cyclodextrin, β-cyclodextrin pectin, whey protein, caseinate, Xanthan gum, locust bean gum, gellan gum, acacia gum, guar gum, Tragacanth gum, polyethylene glycol hydroxystearate polyoxyl-10-oleyl ether, or polyethylene glycol glyceride.

39. The formulation of claim 1, wherein the surfactant comprises polysorbate 80.

40. The formulation of claim 1, wherein the surfactant comprises sorbitan monooleate.

41. The formulation of claim 1, wherein the surfactant comprises polysorbate 80 and sorbitan monooleate.

42. The formulation of claim 1, wherein the LC is derived from a plant.

43. The formulation of claim 42, wherein the plant is a Cannabaceae plant.

44. The formulation of claim 43, wherein the Cannabaceae plant is a cannabis plant.

45. The formulation of claim 44, wherein the cannabis plant is Cannabis sativa, Cannabis indica, or Cannabis ruderalis.

46. The formulation of claim 1, wherein the LC is a cannabinoid.

47. The formulation of claim 46, wherein the cannabinoid includes tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBT), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), and/or mixtures thereof.

48. The formulation of claim 46, wherein the cannabinoid includes CBD.

49. The formulation of claim 46, wherein the cannabinoid includes CBD and THC.

50. The formulation of claim 46, wherein the cannabinoid includes CBD and THC at a ratio of 1:1 (% w/w).

51. The formulation of claim 1, wherein the LC comprises a synthetic and/or artificial cannabinoid.

52. The formulation of claim 43, wherein the Cannabaceae plant is a Humulus plant.

53. The formulation of claim 52, wherein the Humulus plant is Humulus lupulus, Humulus americanus, Humulus cordifolius, Humulus neomexicanus, Humulus pubescens, or Humulus scandens.

54. The formulation of claim 52, wherein the Humulus plant is Humulus lupulus.

55. The formulation of claim 42, wherein the plant is a Rubiaceae plant.

56. The formulation of claim 55, wherein the Rubiaceae plant is a Coffea plant. Page 127 of 138

57. The formulation of claim 56, wherein the Coffea plant is Coffea abbayesii, Coffea affinis, Coffea alleizettii, Coffea ambanjensis, Coffea ambongenis, Coffea andrambovatensis, Coffea ankaranensis, Coffea anthonyi, Coffea arabica, Coffea arenesiana, Coffea augagneurii, Coffea bakossii, Coffea benghalensis, Coffea bertrandii, Coffea betamponensis, Coffea bissetiae, Coffea boinensis, Coffea boiviniana, Coffea bonnieri, Coffea brassii, Coffea brevipes, Coffea bridsoniae, Coffea buxifolia, Coffea canephora, Coffea carrissoi, Coffea charrieriana, Coffea cochinchinensis, Coffea commersoniana, Coffea congensis, Coffea costatifructa, Coffea coursiana, Coffea dactylifera, Coffea decaryana, Coffea dubardii, Coffea ebracteolata, Coffea eugenioides, Coffea fadenii, Coffea farafanganensis, Coffea floresiana, Coffea fotsoana, Coffea fragilis, Coffea fragrans, Coffea gallienii, Coffea grevei, Coffea heimii, Coffea homollei, Coffea horsfieldiana, Coffea humbertii, Coffea humblotiana, Coffea humilis, Coffea jumellei, Coffea kapakata, Coffea kianjavatensis, Coffea kihansiensis, Coffea kimbozensis, Coffea kivuensis, Coffea labatii, Coffea lancifolia, Coffea lebruniana, Coffea leonimontana, Coffea leroyi, Coffea liaudii, Coffea liberica, Coffea ligustroides, Coffea littoralis, Coffea lulandoensis, Coffea mabesae, Coffea macrocarpa, Coffea madurensis, Coffea magnistipula, Coffea malabarica, Coffea mangoroensis, Coffea mannii, Coffea manombensis, Coffea mapiana, Coffea mauritiana, Coffea mayombensis, Coffea mcphersonii, Coffea melanocarpa, Coffea merguensis, Coffea millotii, Coffea minutiflora, Coffea mogenetii, Coffea mongensis, Coffea montekupensis, Coffea montis-sacri, Coffea moratii, Coffea mufindiensis, Coffea myrtifolia, Coffea namorokensis, Coffea neobridsoniae, Coffea neoleroyi, Coffea perrieri, Coffea pervilleana, Coffea pocsii, Coffea pseudozanguebariae, Coffea pterocarpan, Coffea racemose, Coffea rakotonasoloi, Coffea ratsimamangae, Coffea resinosa, Coffea rhamnifolia, Coffea richardii, Coffea sahafaryensis, Coffea sakarahae, Coffea salvatrix, Coffea sambavensis, Coffea sapinii, Coffea schliebenii, Coffea semsei, Coffea sessiliflora, Coffea stenophylla, Coffea tetragona, Coffea togoensis, Coffea toshii, Coffea travancorensis, Coffea tricalysioides, Coffea tsirananae, Coffea vatovavyensis, Coffea vavateninensis, Coffea vianneyi, Coffea vohemarensis, Coffea wightiana, or Coffea zanguebariae.

58. The formulation of claim 56, wherein the Coffea plant is Coffea arabica.

59. The formulation of claim 42, wherein the plant is a Theaceae plant.

60. The formulation of claim 59, wherein the Theaceae plant is a Camellia plant.

61. The formulation of claim 60, wherein the Camellia plant is Camellia sinensis var. sinensis, Camellia sinensis var. assamica, Camellia sinensis var. pubilimba, or Camellia sinensis var. dehungensis.

62. The formulation of claim 60, wherein the Camellia plant is Camellia sinensis var. sinensi.

63. The formulation of claim 1, formulated as a beverage. Page 128 of 138

64. The formulation of claim 63, wherein the beverage is beer, coffee, or tea.

65. The formulation of claim 63, wherein the beverage is tea.

66. The formulation of claim 63, wherein the beverage is soda.

67. The formulation of claim 63, wherein the beverage is a juice-flavored drink.

68. The formulation of claim 63, wherein the beverage is carbonated water.

69. The formulation of claim 1, formulated as a topical composition.

70. The formulation of claim 69, wherein the topical composition is a lotion, cream or gel.

71. The formulation of claim 69, wherein the topical composition is a spray.

72. A product comprised of a mixture of the formulation of claim 1 and suspended particles 10 microns or less in diameter.

73. A beverage kit including the formulation of claim 1, a beverage, and instructions to combine the formulation and the beverage into a vessel suitable for drinking.

74. The beverage kit of claim 73, wherein the beverage is beer, coffee, or tea.

75. The beverage kit of claim 73, wherein the beverage is tea.

76. The beverage kit of claim 73, wherein the beverage is soda.

77. The beverage kit of claim 73, wherein the beverage is a juice-flavored drink.

78. The beverage kit of claim 73, wherein the beverage is carbonated water.

79. A kit for forming a formulation having a stabilized emulsion, the kit comprising a glycoside, a surfactant, and a lipophilic component (LC), wherein the glycoside is not a saponin if the surfactant is a saponin.

80. The kit of claim 79, further comprising at least two glycosides.

81. The kit of claim 79, wherein the LC is a lipophilic active component (LAC) or a regulated LAC (rLAC).

82. The kit of claim 79, further comprising instructions to form an aqueous formulation.

83. The kit of claim 79, further comprising an aqueous media.

84. The kit of claim 79, further comprising instructions to form a dry formulation.

85. The kit of claim 84, wherein the dry formulation is a pill, tablet, mucoadhesive tablet, or capsule.

86. The kit of claim 79, wherein the kit has two to five times more LC than the glycoside within the kit.

87. The kit of claim 80, wherein the kit has five to ten times more LC than an individual glycoside within the kit.

88. The kit of claim 79, wherein the kit has two times more LC than the glycoside within the kit.

89. The kit of claim 80, wherein the kit has two times more LC than a combination of two Page 129 of 138 glycosides within the kit.

90. The kit of claim 89, wherein a formed aqueous formulation has more than 5% LC by weight of the aqueous formulation.

91. The kit of claim 89, wherein a formed aqueous formulation has more than 5%-10% LC by weight of the aqueous formulation.

92. The kit of claim 79, wherein the glycoside comprises a steviol-type glycoside.

93. The kit of claim 79, wherein the glycoside comprises a curcurbitane-type glycoside.

94. The kit of claim 80, wherein at least one of the at least two glycosides comprises a steviol- type glycoside.

95. The kit of claim 80, wherein at least one of the at least two glycosides comprises a curcurbitane-type glycoside.

96. The kit of claim 80, wherein at least one of the at least two glycosides comprises a steviol- type glycoside and at least one of the at least two glycosides comprises a curcurbitane-type glycoside.

97. The kit of claim 79, wherein the glycoside comprises a diterpenoid-type glycoside.

98. The kit of claim 79, wherein the glycoside comprises a triterpenoid-type glycoside.

99. The kit of claim 80, wherein at least one of the at least two glycosides comprises a diterpenoid- type glycoside.

100. The kit of claim 80, wherein at least one of the at least two glycosides comprises a triterpenoid-type glycoside.

101. The kit of claim 80, wherein at least one of the at least two glycosides comprises a diterpenoid-type glycoside and at least one of the at least two glycosides comprises a triterpenoid- type glycoside.

102. The kit of claim 79, wherein the glycoside comprises a rebaudioside glycoside.

103. The kit of claim 79, wherein the glycoside comprises a mogroside-type glycoside.

104. The kit of claim 80, wherein at least one of the at least two glycosides comprises a rebaudioside glycoside.

105. The kit of claim 80, wherein at least one of the at least two glycosides comprises a mogroside-type glycoside.

106. The kit of claim 80, wherein at least one of the at least two glycosides comprises a rebaudioside glycoside and at least one of the at least two glycosides comprises a mogroside- type glycoside.

107. The kit of claim 79, wherein the glycoside comprises amyrin, furostan, Q521 quillaja constituent, glycyrrhizic acid, escin, tea saponin, or bidesmosidic saponin from quillaja. Page 130 of 138

108. The kit of claim 80, wherein at least one of the at least two glycosides comprises amyrin, furostan, Q521 quillaja constituent, glycyrrhizic acid, escin, tea saponin, or bidesmosidic saponin from quillaja.

109. The kit of claim 79, wherein the surfactant comprises a sucrose ester.

110. The kit of claim 79, wherein the surfactant comprises a sorbitan ester.

111. The kit of claim 79, wherein the surfactant comprises a saponin.

112. The kit of claim 79, wherein the surfactant comprises a non-protein-based surfactant.

113. The kit of claim 79, wherein the surfactant comprises a protein-based surfactant that does not consist of soy protein isolate.

114. The kit of claim 79, wherein the surfactant comprises an ionic surfactant.

115. The kit of claim 79, wherein the surfactant comprises an anionic surfactant.

116. The kit of claim 79, wherein the surfactant comprises a zwitterionic surfactant.

117. The kit of claim 79, wherein the surfactant comprise a sorbitan fatty acid ester, polyethylene glycol sorbitan fatty acid ester, polyethylene-polypropylene glycol, saturated polyglycolized glyceride, polyethylene glycol, quillaia, polyethylene glycol stearate, polyethylene glycol hydrogenated castor oil, diethylene glycol monoethyl ether, propylene glycol laurate , D-α- Tocopherol polyethylene glycol 1000 succinate (TPGS), polyvinyl pyrrolidone, iota carrageenan, hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC), microcrystalline cellulose (MCC), lecithin, sucrose laurate, sucrose palmitate, sucrose stearate, gamma- cyclodextrin, β-cyclodextrin pectin, whey protein, caseinate, Xanthan gum, locust bean gum, gellan gum, acacia gum, guar gum, Tragacanth gum, polyethylene glycol hydroxystearate polyoxyl-10-oleyl ether, or polyethylene glycol glyceride.

118. The kit of claim 79, wherein the surfactant comprises polysorbate 80.

119. The kit of claim 79, wherein the surfactant comprises sorbitan monooleate.

120. The kit of claim 79, wherein the surfactant comprises polysorbate 80 and sorbitan monooleate.

121. The kit of claim 79, wherein the LC is derived from a plant.

122. The kit of claim 121, wherein the plant is a Cannabaceae plant.

123. The kit of claim 122, wherein the Cannabaceae plant is a cannabis plant.

124. The kit of claim 123, wherein the cannabis plant is Cannabis sativa, Cannabis indica, or Cannabis ruderalis.

125. The kit of claim 79, wherein the LC is a cannabinoid.

126. The kit of claim 125, wherein the cannabinoid includes tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), Page 131 of 138 cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBT), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), and/or mixtures thereof.

127. The kit of claim 125, wherein the cannabinoid includes CBD.

128. The kit of claim 125, wherein the cannabinoid includes CBD and THC.

129. The kit of claim 125, wherein the cannabinoid includes CBD and THC at a ratio of 1:1 (% w/w).

130. The kit of claim 79, wherein the LC comprises a synthetic and/or artificial cannabinoid.

131. The kit of claim 122, wherein the Cannabaceae plant is a Humulus plant.

132. The kit of claim 131, wherein the Humulus plant is Humulus lupulus, Humulus americanus, Humulus cordifolius, Humulus neomexicanus, Humulus pubescens, or Humulus scandens.

133. The kit of claim 131, wherein the Humulus plant is Humulus lupulus.

134. The kit of claim 121, wherein the plant is a Rubiaceae plant.

135. The kit of claim 134, wherein the Rubiaceae plant is a Coffea plant.

136. The kit of claim 135, wherein the Coffea plant is Coffea abbayesii, Coffea affinis, Coffea alleizettii, Coffea ambanjensis, Coffea ambongenis, Coffea andrambovatensis, Coffea ankaranensis, Coffea anthonyi, Coffea arabica, Coffea arenesiana, Coffea augagneurii, Coffea bakossii, Coffea benghalensis, Coffea bertrandii, Coffea betamponensis, Coffea bissetiae, Coffea boinensis, Coffea boiviniana, Coffea bonnieri, Coffea brassii, Coffea brevipes, Coffea bridsoniae, Coffea buxifolia, Coffea canephora, Coffea carrissoi, Coffea charrieriana, Coffea cochinchinensis, Coffea commersoniana, Coffea congensis, Coffea costatifructa, Coffea coursiana, Coffea dactylifera, Coffea decaryana, Coffea dubardii, Coffea ebracteolata, Coffea eugenioides, Coffea fadenii, Coffea farafanganensis, Coffea floresiana, Coffea fotsoana, Coffea fragilis, Coffea fragrans, Coffea gallienii, Coffea grevei, Coffea heimii, Coffea homollei, Coffea horsfieldiana, Coffea humbertii, Coffea humblotiana, Coffea humilis, Coffea jumellei, Coffea kapakata, Coffea kianjavatensis, Coffea kihansiensis, Coffea kimbozensis, Coffea kivuensis, Coffea labatii, Coffea lancifolia, Coffea lebruniana, Coffea leonimontana, Coffea leroyi, Coffea liaudii, Coffea liberica, Coffea ligustroides, Coffea littoralis, Coffea lulandoensis, Coffea mabesae, Coffea macrocarpa, Coffea madurensis, Coffea magnistipula, Coffea malabarica, Coffea mangoroensis, Coffea mannii, Coffea manombensis, Coffea mapiana, Coffea mauritiana, Coffea mayombensis, Coffea mcphersonii, Coffea melanocarpa, Coffea merguensis, Coffea millotii, Coffea minutiflora, Coffea mogenetii, Coffea mongensis, Coffea montekupensis, Coffea montis-sacri, Coffea moratii, Coffea Page 132 of 138 mufindiensis, Coffea myrtifolia, Coffea namorokensis, Coffea neobridsoniae, Coffea neoleroyi, Coffea perrieri, Coffea pervilleana, Coffea pocsii, Coffea pseudozanguebariae, Coffea pterocarpan, Coffea racemose, Coffea rakotonasoloi, Coffea ratsimamangae, Coffea resinosa, Coffea rhamnifolia, Coffea richardii, Coffea sahafaryensis, Coffea sakarahae, Coffea salvatrix, Coffea sambavensis, Coffea sapinii, Coffea schliebenii, Coffea semsei, Coffea sessiliflora, Coffea stenophylla, Coffea tetragona, Coffea togoensis, Coffea toshii, Coffea travancorensis, Coffea tricalysioides, Coffea tsirananae, Coffea vatovavyensis, Coffea vavateninensis, Coffea vianneyi, Coffea vohemarensis, Coffea wightiana, or Coffea zanguebariae.

137. The kit of claim 135, wherein the Coffea plant is Coffea arabica.

138. The kit of claim 121, wherein the plant is a Theaceae plant.

139. The kit of claim 138, wherein the Theaceae plant is a Camellia plant.

140. The kit of claim 139, wherein the Camellia plant is Camellia sinensis var. sinensis, Camellia sinensis var. assamica, Camellia sinensis var. pubilimba, or Camellia sinensis var. dehungensis.

141. The kit of claim 139, wherein the Camellia plant is Camellia sinensis var. sinensi.

142. The kit of claim 79, comprising an aqueous media comprising a beverage.

143. The kit of claim 142, wherein the beverage is beer, coffee, or tea.

144. The kit of claim 142, wherein the beverage is tea.

145. The kit of claim 142, wherein the beverage is soda.

146. The kit of claim 142, wherein the beverage is a juice-flavored drink.

147. The kit of claim 142, wherein the beverage is carbonated water.

148. A method of forming a composition comprising adding a glycoside, a surfactant, and a lipophilic component (LC) to a media, wherein the glycoside is not a saponin if the surfactant is a saponin.

149. The method of claim 148, wherein the composition further comprises at least two glycosides.

150. The method of claim 148, wherein the LC is a lipophilic active component (LAC) or a regulated LAC (rLAC).

151. The method of claim 148, wherein the composition is a stabilized emulsion.

152. The method of claim 148, wherein the media is an aqueous media.

153. The method of claim 148, wherein the composition is a dry composition.

154. The method of claim 153, wherein the dry composition is a pill, tablet, mucoadhesive tablet, or capsule.

155. The method of claim 148, wherein the composition has two to five times more LC than glycoside within the composition.

156. The method of claim 149, wherein the composition has five to ten more times more LC than Page 133 of 138 an individual glycoside within the composition.

157. The method of claim 148, wherein the composition has two times more LC than glycoside within the composition.

158. The method of claim 157, wherein the composition has two times more LC than a combination of two glycosides within the composition.

159. The method of claim 148, wherein the composition has more than 5% LC by weight of the composition.

160. The method of claim 148, wherein the composition has more than 5%-10% LC by weight of the composition.

161. The method of claim 148, wherein the glycoside comprises a steviol-type glycoside.

162. The method of claim 148, wherein the glycoside comprises a curcurbitane-type glycoside.

163. The method of claim 149, wherein at least one of the at least two glycosides comprises a steviol-type glycoside.

164. The method of claim 149, wherein at least one of the at least two glycosides comprises a curcurbitane-type glycoside.

165. The method of claim 149, wherein at least one of the at least two glycosides comprises a steviol-type glycoside and at least one of the at least two glycosides comprises a curcurbitane- type glycoside.

166. The method of claim 148, wherein the glycoside comprises a diterpenoid-type glycoside.

167. The method of claim 148, wherein the glycoside comprises a triterpenoid-type glycoside.

168. The method of claim 149, wherein at least one of the at least two glycosides comprises a diterpenoid-type glycoside.

169. The method of claim 149, wherein at least one of the at least two glycosides comprises a triterpenoid-type glycoside.

170. The method of claim 149, wherein at least one of the at least two glycosides comprises a diterpenoid-type glycoside and at least one of the at least two glycosides comprises a triterpenoid- type glycoside.

171. The method of claim 148, wherein the glycoside comprises a rebaudioside glycoside.

172. The method of claim 148, wherein the glycoside comprises a mogroside-type glycoside.

173. The method of claim 149, wherein at least one of the at least two glycosides comprises a rebaudioside glycoside.

174. The method of claim 149, wherein at least one of the at least two glycosides comprises a mogroside-type glycoside.

175. The method of claim 149, wherein at least one of the at least two glycosides comprises a Page 134 of 138 rebaudioside glycoside and at least one of the at least two glycosides comprises a mogroside- type glycoside.

176. The method of claim 148, wherein the glycoside comprises amyrin, furostan, Q521 quillaja constituent, glycyrrhizic acid, escin, tea saponin, or bidesmosidic saponin from quillaja.

177. The method of claim 149, wherein at least one of the at least two glycosides comprises amyrin, furostan, Q521 quillaja constituent, glycyrrhizic acid, escin, tea saponin, or bidesmosidic saponin from quillaja.

178. The method of claim 148, wherein the surfactant comprises a sucrose ester.

179. The method of claim 148, wherein the surfactant comprises a sorbitan ester.

180. The method of claim 148, wherein the surfactant comprises a saponin.

181. The method of claim 148, wherein the surfactant comprises a non-protein-based surfactant.

182. The method of claim 148, wherein the surfactant comprises a protein-based surfactant that does not consist of soy protein isolate.

183. The method of claim 148, wherein the surfactant comprises an ionic surfactant.

184. The method of claim 148, wherein the surfactant comprises an anionic surfactant.

185. The method of claim 148, wherein the surfactant comprises a zwitterionic surfactant.

186. The method of claim 148, wherein the surfactant comprise a sorbitan fatty acid ester, polyethylene glycol sorbitan fatty acid ester, polyethylene-polypropylene glycol, saturated polyglycolized glyceride, polyethylene glycol, quillaia, polyethylene glycol stearate, polyethylene glycol hydrogenated castor oil, diethylene glycol monoethyl ether, propylene glycol laurate , D-α- Tocopherol polyethylene glycol 1000 succinate (TPGS), polyvinyl pyrrolidone, iota carrageenan, hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC), microcrystalline cellulose (MCC), lecithin, sucrose laurate, sucrose palmitate, sucrose stearate, gamma- cyclodextrin, β-cyclodextrin pectin, whey protein, caseinate, Xanthan gum, locust bean gum, gellan gum, acacia gum, guar gum, Tragacanth gum, polyethylene glycol hydroxystearate polyoxyl-10-oleyl ether, or polyethylene glycol glyceride.

187. The method of claim 148, wherein the surfactant comprises polysorbate 80.

188. The method of claim 148, wherein the surfactant comprises sorbitan monooleate.

189. The method of claim 148, wherein the surfactant comprises polysorbate 80 and sorbitan monooleate.

190. The method of claim 148, wherein the LC is derived from a plant.

191. The method of claim 190, wherein the plant is a Cannabaceae plant.

192. The method of claim 191, wherein the Cannabaceae plant is a cannabis plant.

193. The method of claim 192, wherein the cannabis plant is Cannabis sativa, Cannabis indica, Page 135 of 138 or Cannabis ruderalis.

194. The method of claim 148, wherein the LC is a cannabinoid.

195. The method of claim 194, wherein the cannabinoid includes tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBT), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarinic acid (THCVA), and/or mixtures thereof.

196. The method of claim 194, wherein the cannabinoid includes CBD.

197. The method of claim 194, wherein the cannabinoid includes CBD and THC.

198. The method of claim 194, wherein the cannabinoid includes CBD and THC at a ratio of 1:1 (% w/w).

199. The method of claim 148, wherein the LC comprises a synthetic and/or artificial cannabinoid.

200. The method of claim 191, wherein the Cannabaceae plant is a Humulus plant.

201. The method of claim 200, wherein the Humulus plant is Humulus lupulus, Humulus americanus, Humulus cordifolius, Humulus neomexicanus, Humulus pubescens, or Humulus scandens.

202. The method of claim 200, wherein the Humulus plant is Humulus lupulus.

203. The method of claim 190, wherein the plant is a Rubiaceae plant.

204. The method of claim 203, wherein the Rubiaceae plant is a Coffea plant.

205. The method of claim 204, wherein the Coffea plant is Coffea abbayesii, Coffea affinis, Coffea alleizettii, Coffea ambanjensis, Coffea ambongenis, Coffea andrambovatensis, Coffea ankaranensis, Coffea anthonyi, Coffea arabica, Coffea arenesiana, Coffea augagneurii, Coffea bakossii, Coffea benghalensis, Coffea bertrandii, Coffea betamponensis, Coffea bissetiae, Coffea boinensis, Coffea boiviniana, Coffea bonnieri, Coffea brassii, Coffea brevipes, Coffea bridsoniae, Coffea buxifolia, Coffea canephora, Coffea carrissoi, Coffea charrieriana, Coffea cochinchinensis, Coffea commersoniana, Coffea congensis, Coffea costatifructa, Coffea coursiana, Coffea dactylifera, Coffea decaryana, Coffea dubardii, Coffea ebracteolata, Coffea eugenioides, Coffea fadenii, Coffea farafanganensis, Coffea floresiana, Coffea fotsoana, Coffea fragilis, Coffea fragrans, Coffea gallienii, Coffea grevei, Coffea heimii, Coffea homollei, Coffea horsfieldiana, Coffea humbertii, Coffea humblotiana, Coffea humilis, Coffea jumellei, Coffea kapakata, Coffea kianjavatensis, Coffea kihansiensis, Coffea kimbozensis, Coffea kivuensis, Coffea labatii, Coffea lancifolia, Coffea lebruniana, Coffea leonimontana, Coffea leroyi, Coffea liaudii, Coffea liberica, Page 136 of 138 Coffea ligustroides, Coffea littoralis, Coffea lulandoensis, Coffea mabesae, Coffea macrocarpa, Coffea madurensis, Coffea magnistipula, Coffea malabarica, Coffea mangoroensis, Coffea mannii, Coffea manombensis, Coffea mapiana, Coffea mauritiana, Coffea mayombensis, Coffea mcphersonii, Coffea melanocarpa, Coffea merguensis, Coffea millotii, Coffea minutiflora, Coffea mogenetii, Coffea mongensis, Coffea montekupensis, Coffea montis-sacri, Coffea moratii, Coffea mufindiensis, Coffea myrtifolia, Coffea namorokensis, Coffea neobridsoniae, Coffea neoleroyi, Coffea perrieri, Coffea pervilleana, Coffea pocsii, Coffea pseudozanguebariae, Coffea pterocarpan, Coffea racemose, Coffea rakotonasoloi, Coffea ratsimamangae, Coffea resinosa, Coffea rhamnifolia, Coffea richardii, Coffea sahafaryensis, Coffea sakarahae, Coffea salvatrix, Coffea sambavensis, Coffea sapinii, Coffea schliebenii, Coffea semsei, Coffea sessiliflora, Coffea stenophylla, Coffea tetragona, Coffea togoensis, Coffea toshii, Coffea travancorensis, Coffea tricalysioides, Coffea tsirananae, Coffea vatovavyensis, Coffea vavateninensis, Coffea vianneyi, Coffea vohemarensis, Coffea wightiana, or Coffea zanguebariae.

206. The method of claim 204, wherein the Coffea plant is Coffea arabica.

207. The method of claim 190, wherein the plant is a Theaceae plant.

208. The method of claim 207, wherein the Theaceae plant is a Camellia plant.

209. The method of claim 208, wherein the Camellia plant is Camellia sinensis var. sinensis, Camellia sinensis var. assamica, Camellia sinensis var. pubilimba, or Camellia sinensis var. dehungensis.

210. The method of claim 208, wherein the Camellia plant is Camellia sinensis var. sinensi.

211. The method of claim 148, further comprising formulating the composition as a beverage.

212. The method of claim 211, wherein the beverage is beer, coffee, or tea.

213. The method of claim 211, wherein the beverage is tea.

214. The method of claim 211, wherein the beverage is soda.

215. The method of claim 211, wherein the beverage is a juice-flavored drink.

216. The method of claim 211, wherein the beverage is carbonated water.

217. The formulation of claim 1, wherein the LC is a protein.

218. The kit of claim 79, wherein the LC is a protein.

219. The method of claim 148, wherein the LC is a protein. Page 137 of 138